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Binding of opioids to µ-receptors within the gastrointestinal (GI) tract can lead to im-
pairment of motility and secretion and induce a variety of symptoms, including nausea, 
gastro-paresis, secondary pseudo-obstruction and constipation1. This complex of im-
pairment and symptoms is called Opioid Induced Bowel Dysfunction (OIBD)1-3. OIC is the 
most common symptom of OIBD2-7. 
In 2014 a consensus definition for OIC was agreed upon and by consensus, OIC is de-
fined as follows: “A change when initiating opioid therapy from baseline bowel habits 
that is characterized by any of the following: reduced bowel movement frequency, de-
velopment or worsening of straining to pass bowel movements, a sense of incomplete 
rectal evacuation, or harder stool consistency”1. Other associated symptoms of OIC are: 
bloating, acid reflux, rectal pain and nausea8,9. OIC is a common side effect of opioid 
treatment and in contrast to other side effects of opioid treatment patients do not 
develop a tolerance to constipation2-7. In literature the incidence of OIC varies between 
15-90% of patients on opioid treatment3,10-13. Besides opioid use also other factors can 
contribute to the development of constipation in patients on opioid treatment. Factors 
that have been identified are disease progression, dehydration, other medications (like 
chemotherapeutic agents), immobility and age10,14,15.
Pathophysiology
The effects that opioids have on the physiological function of the GI tract have been 
extensively studied in animal models and humans1,2,8-10. OIC develops predominantly as 
a result of activation of enteric µ-opioid receptors which are distributed throughout the 
GI tract1,2. They mediate a number of effects that influence the function of the GI-tract 
when activated by opioids1,2. 
Activation of the enteric µ-opioid receptors by opioids for example: causes non-peri-
staltic contractions, decreases gastric motility and emptying, increases pyloric sphincter 
tone; decreases GI, biliary, and pancreatic secretions; inhibits peristalsis in the small 
and large intestines; increases the amplitude of non-propulsive segmental contractions 
in the small intestine; increases water absorption from bowel contents; increases anal 
sphincter tone; and constricts the sphincter of Oddi 2,16. 
The combined action of opioids on inhibition of GI emptying, GI motility, GI transit, 
intestinal fluid secretion and the enhancement of absorption contribute to the consti-
pating effect of opioids; as these effects are localized to the GI tract, it is called peripheral 
action2.
Besides the physical burden of OIC and OIC associated symptoms, OIC has a major im-
pact on patient’s quality of life (QoL)10,12,17-19.  Significant differences are detected in QoL 
between patients depending on the presence and severity of OIC17,20. Besides a direct 
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impact of OIC and associated symptoms on QoL, OIC also has an impact on the treat-
ment of pain. Literature has described that OIC can be intolerable to patients. Nearly 2/3 
of patients changed the opioid dose; either lowering the dose (10.2%) or skipping doses 
and/or irregular use (7.5%) or discontinued opioid treatment (5.4%) all at the expense 
of analgesic efficacy2,12,18,20. The interference of OIC with pain management also results 
in a decrease of QoL20.
Pharmacological treatment of OIC
In current practice the advice for treatment and prevention of OIC is to treat patients 
on opioid analgesics prophylactically with a laxative regime in addition to lifestyle 
modifications, such as increased exercise, greater fluid intake, and dietary changes1,2. 
The pharmacological component of the laxative regimen may include stool softeners, 
bulking agents, osmotic agents, and stimulant-type laxatives1,3,21. In some cases, two or 
more laxatives with complementary mechanisms of action may be prescribed, such as a 
stool softener plus a stimulant. Rectal laxatives, including stimulant suppositories such 
as bisacodyl, lubricants such as glycerin, and enemas are sometimes used, although care 
should be taken with enemas to preserve the patient’s electrolyte balance1,3,21.
Despite this laxative regimen, literature describes that some patients still experience 
OIC and/or do not tolerate the adverse events of the laxative regime; i.e. patients with 
laxative-refractory OIC12,19. Also literature describes that laxatives are ineffective to treat 
OIC1,2. Moreover, treatment with laxatives causes side effects and complications3,14. 
In Dutch clinical practice a prophylactic laxative regime is advised consisting of treat-
ment with at least one laxative in an adequate dosage (e.g. macrogol plus electrolytes or 
lactulose) and if needed addition of a second laxative of a different therapeutic class (e.g. 
bisacodyl)22,23. As the efficacy of this laxative regime for the treatment and prevention of 
OIC has not been established yet, a pilot study was conducted to explore the efficacy of 
the current Dutch prophylactic laxative regime under conditions of daily practice.
Over the last decade opioid receptor antagonists like methylnaltrexone, naloxegol and 
naloxone are increasingly being used for the pathophysiological treatment of OIC24-26. 
Currently described peripherally-acting µ-opioid receptor antagonists (PAMORA’s) in 
literature are methylnaltrexone (MNTX), naloxegol, alvimopan and naldemedine1,2. 
Another agent described in literature is prolonged release combination of oxycodone 
and naloxone (PR OXN), although it acts on peripheral opioid receptors it is sometimes 
considered to be another agent as it relies on the drug combination2. PAMORA’s and PR 
OXN block opioid actions at peripheral opioid receptors that mediate decreased intes-
tinal secretion and propulsive colonic motility1,2. By blocking μ-opioid receptors in the 
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gut, there is restoration of the function of the enteric nervous system, and propulsive 
motility and secretory functions can be generated by local enteric neural circuits in 
response to physiologic stimuli such as meal ingestion, or sensation of a bolus to evoke 
normal peristalsis1,2. 
As the number of PAMORAs increase it is important to explore their efficacy not only 
in randomized controlled trials but also in real-life settings and when possible explore 
their efficacy in comparison to each other. A systematic review and meta-analysis was 
performed to obtain more insights in the efficacy of these opioid receptor antagonist for 
the treatment of OIC. 
The aim of this thesis was to further elucidate the efficacy of PR OXN, specifically for 
patients with laxative-refractory OIC.  PR OXN combines the opioid receptor agonist 
oxycodone and the opioid receptor antagonist naloxone. When administered orally, a 
reduction of constipation can be achieved due to a local action of naloxone in the gut 
without affecting pain relief by oxycodone27-29. PR OXN has proven equivalent analgesic 
efficacy to prolonged release oxycodone (PR OXY) with significant improvements in 
bowel function in chronic non-malignant pain30-35 as well as in moderate/severe malig-
nant pain36-38. 
In order to gain more insights in the efficacy of PR  OXN in patients with laxative-refractory 
OIC a post-hoc analysis was designed to explore the efficacy of PR OXN in this specific 
population. Moreover, two additional observational studies were designed in which 
patients (with and without laxative-refractory OIC) were treated as in daily practice in 
Belgium with PR OXN, investigating the efficacy of treatment in a real-life situation. 
As treatment with PR OXN is more expensive than treatment with PR OXY, it was also 
important to assess cost utility of PR OXN treatment for laxative-refractory patients, 
therefore also a cost-utility analysis was  performed.
The results of the studies in this thesis add to the current knowledge of opioid antagonist 
treatments, especially PR OXN treatment, specifically in patients with laxative-refractory 
OIC. Moreover, the results may, hopefully, improve treatment of OIC in this specific 
patient population.
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absTRaCT
Objective
Dutch clinical guidelines recommend that a standard laxative treatment (SLT)  should be 
prescribed concomitantly when starting opioid treatment  to prevent opioid-induced 
constipation (OIC).
Clinical evidence for SLT in the treatment of OIC is lacking, therefore an observational 
pilot study was performed to explore the efficacy and tolerability of SLT on OIC in pa-
tients treated with the opioid oxycodone. 
Results
Twenty-four patients (58% female, median (range) age 65 (39-92)) were included in this 
pilot study. The analysis showed that 9 out of 21 patients (43%) were non-responders to 
SLT. When also taking into consideration patients tending to develop diarrhea 75% of 
patients are non-responsive to SLT. 
Conclusion
This pilot study indicates that optimal laxative therapy (SLT) might not be effective and 
feasible for the prevention and treatment of OIC. 
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InTRODuCTIOn
Opioids are an option for the pharmacological treatment of moderate to severe pain 
and are generally used when non-opioid treatments are ineffective or contra-indicated 
[1-3]. A significant disadvantage of all opioid use is opioid induced constipation (OIC). 
Although there might be variation in occurrence of OIC depending on the type of opioid 
used, OIC is a side effect of all opioids and has a negative impact on pain treatment, 
quality of life and daily activities [4-12].
Opioid induced constipation (OIC)
To date OIC is defined as:  ‘A change when initiating opioid therapy from baseline bowel 
habits that is characterized by any of the following: reduced bowel movement frequency, 
development or worsening of straining to pass bowel movements, a sense of incomplete 
rectal evacuation, or harder stool consistency’[12]. OIC is characterized by three major 
symptoms: hard and dry stools, impeded and painful defecation and significantly less 
frequent stools than normal for the patient (in general defined as less than 3 bowel 
movements per week).  Other associated symptoms are flatulence, colic pain and pelvic 
pressure pain [4, 13-16]. OIC can lead to an increased morbidity and even mortality of 
patients.  It can result in bleeding, pain, gastro-intestinal reflux, nausea, vomiting and 
rectal pain as well as hemorrhoids, diverticular disease and fecal impaction [4, 13-16]. 
Severe OIC can result in complications like fecal impaction with paradoxical diarrhea 
and incontinence, bowel obstruction, bowel rupture, pseudo-obstruction with anorexia, 
urine retention with overflow incontinence and delirium[6, 14]. Surveys in patients 
suffering from OIC have shown that OIC also has an impact on the treatment of pain. 
Almost 2/3 of patients change their opioid dosage; patients change to a lower dose 
(10.2%), skip dosages and/or are using opioids irregularly (7.5%) or stop using opioids 
for their pain management (5.4%) [6, 11]. Moreover, OIC can in itself also be a cause for 
pain; the majority of patients with OIC report pain caused by OIC. Pain caused by OIC 
results in more discomfort than pain caused by the underlying condition [6, 11, 17].
Current management of OIC in Dutch clinical practice
Management of OIC usually consists of non-pharmacological and pharmacological 
approaches. The international consensus is that treatment of OIC should be focused 
on the prevention of OIC rather than treatment of already manifest OIC [12, 18-22]. 
Pharmacologcial treatments include osmotically acting laxatives (e.g. magnesium oxide, 
lactulose and polyethylene glycol), stimulant laxatives (e.g. bisacodyl and sennosides), 
stool softener (e.g. liquid paraffin and sodium docusate), bulk forming laxatives (e.g. 
isphagula and methylcellulose) or enema’s (e.g. sodium laurylsulfate and sodium phos-
phate). When these laxatives fail opioid antagonists like oxycodone/naloxone combina-
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tion, methylnaltrexone or naloxegol can be considered. These treatment possibilities for 
OIC have already been reviewed in several recent publications by Nelson et al., Argoff et 
al. and Camilleri et al.[12, 21, 22] 
In the Netherlands pharmacological treatment for constipation due to opioid therapy 
is described in Dutch clinical guidelines regarding treatment of cancer pain and for the 
treatment of constipation[23, 24]. These guidelines recommend that laxatives should 
be concomitantly prescribed when starting opioid treatment [23, 24]. As literature on 
treatment of OIC at time of guideline development was sparse and non-conclusive, the 
recommendations were predominantly based on expert opinion taking in consideration 
the high incidence of OIC in patients treated with opioids, the harm it can cause for 
patients and practical experience [23, 24]. 
First choice treatments in the Dutch guidelines were defined based on available stud-
ies at time of guideline development; treatments of first choice are the osmotically act-
ing laxative lactulose and polyethylene glycol plus electrolytes (which is also considered 
to be bulk forming) of which PEG plus electrolytes is the most prescribed laxative. If 
these are not effective enough addition of a stimulant laxative like bisacodyl (orally or 
rectally) can be considered[23, 24]. 
Next to the recognition of OIC in the Dutch guidelines a quality indicator was set up 
within the Dutch Health Care Transparency Program ensuring that all patients with an 
opioid prescription also had a prescription of a laxative, in order to improve outpatient 
drug safety [25, 26]. The Institute for Rational Use of Medicines (IVM) published the 2013 
results of this quality indicator in the Monitor Prescribing Behavior Practitioners. The 
calculation of the quality indicator was based on reimbursement data of community 
pharmacists and dispensing general practitioners collected by Vektis, a national data-
center for healthcare insurers. These data showed that on average 49% (median 48%, 
range 33-64%) of patients on opioids were prescribed a laxative together with their opi-
oid prescription[27].  Also data from the Dutch Foundation for Pharmaceutical statistic, 
gathering data from more than 95% of the community pharmacies in the Netherlands, 
show that  in 90% of participating community pharmacies less than 60% of patients 
were prescribed a laxative together with their opioid prescription in 2013 [28]. These 
results show that, despite implementation of the quality indicator, physicians do not 
always follow guidelines.  Moreover, the Dutch laxative guidelines can be interpreted in 
different ways.
However, to date two main interpretations of the Dutch laxative guidelines are used 
with respect to laxative treatment schedules: 1. Provide a laxative prescription together 
with the opioid prescription and use laxative on an as needed basis  and 2. Standard 
laxative treatment (SLT) consisting of intake of laxative together with the opioid on a 
daily basis, starting at day one. Laxative use is reduced in case of development of diar-
rhea and increased when not effective or on increase of opioid dose . The effect of “as 
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needed” intake of laxatives was already clearly visible in clinical trials investigating the 
efficacy of prolonged-release oxycodone/naloxone  where laxative use in the control 
arm was “as needed” [29-35].   Interestingly, the impact of the SLT for laxative intake 
has not been investigated yet. Moreover, there are no unambiguous incidence- and/or 
prevalence rates for failure of laxatives in OIC.  In this report a descriptive analysis of an 
observational pilot study is described investigating the efficacy of laxative treatment 
according to SLT in the Netherlands with respect to bowel function and tolerability as 
well as patient handling of laxatives.
PaTIenTs anD meThODs
A prospective observational study was performed investigating a standard laxative 
treatment regime (SLT)  consisting of  prophylactic daily intake of polyethylene glycol 
(PEG) with electrolytes and bisacodyl as needed. This SLT was started together with 
opioid-intake at day 1. Nine centers in the Netherlands, in which the laxative regimen 
PEG with electrolytes and bisacodyl was standard of care, participated. Since patients 
were treated as they would have been treated in daily practice and were not subject to 
additional procedures the study did not fall under the scope of the Medical Research 
Involving Human Subjects Act. The Agreement on Medical Treatment Act and the Per-
sonal Data Protection act did apply. All patients who were prescribed at least 2x10 mg 
oxycodone Slow Release (SR) and the SLT regime were followed for 28 days by their 
physician. No other in- and exclusion criteria were applied. 
Bowel function was measured with the Bowel Function Index (BFI), a measure which is 
specific and validated for OIC (BFI[36]; Copyright for the BFI is owned by Mundipharma 
Laboratories GmbH, Switzerland 2002; the BFI is subject of European Patent Application 
Publication No. EP 1 860 988 and corresponding patents and applications in other coun-
tries).  A BFI below 28.8 is considered normal (not constipated) in opioid-treated patients 
and a decrease of at least 12 points in BFI is considered clinically relevant [36-39].
In addition, the Bristol Stool Form Scale (BSFS) was used to assess bowel function. 
BSFS gives an indication of the type of stool from watery stools (diarrhea) to dry and 
hard lumps (constipation). Type 1 and 2 indicate constipation, type 3 and 4 represent 
normal stools, type 5 represents a stool tending towards diarrhea and type 6 and 7 
represent diarrhea [40]. Analgesia was measured with a numerical pain score (Numerical 
Rating Scale (NRS), 0-100). Laxative use (daily dosage and treatment duration) as well as 
adverse events were also registered.
Descriptive analyses of the results are presented. To evaluate the efficacy of the SLT 
regime a responder analysis was performed.
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Responder analysis: A responder to laxative treatment was defined as: 
1. a patient with a clinically relevant improvement of already present constipation (de-
crease of BFI with 12 points or more) or as a patient who did not develop constipation 
as measured with the BFI (BFI remains below 30 points throughout the observation) 
anD 
2. a patient without development of diarrhea (type 6 or 7 of the Bristol Stool Form 
Scale) anD 
3. a patient without  early discontinuation due to  adverse events of laxative treatment.
ResulTs
Of the nine centers asked to participate six included a total of 24 patients in the period 
July 2012 until October 2013. The majority of patients were female (58%), which is con-
sistent with the patient population with chronic pain, median (range) age of patients 
was 65 (39-92) years, and all but one patient had non-malignant pain. At the start of the 
study 22 of 24 patients had severe pain (pain NRS score ≥60). Table 1 describes the de-
mographics of the included patient population. The average (sd) pain score decreased 
from 74.2 (14.5) (median(range) 80 (30-90)to 53.0 (26.2) (median(range) 53 (5-90)) after 
4 weeks of treatment. 
Table 1: Demographics of included patients
Gender 
male, n (%)
female, n (%)
10 (42%)
14 (58%)
Median (range) age (yrs) 65 (39-92)
Previous medication, n( %)
WHO-step I
WHO-step II
WHO-step III
adjuvantia
5 (21%)
11 (46%)
6 (25%)
2 (8%)
Painscore (NRS)  at start of observation
average (sd)
median (range)
 
74 (14)
80 (30-90)
Origin of pain, n (%)
malignant
non-malignant
1 (4%)
23 (96%)
BFI at start of observation
average (sd)
median(range)
26.6 (27.3)
21.8 (0-77)
Patients with BFI>28.8 at start of observation, n (%) 9 (37.5%)
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Table 2 lists the BFI at study start, at the final visit and the delta BFI, as well as the highest 
value of the Bristol Stool Form Scale and the three criteria of the responder analysis. For 
three patients data were insufficient to perform a responder analysis. 
Table 2: Patient-level data of constipation at start of study (based on BFI≥28.8), BFI at start of study, BFI at 
study completion, highest BSFS value during the study, individual responder parameters and responder 
analysis
Responder analysis
Patient Constipated 
at start 
(Y/n)
bFI 
start
bFI 
end
ΔbFI bsFs: 
highest 
type 
during 
study
patient 
achieved 
a decrease 
in bFI ≥12 
or had a 
bFI<28.8 
during 
observation 
(Y/n)
patient 
did not 
experience 
diarrhea 
(type 6 or 7) 
during the 
observation 
(Y/n)
patient 
did not 
experience 
adverse 
events due 
to laxative 
use (Y/n)
responder 
(Y/n)
1 N 7 6.7 -0.3 6 Y N Y N
2 N 6.7 3.3 -3.4 5 Y Y Y Y
3 N 0 0 0 5 Y Y Y Y
4 N 1.7 3.3 1.6 5 Y Y Y Y
5 N 20 20 0 4 Y Y Y Y
6 N 23.6 20 -3.6 5 Y Y Y Y
7 N 16 12 -4 4 Y Y Y Y
8 Y 77 43 -34 7 Y N Y N
9 Y 60 4 Y Y
10 Y 50 43 -7 6 N N Y N
11 Y 50 23 -27 6 Y N Y N
12 Y 56 30 -26 4 Y Y Y Y
13 N 0 23 23 5 Y Y Y Y
14 N 16.6 46.7 30.1 5 N Y Y N
15 Y 50 43.3 -6.7 5 N Y Y N
16 N 0 13.3 13.3 6 Y N Y N
17 Y 53 50 -3 3 N Y N N
18 N 20 20 0 5 Y Y Y Y
19 N 0 0 0 5 Y Y Y Y
20 N 0 0 0 5 Y Y Y Y
21 N 0 10 10 6 Y N Y N
22 Y 53 2 Y Y
23 N 0 3 Y Y
24 Y 77 50 -27 5 Y Y Y Y
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At the start of the observational study 38% (9/24) of patients already suffered from con-
stipation (BFI>30), constipation could even be rated as severe OIC (BFI>50). Five of these 
9 patients were using WHO-step 3 medication, 3 were using WHO-step 2 medication and 
one patient was using WHO-step 1 medication only (diclofenac+paracetamol). Despite 
the observed constipation (based on BFI) none of the patients were using laxatives on a 
regular (daily) basis as recommended in the Dutch guidelines. At study start all patients 
(constipated and non-constipated) were switched to standard laxative treatment regime 
with daily intake of PEG+electrolytes and as needed bisacodyl (orally). 
The responder analysis showed that 9 out of 21 patients (43%) were non-responders 
to SLT. Of the 7 patients with severe OIC at start of the study (BFI>50) completing the 
observation,  5 were  non-responders (71%).
Non-responsiveness was primarily due to constipation (BFI) and the development of 
diarrhea. Only one patient experienced adverse events that were clearly related to the 
laxative use according to the investigator. Based on BFI-results laxative use was not effec-
tive in 4 patients, i.e. 1 non-constipated patient developed constipation despite the use 
of laxatives and 3 constipated patients did not reach a clinically relevant improvement 
of BFI. Another problem of laxative use appeared to be the development of diarrhea (a 
BSFS type 6 or 7) in 6 patients.
Further investigation of laxative use could be performed for 20 out of 24 patients 
(83%); these patients returned patient diaries with information on laxative use (data 
missing for patient 7, 9, 22 and 23). From the returned patient diaries it could be derived 
that less than half of the patients took daily laxative intake as defined in SLT, 9 out of 20 
patients (45%) switched to laxative intake on an ‘’as needed basis” (patient 6, 8, 11, 12, 
16, 17, 18, 21 and 24). In 5 out of 9 cases this switch from “intake on a daily basis starting 
at day 1 with the opioid’’ to ‘’as needed” laxative intake’ was due to problems with daily 
laxative intake, like the development of diarrhea (4 out of 9) or adverse events caused 
by laxatives (1 out of 9). For the other 4 patients no reason for the switch to “as needed” 
laxative intake could be identified from the patient diaries. The switch to an “as needed” 
laxative intake by the patients resulted in a daily dose of PEG+electrolytes which varied 
per patient and even within patients between 0-3 sachets per day (according to the 
SmPC of PEG+electrolytes daily dose is 1-2 sachets). For the 5 patients using additional 
biacodyl the daily dose of bisacodyl varied between 5-20 mg.
DIsCussIOn
OIC is a common opioid-related side effect, which may vary between opioids, and it 
is known to have a major impact on opioid treatment, pain and quality of life, justify-
ing a strong need for clear guidance. Unfortunately, the current Dutch guidelines on 
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prophylactic laxative treatment are not helpful in this respect. The two main interpreta-
tions of the recommendations in the guidelines are: 1. Prophylactic daily intake of  a 
concomitant standard laxative regime (SLT) starting together with first opioid-intake at 
day 1 and 2. Intake of laxatives together with the opioid on an ‘’as needed basis’’ . 
This pilot study was designed to explore the impact of SLT on OIC during treatment 
with the opioid oxycodone. Only patients on oxycodone were enrolled, to avoid variation 
in results due to differences within opioids, moreover oxycodone is the most prescribed 
opioid in the Netherlands.
This pilot study shows that the efficacy of laxatives is highly variable. 43% of patients 
did not respond to the treatment with laxatives in a defined SLT regime. The percentage 
of non-responders was much higher for patients who had severe OIC (BFI>50) at study 
entry;  71% of these patients did not respond to SLT. These results are reflected in the 
literature in which 40-70% of all opioid treated patients  eventually develop OIC [19, 
41].  This suggests that SLT might not be effective for the prevention and treatment of 
OIC, however the results need to be confirmed in a clinical study with a larger number 
of patients. 
It is well-known that laxatives do not address the actual cause of OIC [37]. Laxatives 
stimulate bowel-motility in the colon, while OIC is predominantly caused by inhibition 
of the motility of the small intestine[42, 43]. This might be an explanation why, in daily 
practice, laxatives are not always effective in the prevention and treatment of OIC [18, 
41, 44, 45].
Another more common problem with laxative use is the development of laxative-
related side effects[46]. Diarrhea, one of the common side effects of laxative use, was 
also noted in this pilot study. 6 patients developed diarrhea (type 6 and 7 of the BSFS). 
When looking more closely at patients with type 5 of the BSFS, we found that 11 patients 
tended to develop diarrhea and only 6 patients had an ideal stool consistency (type 3 
and 4 of the BSFS).  Using a BSFS of 5 as cut-off value for diarrhea would result in 18 out 
of 24 patients (75%) being classified as non-responders to laxative treatment. 
Moreover, in this pilot study 45% of patients switched from daily laxative intake in the 
SLT to ” as needed” laxative intake. In half of the patients switching from ‘’daily intake’’ 
to an ‘’as needed intake’’ the development of diarrhea and other adverse events were 
responsible for this switch. Interestingly, the development of diarrhea was already 
anticipated in the guidelines; laxative treatment could potentially result in the develop-
ment of diarrhea resulting in lowering or skipping of laxative dosages[19].
Although evidence is limited for laxatives in the treatment and prevention of OIC, 
laxatives are still considered a first-line treatment for OIC because of their accessibility, 
safety and low costs[12, 21]. This pilot study adds to already present data that laxatives 
might not be adequate for the prevention and treatment of OIC[47].  A more pharmaco-
logical treatment approach targeting the opioid receptors with opioid antagonists (e.g. 
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oxycodone/naloxone, methylnaltrexone and naloxegol) might be a good alternative for 
the treatment and prevention of OIC[12, 21, 22].
A limitation of this pilot study is the  exploratory nature of the study. In order to design 
a clinical trial investigating prevention of OIC with a defined SLT taken concomitantly 
with opioid intake from day 1 some information is required concerning efficacy of this 
SLT regime. However, existing clinical trials are sparse and inconclusive necessitating a 
pilot study investigating the efficacy of SLT.  
Another limitation of this pilot study was the impeded recruitment of patients. This 
might be caused by a resistance of physicians to treat patients with SLT. For most pa-
tients an ‘’as needed’’ laxative treatment was expected to be more appropriate to treat 
and prevent OIC. Slow patient inclusion has been described before in studies address-
ing laxative regimens. In 2009 de Graeff et al. started a project to assess the efficacy 
of two laxatives (polyethylene glycol (PEG) with electrolytes versus magnesium(hydr)
oxide) on the prevention of OIC. This project was terminated early due to insufficient 
patient recruitment (5 patients in 1.5 years) (source: http://www.zonmw.nl/nl/projecten/
project-detail/preventie-van-obstipatie-bij-gebruik-van-opioiden-magnesiumhydrox-
ide-versus-macrogolelektrolyte/voortgang/). This illustrates that patient recruitment is 
a problem in studies investigating the efficacy of defined SLT for the prevention of OIC.
COnClusIOn
In conclusion, this pilot study indicates that optimal laxative therapy (SLT), as defined by 
intake of laxatives starting on day 1 together with the opioid, might not be effective and 
feasible for the prevention and treatment of OIC. The responder analysis showed that 
43% of patients were non-responders to SLT and results suggested that responder rate 
was even lower (71%) in patients with severe OIC (BFI>50). When taking into consider-
ation patients tending to develop diarrhea 75% of patients are non-responsive to SLT. 
These results show that a larger clinical study is warranted investigating  the efficacy and 
tolerability of SLT for the prevention and treatment of OIC.
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absTRaCT
background
Opioid-induced constipation (OIC) is a common and dominant adverse effect of opioid 
treatment. Current treatment standards of OIC advice general non-pharmacological 
measures, like dietary advices and exercise, and the treatment with non-specific laxatives 
like bisacodyl, poly ethylene glycol with electrolytes and lactulose. Over the last decade 
peripherally acting mu-opioid receptor antagonists (PAMORAs) and other agents have 
been developed for the treatment and prevention of OIC. Currently approved agents by 
the European Medicines Agency (EMA) for OIC are methylnaltrexone (MNTX), naloxegol, 
alvimopan, naldemedine and prolonged release oxycodone/naloxone (PR OXN).
Objectives
As the number of PAMORAs increase it is important to explore their efficacy not only in 
randomized controlled trials but also in real-life settings and when possible explore their 
efficacy in comparison to each other. Therefore we performed a systematic literature 
review to describe the current evidence for the efficacy of opioid receptor antagonists 
in the treatment of opioid induced constipation caused by opioid treatment in patients 
with chronic pain.
methods
A systematic review and analysis in accordance with the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) guidelines was performed. Medline, 
the Cochrane Central Register of Controlled Trials, Embase, Web of Science and Google 
Scholar were searched, without language restrictions. Included studies were random-
ized controlled trials as well as prospective observational studies, we excluded animal 
studies, review studies and retrospective analyses.
selection criteria
The studied population was adult patients on opioids for treatment of pain. The inter-
ventions used should be peripherally acting (locally or non-systemically acting) opioid 
receptor antagonists (like oxycodone/naloxone combinations, methylnaltrexone, nalox-
egol, alvimopan and other PAMORA’s). Exclusion criteria were studies including subjects 
treated for addiction in methadone maintenance programs or with buprenorphine/
naloxone combinations, studies on healthy volunteers with opiate- or opioid-related 
constipation as a model to mimic the condition of patients on opioids, animal studies 
and basic laboratory-based research.
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Data collection and analysis
For the data synthesis and the statistical analysis Review Manager (RevMan) and the 
GRADEpro Guideline Development Tool were used.
main results
We included 57 articles in the meta-analysis clustered them based on unique studies, 
as for some studies multiple papers appeared. This resulted in the identification of 38 
unique studies (13 RCTs and 25 observational studies). For all unique studies outcomes 
were extracted. The proportion of patients obtaining normal bowel function (according 
to ROME-3 criteria) was evaluated in 12 RCTs (2 naloxegol, 2 PR OXN, 2 MNTX, 3 alvimo-
pan and 3 naldemedine RCTs). In these trials, 2812 patients received a drug and 2042 
received control treatment. Treatment with opioid antagonists resulted in a statistically 
significant improvement of bowel function compared with rescue laxative use when 
looking at the proportion of patients with normal bowel movements according to ROME 
3-criteria  (RR:1.56; 95% CI 1.37-1.76; P<0.00001), although there was significant hetero-
geneity between the RCTs. The quality of the evidence varied from low too high, overall 
the risk difference of the proportion of patients with normal bowel function on opioid 
antagonist treatment was 206 (136 to 280) more per 1,000 treated patients. Besides the 
proportion of patients with normal bowel function all other assessed parameters were 
in favor of opioid antagonist treatment.
Analysis of observational study data showed that the vast majority of observational 
study data were generated for PR OXN. For PR OXN 15 studies were identified that 
included patients with OIC at study start (n=17085). The studies mainly differed in the 
included pain population (e.g. non-malignant pain, malignant pain, elderly, neuropathic 
pain and laxative refractory pain patients), resulting in considerable heterogeneity. 
Despite the heterogeneity the mean weighted improvement in BFI was -29.22 95 % CI 
[-35.22, -23.22] (p<0.00001) similar to the improvement seen in the RCTs  -27.4  95%CI 
[ -19.1 to -35.7]. Another 10 studies with PR OXN were identified that included patients 
without OIC at study start (n=4693). The mean weighted improvement was -3.38 95% 
CI [-10.37, 3.61]. The studies differed substantially, mainly in the included pain popula-
tion (e.g. non-malignant pain, malignant pain, elderly, neuropathic pain and laxative 
refractory pain patients), resulting in considerable heterogeneity (I2=96%, Chi2=215.39, 
df=9).
Conclusion
Opioid antagonists, have been approved for the treatment of opioid induced constipa-
tion for a decade (first approval in EU dating from 2008 for PR OXN and MNTX). Despite 
approval and growing consensus with regard to using these agents in clinical practice 
the uptake in formal guidelines is still minimal. Together with the study by Nee et al. 2018 
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(describing the safety and efficacy with regard to non-responders on opioid antagonists) 
this study provides further evidence on the efficacy with respect to bowel function and 
pain of opioid antagonists, like naloxegol, alvimopan, naldemedine, PR OXN and MNTX, 
in the treatment of OIC in patients with opioid treatment for chronic pain.  
baCkgROunD  
Opioid-induced constipation (OIC) is a common and dominant adverse effect of opioid 
treatment affecting up to 80% of patients treated with opioids1-4. OIC is frequently re-
ported to be the most bothersome side effect associated with opioid therapy 2,5-7. OIC 
has a negative impact on patients’ quality of life, and has also been shown to be associ-
ated with lower work productivity, absenteeism and significant utilization of healthcare 
resources2,6-9.
In the gastro-intestinal (GI) tract mu-opioid receptors are located throughout the 
entire enteral nervous system10,11. At a physiological level opioids cause inhibition of GI 
emptying by delaying GI transit, stimulating nonpropulsive motor activity, increasing 
intestinal tone, increasing fluid absorption by prolonging contact time, and decreas-
ing the secretion of electrolytes and water into the intestinal lumen.10-12. Pancreatic, 
biliary, and intestinal secretions are depressed by opioid administration. The combined 
inhi bition of intestinal fluid secretion and the enhancement of absorption contribute 
to the constipating effect of opioids11,12. At the tissue level, opioids exert effects on 
the smooth muscle located along the GI tract4,11,12. At the molecular level  binding of 
opioids to GI-localized mu-opioid receptors inhibits gut motility. Opioids inhibit the 
firing of secretomotor and submucosal neurons as well as the release of vesicular-stored 
presynaptic neurotransmitters from these neurons11,12. Opioids inhibit the effects of 
the autonomic nervous system on GI smooth muscle and, thereby, decrease propulsive 
motility along the GI tracts11,12. Opioids further suppress GI motility by increasing auto-
nomic nervous system sympathetic activity, which is mediated by enhanced release of 
vesicular-stored norepinephrine (noradrenaline) that subsequently acts on presynaptic 
α2-adrenoceptors located on enteric neurons11,12. The combined inhibition of enteric 
nerve activity, inhibition of propulsive motor activity and the inhibition of ion and fluid 
secretion all contribute to the development of constipation by opioid analgesics11,12.
Current treatment standards and guidelines of OIC advice general non-pharmaco-
logical measures, like dietary advices and exercise, and the treatment with non-specific 
laxatives like bisacodyl, poly ethylene glycol with electrolytes and lactulose. However, 
about half of all opioid treated patients requiring laxatives do not achieve satisfactory 
relief from OIC, as most used laxative treatments for OIC are non-specific and do not 
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target the underlying cause of OIC13-15. Furthermore, laxatives themselves may lead to 
gastrointestinal adverse events and complications4,13,15. 
Over the last decade peripherally acting mu-opioid receptor antagonists (PAMORAs) 
and other locally, non-systemically acting agents have been developed for the treatment 
and prevention of OIC. In this review PAMORAs like methylnaltrexone (MNTX), naloxegol, 
alvimopan and naldemedine were considered as was as the locally, non-systemically 
acting prolonged release combination of oxycodone and naloxone (PR OXN)12.  
Peripherally-acting opioid receptor antagonists and the prolonged release combina-
tion of oxycodone and naloxone (PR OXN)  block opioid actions at peripheral opioid 
receptors that mediate decreased intestinal secretion and propulsive colonic motil-
ity10,12. By blocking μ-opioid receptors in the gut, there is restoration of the function 
of the enteric nervous system, and propulsive motility and secretory functions can be 
generated by local enteric neural circuits in response to physiologic stimuli such as meal 
ingestion, or sensation of a bolus to evoke normal peristalsis10,12.
As the number of PAMORAs increase it is important to explore their efficacy not only in 
randomized controlled trials but also in real-life settings and when possible explore their 
efficacy in comparison to each other. Therefore we performed a systematic literature 
review to describe the current evidence for the efficacy of opioid receptor antagonist 
in the treatment of opioid induced constipation caused by opioid treatment in patients 
with pain. The review questions of this publication is: What is the efficacy of opioid an-
tagonists and PAMORA’s with regard to improvement of OIC? Also the efficacy in special 
subgroups (e.g. laxative-refractory patients) was assessed when available.
meThODs
We conducted the systematic review and analysis in accordance with the PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines16.
Data sources and searches
We searched Medline, the Cochrane Central Register of Controlled Trials, Embase, Web 
of Science and Google Scholar from inception to August 4th 2016, without language 
restrictions. The search strings for the different databases are depicted in table 1. We 
also manually checked reference lists of the identified reports and relevant reviews to 
identify potentially eligible articles. On February 8th, 2018 a PubMed search was per-
formed searching published papers between August 4th 2016 to February 8th, 2018 to 
identify new RCT’s using the PubMed search string depicted in table 1.
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study selection
Two reviewers (G. K. and Y. v. M.) independently assessed the eligibility of studies. Dis-
crepancies, if any, were resolved by consensus by a third independent investigator (F.H.). 
Included studies were randomized controlled trials as well as prospective observational 
studies, we excluded animal studies, review studies and retrospective analyses. The 
prospective observational studies were divided in studies with prospective control arms 
and studies without control arms. All studies had to comply with predefined in- and 
exclusion criteria. 
Table 1: Overview of used search strings per database.
Database search string
Embase.com (‘narcotic analgesic agent’/exp OR (buprenorphine* OR fentanyl* OR hydromorphone* 
OR morphine* OR opioid* OR opiate* OR oxycodone* OR tapentadol* OR tramadol* OR 
(narcotic* NEXT/1 analgesic*)):ab,ti) anD (‘constipation’/mj OR (constipat* OR obstipat* OR 
((bowel* OR intestin*) NEAR/3 (function* OR dysfunction*))):ab,ti) anD (‘opiate antagonist’/
exp OR (((opioid* OR opiate*) NEAR/4 (antagonist*)) OR alvimopan* OR methylnaltrexone* 
OR naloxegol* OR naloxone* OR PAMORA*):ab,ti) nOT ([animals]/lim NOT [humans]/lim) nOT 
(‘conference abstracts’/it)
Medline 
Epub (Ovid)
(exp “Analgesics, Opioid”/ OR exp “Morphinans”/ OR “Fentanyl”/ OR “Tramadol”/ OR 
(buprenorphine* OR fentanyl* OR hydromorphone* OR morphine* OR opioid* OR opiate* 
OR oxycodone* OR tapentadol* OR tramadol* OR (narcotic* ADJ1 analgesic*)).ab,ti.) AND 
(“Constipation”/ OR (constipat* OR obstipat* OR ((bowel* OR intestin*) ADJ3 (function* 
OR dysfunction*))).ab,ti.) AND (exp “Narcotic Antagonists”/ OR (((opioid* OR opiate*) ADJ4 
(antagonist*)) OR alvimopan* OR methylnaltrexone* OR naloxegol* OR naloxone* OR 
PAMORA*).ab,ti.) nOT (animals NOT humans).sh. nOT (abstracts).pt.
Cochrane 
Central
(buprenorphine* OR fentanyl* OR hydromorphone* OR morphine* OR opioid* OR opiate* 
OR oxycodone* OR tapentadol* OR tramadol* (narcotic* NEXT/1 analgesic*)):ab,ti AND 
(constipat* OR obstipat* OR ((bowel* OR intestin*) NEAR/3 (function* OR dysfunction*))):ab,ti 
AND (((opioid* OR opiate*) NEAR/4 (antagonist*)) OR alvimopan* OR methylnaltrexone* OR 
naloxegol* OR naloxone* OR PAMORA*):ab,ti
Web of 
Science
Ts=((buprenorphine* OR fentanyl* OR hydromorphone* OR morphine* OR opioid* OR opiate* 
OR oxycodone* OR tapentadol* OR tramadol* (narcotic* NEAR/1 analgesic*)) anD (constipat* 
OR obstipat* OR ((bowel* OR intestin*) NEAR/2 (function* OR dysfunction*))) anD (((opioid* 
OR opiate*) NEAR/3 (antagonist*)) OR alvimopan* OR methylnaltrexone* OR naloxegol* OR 
naloxone* OR PAMORA*) nOT (animal* OR mice OR mouse OR rat OR rats nOT (human* OR 
patient*))) anD DT=(Article)
Google 
Scholar
buprenorphine|fentanyl|hydromorphone|morphine|opioid|opiate|oxycodone|tapentadol|tram
adol constipation|obstipation|”bowel|intestine function|dysfunction” antagonist|alvimopan|me
thylnaltrexone|naloxegol|naloxone|PAMORA
Additional 
PubMed 
search Feb 
8th
(buprenorphine*[tiab] OR fentanyl*[tiab] OR hydromorphone*[tiab] OR morphine*[tiab] OR 
opioid*[tiab] OR opiate*[tiab] OR oxycodone*[tiab] OR tapentadol*[tiab] OR tramadol*[tiab])  
AND ((constipat*[tiab]  OR obstipat*[tiab]) OR ((bowel*[tiab] OR intestin*[tiab]) AND 
(function*[tiab] OR dysfunction*))) AND (alvimopan*[tiab] OR methylnaltrexone*[tiab] 
OR naloxegol*[tiab] OR naloxone*[tiab] OR naltrexone*[tiab] OR naldemedine*[tiab] OR 
PAMORA*[tiab]) NOT (animals[mesh] NOT humans[mesh])
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study in- and exclusion criteria
Included studies had to comply with the following inclusion criteria. The studied popu-
lation was adult patients on opioids for treatment of pain. The sample size (n) of each 
arm (or no. of included patients in case of uncontrolled studies) was set at n≥10. The 
interventions used should be peripherally acting (locally or non-systemically acting) 
opioid receptor antagonists (like opioid/naloxone combinations (PR OXN), methyln-
altrexone (MNTX), naloxegol, alvimopan and other PAMORA’s). Exclusion criteria were 
studies including subjects treated for addiction in methadone maintenance programs 
or with buprenorphine/naloxone combination, studies on healthy volunteers with opi-
ate- or opioid-related constipation as a model to mimic the condition of patients on 
opioids, animal studies and basic laboratory-based research as well as studies with a 
group size of <10.
Outcome measures
The primary endpoint was opioid induced constipation (OIC). There is not one specific 
measure for OIC. A systematic review and consensus article by Gaertner et al.17 has sug-
gested that when measuring OIC a combination of outcomes should be measured, 
consisting of objective outcome measures, patient reported outcome measures and 
patient-reported global burden measures of OIC. Therefore the measures evaluated 
when looking at OIC consisted of a) objective measures of bowel movements (e.g. pro-
portion of patients with normal bowel function based on ROME-3 criteria, complete 
spontaneous bowel movements [CSBM], spontaneous bowel movements [SBMs], 
rescue medication free bowel movements [RFBM], and bowel movements [BM], time 
to laxation, transit time, laxation within 4 hours and Brsitol Stool Form Scale [BSFS]) b) 
patient reported outcome measures (like Bowel Function Index [BFI], Patient Assess-
ment of Constipation-symptom score [PAC-SYM], Global Clinical Impression of Change 
[GCIC]) c) patient-reported global burden measures of OIC (like Patient Assessment of 
Constipation-Quality of Life [PAC-QoL] and constipation distress)  and d) additional laxa-
tive use. Secondary endpoint of the systematic search was pain relief measured with 
scales like Numeric Rating Scale (NRS), Numeric Analogue Scale (NAS), Verbal Rating 
Scale (VRS) or Verbal Analogue Scale (VAS). 
Data extraction and Quality assessment 
The predetermined outcome measures were extracted from each included study. The 
following items were recorded per study: registry number; registry number of extension 
study; treatment groups; study sample size; length of follow-up; and relevant patient 
characteristics including age, sex, predominant indication of pain. Two reviewers 
independently evaluated the potential risk of bias of each trial according to the GRADE-
evaluation systematic.
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Data synthesis and statistical analysis
For the data synthesis and the statistical analysis Review Manager (RevMan) [Computer 
program]. (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Col-
laboration, 2014) and the GRADEpro Guideline Development Tool [Software] (McMaster 
University, 2015, developed by Evidence Prime, Inc.., Available from gradepro.org) were 
used. As all data were prospectively generated relative risks (RR), were used as sum-
mary statistics for binary variables, resulting in more easily interpretable data. Weighted 
(standardized) mean differences (WMDs) were effect estimates for continuous variables. 
The RR with a 95% CI as well as the  W(S)MDs with 95% were derived from published 
study data. No enquiries for missing variables were performed. . 
RCTs and prospective observational studies were analyzed separately. Not all out-
comes were present in all studies. Only outcomes that were identified for multiple 
substance were compared. Pooled analyses were calculated with fixed-effect models 
(Mantel–Haenszel method) or random-effect models (DerSimonian and Laird) accord-
ing to the extent of heterogeneity. Heterogeneity was assessed with the I2 statistic and 
the Chi2-test (Cochran Q-test). A p-value < 0.10 indicates significant heterogeneity and 
I-squared of 0% to 40%, 30% to 60%, 50% to 90% and 75% to 100% represent heteroge-
neity that might not be important, moderate heterogeneity, substantial heterogeneity 
and considerable heterogeneity, respectively. To test the robustness of the findings, we 
performed, when available, subgroup analyses on laxative refractory patients. Publica-
tion bias was assessed visually by performing Funnel plot analyses.
ResulTs
study selection and Characteristics
The systematic literature review identified 1279 unique citations and the  additional lit-
erature check in PubMed on February 8th retrieved another 77 citations resulting in 1356 
citations of which the title/abstracts (tiab) were independently scanned by 2 researchers 
as described by Bramer et al. 2017 using EndNote18. 1004 abstracts were dismissed by 
both reviewers and another 54 articles were discussed between both authors and there-
after dismissed. Resulting in 1058 excluded citations. The resulting 298 articles were 
reviewed again on article type. A further 226 articles were dismissed for being review 
articles, articles that were not in English or German, articles that were cost-effectiveness 
studies or articles that were abstracts presented on congresses. Together this resulted in 
the definite inclusion of 72 articles in the systematic review (Figure 1)4,15,19-89. Although 
sample size was part of the inclusion and exclusion parameters none of the studies were 
dismissed solely based on this criterion. 
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All 72 articles that were labelled as defi nite inclusion were uploaded in Review Man-
ager (version 5.3) and clustered based on unique studies, as for some studies multiple 
papers appeared. This resulted in the identifi cation of 44 unique studies (21 RCTs and 
23 observational studies). For all unique studies outcomes were extracted. Detailed 
baseline characteristics as well as risk of bias assessment of included RCTs are presented 
in Table 2.
Figure 1: Flow diagram of studies identifi ed, excluded, and fi nally included for the meta-analysis. 
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Table 2: Baseline characteristics and risk of bias assessment of included RCTs
study
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Naloxegol
KODIAC-04 NCT01309841 Australia, Ger-
many, Slovakia, 
United States, 
115 centers, 
outpatient
non-cancer-
related pain, 
history of OIC 
(back pain 
56.0%)
<3 spontaneous bowel movements 
(SBMs)/week and at least 1 OIC associ-
ated symptom at screening and had a 
confirmed diagnosis of OIC. Confirmed 
OIC was defined as: documented <3 
SBMs/week on average over the 2-week 
OIC confirmation period. In addition to 
the SBM frequency criterion, patients 
must have reported ≥1 of the following 
symptoms in at least 25% of the bowel 
movements (BMs) recorded in the  lec-
tronic diary during the OIC confirmation 
period: Bristol Stool Scale stool type 1 or 
2; moderate,severe, or very severe strain-
ing; incomplete BM. 
641 
(61.3%)
12 weeks 
(open label 
extension 
data avail-
able)
KODIAC-05 NCT01323790 Belgium, 
Croatia, Czech 
Republic, 
Hungary, Spain, 
Sweden, United 
Kingdom, and 
the United 
States (US), 
142 centers, 
outpatient
non-cancer-
related pain, 
history of OIC 
(back pain 
56.8%)
<3 spontaneous bowel movements 
(SBMs)/week and at least 1 OIC associ-
ated symptom at screening and had a 
confirmed diagnosis of OIC. Confirmed 
OIC was defined as: documented <3 
SBMs/week on average over the 2-week 
OIC confirmation period. In addition to 
the SBM frequency criterion, patients 
must have reported ≥1 of the following 
symptoms in at least 25% of the bowel 
movements (BMs) recorded in the  lec-
tronic diary during the OIC confirmation 
period: Bristol Stool Scale stool type 1 or 
2; moderate,severe, or very severe strain-
ing; incomplete BM. 
696 
(63.4%)
12 weeks 
(open label 
extension 
data avail-
able)
Naloxone (OXN)
OXN2001 NCT00513656 UK, 1 center, 
outpatient
diagnosis 
of cancer and 
a documented 
history of 
moderate/ 
severe, chronic 
cancer pain.
(breast 
(19%), lung 
(13%) and 
prostate (10%) 
cancer)
No criteria for OIC at inclusion 184 
(49%)
4 weeks 
(open label 
extension 
available)
OXN10-KR-002 NCT01313780 Korea, 7 cen-
ters, outpatient
moderate to 
severe cancer- 
related pain 
(colorectal 
cancer, 40.9%)
No criteria for OIC at inclusion 117 
(29.9%)
4 weeks
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-response rate 
with respect 
to bowel 
function 
-rescue laxa-
tive use 
-change from 
baseline num-
ber of SBMs 
per week 
-PAC-SYM 
score 
-pain relief
Response rate defined as 
three or more spontaneous 
bowel movements (bowel 
movements without the use 
of rescue laxative treatment 
in the previous 24 hours) per 
week and an increase of one 
or more spontaneous bowel 
movements over baseline 
for at least 9 of 12 treatment 
weeks and at least 3 of the 
final 4 treatment weeks.
*Chey 2014, 
Coyne 2017, 
Holzer 2015, 
Lawson 
2016, Tack 
2015, Web-
ster 2014, 
Webster 
2017
LOW LOW LOW LOW LOW LOW LOW
-response rate 
with respect 
to bowel 
function 
-rescue laxa-
tive use 
-change from 
baseline num-
ber of SBMs 
per week
Response rate defined as 
three or more spontaneous 
bowel movements (bowel 
movements without the use 
of rescue laxative treatment 
in the previous 24 hours) per 
week and an increase of one 
or more spontaneous bowel 
movements over baseline 
for at least 9 of 12 treatment 
weeks and at least 3 of the 
final 4 treatment weeks.
*Chey 2014, 
Coyne 2017, 
Lawson 
2016, Tack 
2015, Web-
ster 2014, 
Webster 
2017
LOW LOW LOW LOW LOW LOW LOW
-Bowel Func-
tion Index 
(BFI-score) 
-PAC-SYM 
total score 
-pain relief 
 
The null hypothesis for BFI 
was a zero difference 
(on average) between treat-
ment groups at the final 
visit. The 
null hypothesis for BPI-SF was 
a difference of -1 (on average) 
between treatment groups at 
the final visit, in favour 
of Oxy PR (OXN PR inferior to 
OxyPR).
*Ahmedzai 
2012, 
Ahmedzai 
2014, Koop-
mans 2014
LOW LOW LOW LOW HIGH LOW LOW
-pain relief Change of pain intensity Lee 2017 LOW LOW LOW LOW LOW LOW LOW
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Table 2: Baseline characteristics and risk of bias assessment of included RCTs (continued)
study
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OXN3001 NCT00412152 UK, Gemany, 
Spain, Czech 
Republic, 93 
sites, outpa-
tient
moderate-to-
severe noncan-
cer pain and 
constipation 
caused or ag-
grevated by an 
opioid (82.9% 
musculo-skele-
tal pain)
Citeria for constipation caused or ag-
grevated by an opioid not defined in 
publication
316 
(unpub-
lished)
12 weeks 
(open label 
extension 
data avail-
able)
OXN3006 NCTO0412100 Germany, 
Czech Repub-
lic, Finland, 
Hungary, 
Netherlands, 
UK, Spain, 
172 centers, 
outpatient
moderate-
to-severe, 
non-malignant 
pain and 
constipation (< 
3 CSBMs/ week) 
caused or 
aggrevated by 
opioid therapy 
(back pain 
61%) 
constipation defined as <3 CSBMs/week 265 
(68.3%)
12 weeks 
(open label 
extension 
data avail-
able)
OXN3506 NCT01438567 Australia, Czech 
Republick, 
Denmark, 
Finland, France, 
Germany, Israel, 
Poland, Ro-
mania, South 
Korea and UK, 
66 centers, 
outpatient
cancer and 
non-cancer 
pain suffering 
from opioid-
induced consti-
pation caused 
or aggrevated 
by opioids. 
Constipation caused or aggravated by 
opioids was confirmed by the patient 
and the investigator as an effect of the 
patient’s pre-study opioid medication 
(at a comparable dose) and evidenced 
by a medical need of regular intake of 
laxatives to have at least three bowel 
evacuations per week or by having less 
than three bowel evacuations when not 
taking a laxative
243 
(58.8%)
5 weeks 
(open label 
extension 
data avail-
able)
Kokki 2017 NCT02573922 Finland, 1 
center, spinal 
surgery
patients 
scheduled to 
have an 
elective lumbar 
or cervical 
spinal surgery 
(spinal surgery, 
100%)
No criteria for OIC at inclusion 180 
(45%)
3 weeks
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-Bowel Func-
tion Index 
(BFI-score) 
-proportion of 
patients with 
laxative use 
-PAC-SYM 
total score 
-proportion 
of patients 
with normal 
number of 
CSBMs (≥3/
week) 
-pain relief
improvement in constipation 
as measured 
using the Bowel Function 
Index (BFI)
Blagden 
2014, Koop-
mans 2014, 
Löwenstein 
2010, 
Sandner-
Kiesling 
2010, *Simp-
son 2008
HIGH HIGH LOW LOW HIGH LOW LOW
-Bowel Func-
tion Index 
(BFI-score) 
-proportion of 
patients with 
laxative use 
-PAC-SYM 
total score 
-proportion 
of patients 
with normal 
number of 
CSBMs (≥3/
week) 
improvements in symptoms 
of constipation, as measured 
by 
the Bowel Function Index (BFI)
Blagden 
2014, Koop-
mans 2014, 
Löwenstein 
2010, 
*Löwenstein 
2009
LOW HIGH LOW LOW HIGH LOW LOW
-Bowel Func-
tion Index 
(BFI-score) 
-pain relief
improvement in symptoms of 
constipation as mea- 
sured by the Bowel Function 
Index (BFI)non-inferiority of 
OXN PR com- 
pared with OxyPR with 
respect to the analgesic effi- 
cacy
*Dupoiron 
2017a, 
Dupoiron 
2017b
LOW LOW LOW LOW UN-
CLEAR
UN-
CLEAR
LOW
-proportion of 
patients with 
laxative use
prevalence of constipation at 
7 days after 
surgery
Kokki 2017 LOW LOW HIGH HIGH LOW LOW LOW
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Table 2: Baseline characteristics and risk of bias assessment of included RCTs (continued)
study
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methylnaltrexone (MNTX) 
Michna 2011 NCT00529087 US, 78 centers, 
outpatient
chronic non-
malignant pain 
and a history 
of constipation 
due to opioid 
use and fewer 
than 3 RFBMs 
per 
week (back 
pain, 60.4%)
Constipation during the screening 
period was defined as fewer than 3 
RFBMs per week (no laxative use within 
24 hours prior to any bowel movement) 
that were associated with one or more of 
the following: a) a Bristol StoolFormScale 
score of 1 or 2 for at least 25% of the 
bowel movements; b) straining during at 
least 25% of the bowel movements; c) a 
sensation of incomplete evacuation after 
at least 25% of the bowel movements.
460 
(60.2%)
4 weeks
Rauck 2017 NCT01186770 US, 117 centers, 
outpatient
chronic non-
malignant pain 
and a history of 
OIC (back pain, 
68.2%)
OIC defined as having < 3 rescue-free 
bowel movements (RFBMs) per week 
that were associated with ≥ 1 of the fol-
lowing: ≥ 25% of RFBMs categorized as 
type 1 or type 2 on theBristol Stool Form 
Scale; straining during ≥ 25% of RFBMs 
or ≥ 25% of RFBMs with a sensation of 
incomplete evacuation.
803 
(62.9%)
4  weeks, 
extended 
with 8 
weeks (4 
weeks 
results pre-
sented)
study 4000/4001 NCT00672477 
and 
NCT00672139
US, Australia, 
Belgium, Brazil, 
Canada, France, 
Germany, Italy, 
Mexico, Spain, 
Sweden, UK, 
60, outpatient
advanced 
illness (defined 
as a terminal 
illness [e.g., 
incurable 
cancer or other 
end-stage dis-
ease]), a life 
expectancy 
of ≥ 1 month, 
and OIC and 
were receiving 
stable doses of 
laxatives and 
opioids (cancer 
66.0%)
OIC defined as < 3 bowel movements in 
the last week and no bowel movement 
in 24 hours or no bowel movement in 
48 hours
230 
(48.7%)
2 weeks 
(10 weeks 
open label 
extension) 
(4 week 
results pre-
sented)
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- RFBMs 
within 4 hrs of 
first dose 
-RFBMs within 
24 hrs of first 
dose 
-No. of 
RFBMs/week 
-Rescue laxa-
tive use 
-Proportion of 
patients with 
normal bowel 
function 
-PAC-SYM 
score 
-pain relief
1) the proportion of subjects 
having a rescue-free 
bowel movement (RFBM) 
within 4 hours of the first 
dose, and 
2) the percentage of active 
injections resulting in any 
RFBM 
within 4 hours
*Michna 
2011, Iyer 
2011
LOW LOW LOW LOW UN-
CLEAR
UN-
CLEAR
LOW
- RFBMs 
within 4 hrs of 
first dose 
-No. of 
RFBMs/week
mean percentage of dosing 
days that resulted in an RFBM 
within 4 hours of dosing dur-
ing weeks 1 to 4
Rauck 2017 LOW LOW LOW LOW LOW LOW LOW
- RFBMs 
within 4 hrs of 
first dose 
-No. of 
RFBMs/week 
-Rescue laxa-
tive use
percentage of 
patients with a rescue-free 
bowel movement (RFBM) 
within 
four hours after ‡ 2 of the first 
4 doses (i.e., the first week of 
treatment).RFBMwas defined 
as a bowel movement without 
use of any rescue medication 
or procedure within four 
hours 
before the bowel movement.
Bull 2015 LOW UN-
CLEAR
LOW LOW HIGH LOW LOW
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Table 2: Baseline characteristics and risk of bias assessment of included RCTs (continued)
study
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Thomas 2008 NCT00402038 US, Canada, 
27 , nursing 
homes, hospice 
sites, and 
palliative care 
centers.
advanced ill-
ness, which 
was defined 
as a terminal 
disease (incur-
able can- 
cer or other 
end-stage dis-
ease) with a life 
expectancy and 
OIC (cancer, 
58.2%)
opioid-induced constipation with either 
fewer than three laxations during the 
preceding week and no clinically mean-
ingful laxation (as determined by the 
investigator) within 24 hours before the 
first study dose or no 
clinically meaningful laxation within 48 
hours before the first study dose.
134 
(56.7%)
2 weeks 
(3 month 
open label 
extension)
MNTX 301 NCT00401362 US, 17 centers, 
hospices and 
palliative care 
centers
advanced 
illness (life ex-
pectancy of 1-6 
months) and 
OIC (cancer, 
81.2%)
No clinically signifcant laxation within 48 
hours prior to the frst study drug dose
154 
(45.5%)
single-
dose, 28 
day open-
label and 
3 month 
extension
Alvimopan
Paulson 2005   US, 22 centers, 
secondary and 
tertiary care
Patients on 
opioid therapy 
(88% chronic 
pain) with OIC 
(back pain, 
38.7%)
<3 bowel movements per week without 
laxative use or enemas and at least one 
associated symptom: lumpy or hard 
stools, straining, sensation of anorectal 
obstruction, or sensation of incomplete 
evacuation
168 
(58.3%)
3 weeks
SB767905/011   Australia, Ger-
many, Greece, 
Italy, Portugal, 
US, Belgium, 
Canada, 
Denmark, 113 
centers, outpa-
tients 
bowel dysfunc- 
tion resulting 
from chronic 
opioid treat-
ment for the 
manage- 
ment of pain of 
a non-cancer 
origin (back 
pain, 58.2%)
history of decreased bowel movement 
frequency since initiating opioid therapy 
and ≥1of the following symptoms: 
incomplete evacuation, hard stools, or 
straining, in ≥25% of bowel movements
522 
(63.8%)
6 weeks
SB-767905/012   US, Canada, 
Europe, 148 
centers, stand-
alone research 
centers, pain 
centers, and 
non-pain 
practice exter-
nal research 
centers.
persistent non-
cancer pain 
and a recalled 
history of 
opioid-induced 
bowel dysfunc-
tion (back pain, 
59%)
<3 spontaneous BMs (SBMs) per week 
and occurrence of at 
least 1 of the following symptoms for 
$25% of BMs— 
sense of incomplete evacuation after 
passing a stool, 
straining to pass a stool, or lumpy hard 
stools, or small 
pellets.
518 
(63%)
12 weeks
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O
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er
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s
- RFBMs 
within 4 hrs of 
first dose 
-RFBMs within 
24 hrs of first 
dose 
-Proportion of 
patients with 
normal bowel 
function 
-pain relief
proportion of patients with 
rescue-free 
laxation within 4 hours after 
the first dose of the 
study drug and the propor-
tion of patients with 
rescue-free laxation within 4 
hours after two or 
more of the first four doses.
Thomas 
2008
LOW LOW LOW LOW HIGH LOW LOW
- RFBMs 
within 4 hrs of 
first dose 
-RFBMs within 
24 hrs of first 
dose 
-pain relief
proportion of patients with 
laxation within 4 hours after 
administration of the double- 
blind dose.
Nalamachu 
2015, *Slat-
kin 2009
LOW LOW LOW LOW UN-
CLEAR
UN-
CLEAR
LOW
-number of 
bowel move-
ments per 
week 
-pain relief
proportion of 
patients with at least 1 BM 
within 8 hours of study 
drug administration on each 
day during the 21-day 
treatment period, averaged 
across all patients.
Paulson 
2005
LOW LOW LOW LOW UN-
CLEAR
UN-
CLEAR
LOW
-Proportion of 
patients with 
normal bowel 
function 
-number of 
bowel move-
ments per 
week
change in weekly spon- 
taneous bowel movement 
frequency during the first 3 
weeks of 
the 6-week treatment period.
Webster 
2008
LOW UN-
CLEAR
LOW LOW UN-
CLEAR
LOW LOW
-Proportion of 
patients with 
normal bowel 
function 
-number of 
bowel move-
ments per 
week 
-proportion of 
patients using 
concomittant 
laxatives
proportion of ‘responders’, 
with responder defined as 
a patient experiencing 3 or 
more SBMs per week over the 
treatment period and an aver-
age increase from  baseline of 
at least 1 SBM per week.
Jansen 2011 LOW UN-
CLEAR
LOW LOW HIGH UN-
CLEAR
LOW
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Table 2: Baseline characteristics and risk of bias assessment of included RCTs (continued)
study
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SB-767905/013   US, Canada, 
Europe, 153 
centers, non–
pain-practice 
research center 
extensions of 
clinical sites, 
research cen-
ters, and  pain 
centers
persistent non-
cancer pain 
and a recalled 
history of 
opioid-induced 
bowel dysfunc-
tion (back pain, 
60%)
<3 spontaneous BMs (SBMs) per week 
and occurrence of at 
least 1 of the following symptoms for 
$25% of BMs— 
sense of incomplete evacuation after 
passing a stool, 
straining to pass a stool, or lumpy hard 
stools, or small 
pellets.
485 
(64%)
12 weeks
Naldemedine
COMPOSE-1 NCT01965158 USA, Austria, 
Czech Republic, 
Germany, Po-
land, Spain, UK, 
68, outpatient
chronic 
non-cancer 
pain and OIC 
(unknown)
no more than four spontaneous bowel 
movements 
(SBMs) over the 14-day qualifying period 
with no more 
than three SBMs in a given week; at 
least one bowel symptom (presence of 
straining, lumpy or hard stools, sensation 
of incomplete evacuation, sensation of 
anorectal obstruction or blockage) in at 
least 25% of bowel movements
547 
(60.1%)
12 weeks
COMPOSE-2 NCT01993940 USA, Austria, 
Czech Repub-
lic, Germany, 
Poland, Spain, 
69, outpatient
chronic 
non-cancer 
pain and OIC 
(unknown)
no more than four spontaneous bowel 
movements 
(SBMs) over the 14-day qualifying period 
with no more 
than three SBMs in a given week; at 
least one bowel symptom (presence of 
straining, lumpy or hard stools, sensation 
of incomplete evacuation, sensation of 
anorectal obstruction or blockage) in at 
least 25% of bowel movements
553 
(60.2%)
12 weeks
COMPOSE-4 JAPIC-
CTI-132340
Japan, 70 sites cancer pain 
and OIC (lung 
cancer, 45.1%)
five or fewer spontaneous bowel 
movements (SBMs; a bowel movement 
not induced by rescue laxatives) 
and experience with straining, incom-
plete evacuation, and/or hard stools 
in 25% or more of all BMs during the 2 
weeks before random assignment.
193 
(38.3%)
2 weeks 
(12 weeks 
open label 
extension 
study)
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-Proportion of 
patients with 
normal bowel 
function 
-number of 
bowel move-
ments per 
week 
-proportion of 
patients using 
concomittant 
laxatives
proportion of ‘‘responders,’’ 
with responder defined as 
a patient experiencing 3 or 
more SBMs per week over the 
treatment period and an aver-
age increase from baseline of 
at least 1 
SBM per week.
Irving 2011 LOW UN-
CLEAR
LOW LOW HIGH UN-
CLEAR
LOW
-proportion of 
patients with 
normal bowel 
function 
-change in 
number of 
SBMs per 
week 
-change in 
number of 
CSBMs per 
week 
-pain relief
proportion of 
responders, with a responder 
defined as a patient having 
at least three SBMs per week 
and an increase from 
baseline of at least one SBM 
per week for that week 
(a positive response week) for 
at least 9 weeks out of the 
12-week treatment period 
and at least 3 of the last 
4 weeks of the 12-week treat-
ment period.
Hale 2017 LOW LOW LOW LOW UN-
CLEAR
LOW LOW
-proportion of 
patients with 
normal bowel 
function 
-change in 
number of 
SBMs per 
week 
-change in 
number of 
CSBMs per 
week 
-pain relief
proportion of 
responders, with a responder 
defined as a patient having 
at least three SBMs per week 
and an increase from 
baseline of at least one SBM 
per week for that week 
(a positive response week) for 
at least 9 weeks out of the 
12-week treatment period 
and at least 3 of the last 
4 weeks of the 12-week treat-
ment period.
Hale 2017 LOW LOW LOW LOW UN-
CLEAR
LOW LOW
-proportion of 
patients with 
normal bowel 
function 
-change in 
number of 
SBMs per 
week 
-change in 
number of 
CSBMs per 
week 
-pain relief
proportion of SBM 
responders during the 2-week 
treatment period. An SBM 
responder was 
defined as a patients with 
three or more SBMs/week 
who had an increase of 
one or more SBM/week from 
baseline.
Katakami 
2017
LOW LOW LOW LOW UN-
CLEAR
LOW LOW
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Pain relief 
Pain relief was assessed in all randomized controlled trials. However, for a number of 
studies effects on pain relief were described in writing and no actual pain scores were 
reported. When assessing studies that did report on pain relief (either in numbers or 
graphs) the analysis showed that treatment with opioid antagonists did not interfere 
with pain relief. As expected there were no differences between treatments reflected by 
a standardized mean difference (95% CI) of 0.03 (-0.09, 0.03) and no heterogeneity was 
detected (I2=0%) (see Figure 2). 
The summary of findings table generated from the GradePro GDT platform for this pa-
rameter is presented in Table 3. The quality of the evidence varied from moderate to high. 
bowel function efficacy outcomes
The outcomes proportion of patients with normal bowel movements were available for 
naloxegol, MNTX, alvimopan, PR OXN and naldemedine, the proportion of patients with 
additional laxative use were available for naloxegol, MNTX, alvimopan and PR OXN, PAC-
SYM total scores were available for naloxegol, MNTX and PR OXN. All other identified 
Figure 2: Forest plot of comparison: Effect of opioid antagonist treatment on pain relief (RCTs only). 
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bowel function parameters were analyzed per active ingredient and are presented in 
supplementary figure S1-S7. 
Proportion of patients with normal bowel movements
The proportion of patients with normal bowel function (>3 bowel movements per week) 
was reported in 12 RCTs, 2 studies with naloxegol (KODIAC-04 and KODIAC-0532,36,42,64,82), 
2 studies with MNTX (Michna 201134,37,54,55 and Thomas 200841,53,60,83), 2 studies with PR 
OXN (OXN300145,48,58,66,85 and OXN300658,59,66,85), 3 studies with alvimopan (SB-767905/011, 
SB-767905/012, SB-767905/01335,68,70) and 3 studies with naldemedine (COMPOSE-1, 
COMPOSE-2 and COMPOSE-427,29). None of the observational studies reported propor-
tion of patients with normal bowel function based on ROME-3 criteria, subsequently 
all studies were RCTs. Treatment with opioid antagonists resulted in a statistically 
significant improvement of bowel function compared with rescue laxative use when 
looking at the proportion of patients with normal bowel movements according to ROME 
3-criteria  (RR:1.56; 95% CI 1.37-1.76; P<0.00001; Figure 3). Considerable heterogeneity 
was detected (I2=73%, Chi2=7.12 df=11). 
Table 3. The effect of opioid antagonist treatments compared to placebo on pain relief in patients with 
opioid treatment for pain and opioid induced constipation
Outcome № of participants 
(studies)
Certainty of 
the evidence 
(gRaDe)
Relative 
effect 
(95% CI)
anticipated absolute effects
Risk with 
placebo
Risk difference with 
opioid antagonist 
treatments
Pain relief 4569 
(13 RCTs) 
- - - SMD 0.03 lower
(0.09 lower to 0.03 
higher) 
Naloxegol 1337 
(1 RCT) 
⊕⊕⊕⊕
HIGH 
- - SMD 0 
(0.11 lower to 0.11 
higher) 
PR OXN 1054 
(5 RCTs) 
⊕⊕⊕◯
MODERATE a
- - SMD 0.02 lower
(0.14 lower to 0.1 higher) 
MNTX 747 
(3 RCTs) 
⊕⊕⊕⊕
HIGH 
- - SMD 0.06 higher
(0.1 lower to 0.22 higher) 
Alvimopan 148 
(1 RCT) 
⊕⊕⊕⊕
HIGH 
- - SMD 0 
(0.34 lower to 0.34 
higher) 
Naldemedine 1283 
(3 RCTs) 
⊕⊕⊕⊕
HIGH 
- - SMD 0.12 lower
(0.23 lower to 0.01 lower) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI).  CI: Confidence interval; 
smD: Standardised mean difference  
explanations: a. Risk of bias was identified in  4 out of 5 studies with regard to: random sequence genera-
tion and treatment allocation (OXN3001 and OXN3006), blinding (Kokki 2017 and KF5503/60), incomplete 
outcome data (all but Kokki 2017 and OXN10-KR-002). 
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The summary of findings table generated from the GradePro GDT platform for this 
parameter is presented in table 4. The quality of the evidence varied from low to high, 
overall the risk difference of the proportion of patients with normal bowel function on 
opioid antagonist treatment was 206 (136 to 280) more per 1,000 treated patients.
Proportion of patients with additional laxative use
The proportion of patients with additional laxative use was reported in 9 RCTs, 2 
studies with naloxegol (KODIAC-04 and KODIAC-0532,36,42,64,82), 2 studies with MNTX 
(Michna 201134,37,54,55 and study 4000/400184), 3 studies with PR OXN (Kokki 201726, 
OXN300145,48,58,66,85 and OXN300658,59,66,85) and 2 studies with alvimopan (SB-767905/012, 
SB-767905/01368,70. Treatment with opioid antagonists suggested a significant improve-
Figure 3: Forest plot of comparison: Effect of opioid antagonist treatment on bowel function (RCTs only), 
measured with the proportion of patients with normal bowel function (>3 bowel movements per week).
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ment of bowel function compared with rescue laxative use when looking at the propor-
tion of patients using additional laxatives (RR:0.76; 95% CI 0.69-0.84; P<0.001; Figure 4). 
However, substantial heterogeneity was detected (I2=65%, Chi2=22.60 df=8). The 
summary of findings table generated from the GradePro GDT platform for this param-
eter is presented in table 5. The quality of the evidence varied from moderate to high, 
overall the risk difference of the proportion of patients using additional rescue laxatives 
on opioid antagonist treatment was 157 (202 to 104) fewer per 1,000 treated patients.
PaC-sYm total score
The PAC-SYM total score was reported in 5 RCTs, 1 study with naloxegol (KO-
DIAC-0432,36,42,64,82), 1 study with MNTX (Iyer 201169) and 3 studies with PR OXN 
(OXN200166,88,89, OXN300145,48,58,66,85 and OXN300658,59,66,85). None of the observational 
Table 4. The effect of opioid antagonist treatment compared to placebo on the proportion of patients with 
normal bowel function in patients with opioid treatment for pain and opioid induced constipation
Outcomes
no. of 
participants 
(studies) 
Follow-up
Certainty of 
the evidence 
(gRaDe)
Relative 
effect 
(95% CI)
anticipated absolute effects
Risk with 
placebo
Risk difference with 
opioid antagonist 
treatments
Proportion of 
patients with 
normal bowel 
function
4854 
(12 RCTs) 
- 
RR 1.56
(1.37 to 1.76) 
368 per 1,000 
206 more per 1,000
(136 more to 280 
more) 
Naloxegol 
1337 
(2 RCTs) 
⊕⊕⊕⊕
HIGH 
RR 1.36
(1.15 to 1.60) 
294 per 1,000 
106 more per 1,000
(44 more to 176 more) 
PR OXN 
546 
(2 RCTs)
⊕⊕⊕◯
MODERATE a
RR 1.78
(1.46 to 2.16) 
324 per 1,000 
252 more per 1,000
(149 more to 375 
more) 
MNTX 
421 
(2 RCTs) 
⊕⊕⊕◯
MODERATE b
RR 1.89
(1.24 to 2.89) 
406 per 1,000 
361 more per 1,000
(97 more to 766 more) 
Alvimopan 
1262 
(3 RCTs) 
⊕⊕◯◯
LOW c,d
RR 1.34
(1.09 to 1.64) 
484 per 1,000 
165 more per 1,000
(44 more to 310 more) 
Naldemedine 
1288 
(3 RCTs) 
⊕⊕⊕◯
MODERATE e
RR 1.60
(1.31 to 1.97) 
341 per 1,000 
205 more per 1,000
(106 more to 331 
more) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: 
Risk ratio.
explanations: a. Downgraded because of uncertainty about Random Sequence Generation and treat-
ment allocation (OXN3001 and OXN3006) as well as uncertainty about incomplete outcome data handling 
(OXN3001 and OXN3006) b. Downgraded because of significant heterogeneity between studies (I2=80%). 
c. Downgraded because of uncertainty about treatment allocation (all three studies) and uncertainty about 
handling of incomplete outcome data (all three studies)  d. Downgraded because of significant hetero-
geneity between studies (I2=77%) e. Downgraded because of uncertainty about handling of incomplete 
outcome data
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Figure 4: Forest plot of comparison: Effect of opioid antagonist treatment on bowel function (RCTs only), 
measured with the proportion of patients using rescue laxatives.
Figure 5: Forest plot of comparison: Effect of opioid antagonist treatment on bowel function (RCTs only), 
measured with the PAC-SYM total score.
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studies reported a PAC-SYM total score, subsequently all studies were RCTs. Treatment 
with opioid antagonists resulted in a statistically significant improvement of PAC-
SYM total score compared with rescue (St. Mean Difference: -0.43; 95% CI -0.53, -0.34; 
P<0.00001; Figure 5). 
No heterogeneity was detected (I2=0%, Chi2=3.71 df=4). The summary of findings 
table generated from the GradePro GDT platform for this parameter is presented in table 
6. The quality of the evidence varied from moderate to high. 
bowel function efficacy within the laxative refractory population
For naloxegol (KODIAC-04 and KODIAC-0532,36,42,64,82) and PR OXN (OXN2001, OXN3001 
and OXN300666) efficacy data with respect to bowel function were available. However, 
the reported data were not suitable for inclusion in the meta-analysis. For laxative re-
fractory patients using naloxegol the proportion of patients responding to therapy 
Table 5. The effect of opioid antagonist treatments compared to placebo on the proportion of patients us-
ing rescue laxatives in patients with opioid treatment for pain and opioid induced constipation
Outcome № of 
participants 
(studies) 
Follow-up
Certainty of 
the evidence 
(gRaDe)
Relative 
effect 
(95% CI)
anticipated absolute effects
Risk with 
placebo
Risk difference with 
opioid antagonist 
treatments
Proportion of 
patients using rescue 
laxatives 
3538 
(9 RCTs) 
- RR 0.76
(0.69 to 
0.84) 
653 per 
1,000 
157 fewer per 1,000
(202 fewer to 104 
fewer) 
Naloxegol 1319 
(2 RCTs) 
⊕⊕⊕⊕
HIGH 
RR 0.82
(0.75 to 
0.89) 
713 per 
1,000 
128 fewer per 1,000
(178 fewer to 78 fewer) 
PR OXN 674 
(3 RCTs) 
⊕⊕⊕◯
MODERATE a
RR 0.62
(0.53 to 
0.73) 
584 per 
1,000 
222 fewer per 1,000
(275 fewer to 158 
fewer) 
MNTX 542 
(2 RCTs) 
⊕⊕⊕⊕
HIGH 
RR 0.64
(0.52 to 
0.78) 
529 per 
1,000 
190 fewer per 1,000
(254 fewer to 116 
fewer) 
Alvimopan 1003 
(2 RCTs) 
⊕⊕⊕◯
MODERATE b
RR 0.88
(0.81 to 
0.96) 
744 per 
1,000 
89 fewer per 1,000
(141 fewer to 30 fewer) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: 
Risk ratio. 
explanations: a. Downgraded because of uncertainty about Random Sequence Generation and treat-
ment allocation (OXN3001 and OXN3006) as well as uncertainty about incomplete outcome data handling 
(OXN3001 and OXN3006) and uncertainty about blinding (Kokki 2017) 
b. Downgraded because of uncertainty about treatment allocation (all studies) and uncertainty about han-
dling of incomplete outcome data (all studies) 
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significantly improved in line with results in the total study population (RR: 1.50; 95% CI 
[1.21, 1.86]; p=0.0003; Supplementary figure S8).
For patients using PR OXN a significant improvement in BFI-score was seen similar to 
the improvement seen in the total population (WMD: -8.93; 95%CI [-16.26, -1.59]; P=0.02; 
supplementary figure S7). However, the lower patient numbers result in uncertainty 
about the results.
bowel function efficacy in observational studies
Most identified published observational studies were performed with PR OXN (22 
unique studies). One prospective uncontrolled study with MNTX was identified34. In 
this phase 3, multicenter, open-label trial, adults with chronic noncancer pain (n=1034) 
received subcutaneous methylnaltrexone 12 mg once daily for 48 weeks. 64.7% of 
included patients were female and the most common indication for pain treatment was 
back pain 53.8%. The median number of weekly methylnaltrexone injections was 5.98 
(range 0.05–7.14), with the greatest number of patients (49.6%) requiring more than 
six or seven doses per week. A statistically significant increase in mean weekly BM rate 
from baseline (mean=1.5 BM/wk) was observed throughout the entire 48-week period 
(mean=5.3 BMs; mean change=1.5 BM/wk;P<0.001). After 48 weeks 34.1% of the 1034 
Table 6. The effect of opioid antagonist treatments compared to placebo on the PAC-SYM total score in 
patients with opioid treatment for pain and opioid induced constipation
Outcome № of participants 
(studies) 
Follow-up
Certainty of 
the evidence 
(gRaDe)
Relative 
effect 
(95% CI)
anticipated absolute effects
Risk with 
placebo
Risk difference with 
opioid antagonist 
treatments
PaC-sYm total 
score 
1748 
(5 RCTs) 
- - - SMD 0.43 lower
(0.53 lower to 0.34 
lower) 
Naloxegol 557 
(1 RCT) 
⊕⊕⊕⊕
HIGH 
- - SMD 0.39 lower
(0.56 lower to 0.21 
lower) 
PR OXN 731 
(3 RCTs) 
⊕⊕⊕◯
MODERATE a
- - SMD 0.53 lower
(0.68 lower to 0.38 
lower) 
MNTX 460 
(1 RCT) 
⊕⊕⊕◯
MODERATE b
- - SMD 0.32 lower
(0.51 lower to 0.13 
lower) 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI).  CI: Confidence interval; RR: 
Risk ratio; smD: Standardised mean difference
explanations: a. Downgraded because of uncertainty about Random Sequence Generation and treat-
ment allocation (OXN3001 and OXN3006) as well as uncertainty about incomplete outcome data handling 
(OXN2001, OXN3001 and OXN3006) b. Downgraded because of uncertainty about treatment allocation and 
incomplete data handling 
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injections resulted in a BM within 4 hrs, which is comparable to the values found in the 
RCTs, suggesting that effects seen in daily practice resemble the effects seen in RCTs.
For PR OXN 15 studies (17 publications) included patients with OIC at study start (n
=17085)4,28,33,38,46,49,56,61,62,67,71-73,77-79,81. The studies mainly differed in the included pain 
population (e.g. non-malignant pain, malignant pain, elderly, neuropathic pain and 
laxative refractory pain patients), resulting in considerable heterogeneity, Despite the 
heterogeneity the mean weighted improvement in BFI was -29.22 95 % CI [-35.22, -23.22] 
(p<0.00001) similar to the improvement seen in the RCTs -27.4  95%CI[ -19.1 to -35.7] 
(see supplementary figure S9), suggesting that effects seen in daily practice resemble 
the effects seen in RCTs. Patients with laxative refractory OIC (3 studies, n=110) had 
the largest improvement in BFI-scores, mean weighted improvement in BFI was -49.03 
95% CI [-53.63, -44.42] (P<0.00001). This improvement. is greater than mean weighted 
improvement seen in the laxative refractory subpopulation of the RCTs (-20.1; 95% CI 
[-13.6 to -26.6]). Together this suggests that effects seen in daily practice are at least 
comparable to the effects seen in RCTs.
In 10 studies (14 publications) patients without OIC at study start were included (n
=4693)21,24,38-40,46,50,57,63,71-75. The mean weighted improvement was -3.38 95% CI [-10.37, 
3.61]. The studies differed substantially, mainly in the included pain population (e.g. 
non-malignant pain, malignant pain, elderly, neuropathic pain and laxative refractory 
pain patients), resulting in considerable heterogeneity (I2=96%, Chi2=215.39, df=9) (see 
supplementary figure S10). Within these heterogeneous studies three groups of studies 
could be identified, studies reporting no change in BFI, studies reporting an improve-
ment in BFI and studies reporting a worsening of BFI, where all individual publications 
reported no significant and clinically relevant changes in BFI (a clinically relevant change 
in BFI is defined as a change of 12 points or more). Five studies showed a substantial 
improvement of BFI-score and mean weighted improvement of BFI in this group was 
-11.83 95% CI [-13.25, -10.41](p<0.00001) with no important heterogeneity in this sub-
group (I2=0%). Two studies showed a worsening of the BFI score with mean weighted 
worsening of 11.25 95% CI [8.13, 14.37] (p<0.00001), with no important heterogeneity 
(I2= 6%). Another 3 studies did not show a difference in BFI-score and mean weighted 
improvement in this subgroup was -0.17 95% CI [-2.85, 3.19] (p=0.91), with no important 
heterogeneity (I2=4%). Results of these analyses suggest that there appeared to be no 
significant clinically relevant changes in the bowel function index (a change in BFI of 12 
points or more) even when the data are analyzed in the defined subgroups, suggest-
ing that patients do not develop OIC during treatment with an opioid (supplementary 
figures S10-S13).
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DIsCussIOn
This study aimed to demonstrate that treatment with opioid antagonists is a valuable 
treatment option in patients that experience OIC when using opioid treatment for pain. 
Moreover, available observational data were analyzed to provide insight in to usage of 
opioid antagonist treatment in daily practice. 
Despite significant heterogeneity between studies all identified randomized con-
trolled trials showed that the efficacy of opioid antagonist treatment was superior to 
control treatment with respect to the proportion of patients achieving normal bowel 
function, the proportion of patients needing additional laxatives as well as the PAC-SYM 
total score.  The Number Needed to Treat (NNT) to obtain normal bowel function is ~5 
(~3.5-7; the reciproke of the anticipated absolute risk difference with opioid antagonist 
treatments), which is comparable to the meta-analysis by Nee et al.  Also variables that 
were not studied for all agents, like (change in) BFI and (change in) number of bowel 
movements, showed that opioid antagonist treatments were superior to control treat-
ment. 
With respect to pain relief the RCTs showed that treatment with opioid antagonists 
did not significantly interfere with pain relief (13 RCTs, 4569 participants, SMD 0.03 lower 
(0.09 lower to 0.03 higher). The quality of the evidence using the GRADE-systematic was 
rated low for alvimopan, moderate for PR OXN, MNTX and naldemedine and high for 
naloxegol. 
A further indication on the efficacy of opioid antagonist treatment in daily practice 
could be derived from prospectively designed observational studies predominantly 
performed with PR OXN. When analyzing the Bowel Function Index at start of opioid 
antagonist treatment and at final study visit it was shown that the BFI decreased sig-
nificantly with 29.2 points (ΔBFI=-29.9 95% CI -35.2to -23.2; n=8524) in patients with 
OIC at study entry, a decrease that is considered to be clinically relevant (a change in 
BFI of 12 points or more is considered clinically relevant) indicating that bowel function 
improves significantly and that the improvement is also clinically relevant. For patients 
without OIC at study start the BFI did not significantly change (ΔBFI -3.4 95%CI -10.4 to 
3.6; n=2341), indicating that treatment with PR OXN might prevent worsening of bowel 
function usually seen on opioid treatment. 
An interesting population with respect to opioid induced constipation is the laxative 
refractory population. Therefore we also included analyses for the subgroup of laxative 
refractory patients. Five RCTs (KODIAC-4, KODIAC-5, OXN2001, OXN3001 and OXN3006) 
were identified that reported on bowel function efficacy in laxative refractory patients 
or laxative inadequate responders. 
For naloxegol the RR was 1.5 (95% CI 1.21 to 1.86; n=481), resulting in an NNT of ~6.7. 
For PR OXN the change in BFI was less pronounced compared with the total popula-
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tion (MD -8.93 95%CI -16.26 to -1.59; n=75). Within the naloxegol and PR OXN studies 
no heterogeneity was detected. However, a difference between both studies was the 
definition with respect to laxative refractory patients and laxative inadequate responder 
patients. For the PR OXN study a patient was considered laxative refractory if the pa-
tients still experienced OIC (defined as a BFI>28.8) despite the use of at least 2 laxatives 
from a different therapeutic class (e.g. macrogol and bisacodyl). For naloxegol a patient 
was considered a laxative inadequate responder when the patient took medication from 
one or more laxative classes for a minimum of 4 days within 2 weeks before screening 
and still experienced moderate, severe, or very severe symptoms in at least one of four 
stool-symptom domains of a laxative-response questionnaire.
For PR OXN also prospective observational studies were available in this population. In 
the observational studies the definition for laxative refractory patients was comparable 
to the laxative regimens used in daily practice, a patient that was considered laxative 
refractory had failed on the standard of care laxative regimens used in daily practice. 
The analysis showed a significant and clinically relevant improvement of the BFI in this 
population (ΔBFI -49.0 95%CI -53.6 to -44.4; n=110), suggesting that despite failing nor-
mal laxative regimens patients can still benefit from using opioid antagonist treatment.
Although no direct comparisons between PAMORA’s and/or PR OXN are available, we 
did not observe differences in efficacy between PAMORA’s and PR OXN in the meta-
analyses. As no differences are observed in efficacy and side effects, treatment choice 
should be made on pharmaceutical properties of the products, patient preferences, costs 
and product availability. For instance, MNTX is only available as subcutaneous injection 
which might be perceived a burden to patients, whereas first results of treatment can 
occur already within 4 hours of the first injection. PR OXN is an oral combination product 
limiting the choice of opioid to oxycodone. The oral combination however might be a 
benefit to therapy adherence in comparison to single oral products, but this remains to 
be elucidated. Furthermore, between countries differences exist between products with 
regard to availability to patients due to differences in registered indication (e.g. between 
EU versus US) and local reimbursement decisions which can differ per country.
limitations
There are some limitations to our analyses. Firstly, there is heterogeneity in the analyses 
of the bowel function outcomes, this heterogeneity might be caused by differences 
in the trial populations. Detected differences identified were differences with respect 
to OIC at baseline due to differences in definitions for OIC as well as differences is the 
underlying pain conditions (e.g. malignant pain and non-malignant pain). Other differ-
ences that could affect bowel function might have been: use of chemotherapeutics and 
other drugs90, level of physical activity and co-morbidities11. To reduce heterogeneity 
due to trial populations when studying OIC and the efficacy/effect with respect to OIC, 
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Poulsen et al. have developed a model for OIC in healthy volunteers, in which these 
population differences can be ruled out and it will be interesting to see results of com-
paring opioid antagonists in healthy volunteers with laxative-refractory OIC with at least 
4 weeks treatment duration91. 
Another limitation was the fact that we could not rule out publication bias for all 
studies as not all protocols were published online. For this we acknowledge a positive 
trend that the more recent studies protocols were freely available. Finally, although the 
observational study data support the data from clinical trials (at least for PR OXN and in 
patients with OIC at study entry), it is not possible to use these data for definite conclu-
sions as there is a strong heterogeneity in the data and publication bias could not be 
ruled out. 
Another limitation of the study is related to increasing concerns in the US and Europe 
with respect to opioid therapy, especially in non-malignant pain patients. In this system-
atic review also studies were included in which patients with non-malignant pain were 
treated. For the patients in these studies physicians decided that opioid therapy was 
required and could not be stopped. In daily practice an alternative option in especially 
non-malignant pain patients might be strictly evaluating the need for opioid therapy, as 
cessation of opioid therapy will also improve OIC.
COnClusIOn
Opioid antagonists, have been approved for the treatment of opioid induced constipa-
tion for a decade (first approval in EU dating from 2008 for PR OXN and MNTX). Despite 
approval and growing consensus with regard to using these agents in clinical practice 
the uptake in formal guidelines is still minimal. Together with the study by Nee et al. 2018 
(describing the safety and efficacy with regard to non-responders on opioid antagonists) 
this study provides further evidence on the efficacy with respect to bowel function and 
pain of opioid antagonists, like naloxegol, alvimopan, naldemedine, PR OXN and MNTX, 
in the treatment of OIC in patients with opioid treatment for chronic pain.  
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suPPlemenTaRY FIguRes
supplementary Figure 1: Forest plot of comparison: Effect of methylnaltrexone on bowel function efficacy 
(RCTs) with respect to Rescue Free Bowel movements (within 4 hours after first dose).
supplementary figure 2: Forest plot of comparison: Effect of methylnaltrexone on bowel function efficacy 
(RCTs), with respect to Rescue Free Bowel movements (within 24 hours).
supplementary figure 3: Forest plot of comparison: Effect of alvimopan on bowel function efficacy (RCTs), 
with respect to Number of bowel movements per week.
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supplementary figure 4: Forest plot of comparison: Effect of naloxegol treatment on bowel function ef-
ficacy (RCTs), with respect to Change from baseline number of SBMs per week.
supplementary figure 5: Forest plot of comparison: Effect of naldemedine treatment on bowel function 
efficacy (RCTs), with respect to Change in number of SBMs per week.
supplementary figure 6: Forest plot of comparison: Effect of naldemedine treatment on bowel function 
efficacy (RCTs), with respect to Change in number of CSBMs per week.
supplementary figure 7: Forest plot of comparison: Effect of oxycodone/naloxone treatment on bowel 
function efficacy (RCTs), with respect to Bowel Function Index.
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supplementary figure 8: Forest plot of comparison: Effect of naloxegol treatment on bowel function ef-
ficacy (RCTs), with respect to Response rate (≥3 SBMs per week and increase of ≥1 SBMs for ≥9 of 12 weeks 
and for ≥3 of the 4 final weeks).
supplementary figure 9: Forest plot of comparison: Effect of oxycodone/naloxone treatment on bowel 
function efficacy in patients with OIC at study start (observational studies), with respect to Bowel Function 
Index.
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supplementary figure 10: Forest plot of comparison: Effect of oxycodone/naloxone treatment on bowel 
function efficacy in patients without OIC at study start (observational studies), with respect to Bowel Func-
tion Index.
supplementary figure 11: Forest plot of comparison: Effect of oxycodone/naloxone treatment on bowel 
function efficacy in patients without OIC at study start (observational studies, improvement of BFI), with 
respect to Bowel Function Index.
supplementary figure 12: Forest plot of comparison: Effect of oxycodone/naloxone treatment on bowel 
function efficacy in patients without OIC at study start (observational studies, worsening BFI), with respect 
to Bowel Function Index.
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supplementary figure 13: Forest plot of comparison: 12 Effect of oxycodone/naloxone treatment on 
bowel function efficacy in patients without OIC at study start (observational studies, unchanging BFI), with 
respect to Bowel Function Index.
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Objective
The effects of combined oxycodone/naloxone prolonged release tablets (OXN PR) were 
investigated in patients with moderate-to-severe chronic cancer-related or non-cancer 
pain. All patients had opioid induced constipation (OIC) which persisted despite sub-
stantial laxative therapy.
Research design and methods
This pooled analysis included 75 patients with OIC at study entry that was refractory to 
at least two laxatives with different modes of action. Patients completed randomized, 
double-blind treatment with OXN PR 20–120 mg/day for either 12 weeks (OXN 9001: 
non-cancer pain study) or 4 weeks (OXN 2001: cancer-related pain study). Analgesia 
and bowel function were assessed using the Brief Pain Inventory Short Form and Bowel 
Function Index (BFI), respectively. Use of laxative medication and safety were assessed 
throughout the studies.
Clinical trial registration
NCT00513656, EudraCT 2005-002398-57, EudraCT 2005-003510-15.
Results
Statistically and clinically significant improvements in bowel function were observed 
following double-blind treatment with OXN PR. Mean (SD) reduction in BFI score was 
21.2 (28.8) and comparable in patients with cancer-related (19.0 [28.9]) and non-cancer 
pain (23.3.[29.0]; P_0.0002). Furthermore, the proportion of patients with a BFI score 
within normal range (_28.8) increased from 9.5% at screening to 43.1% at Day 15 of OXN 
PR. While all patients used _2 laxatives of different classes at screening, during study 
treatment 36% stopped using laxatives (P50.001). OXN PR provided effective analgesia, 
evidenced by stable pain scores during study treatment, and there were no unantici-
pated adverse events.
Conclusions
OXN PR significantly improved bowel function and reduced the use of laxatives in pa-
tients with OIC, previously unresponsive to at least two different classes of laxatives. OXN 
also provided effective analgesia for patients with moderate-to-severe cancer-related 
pain and non-cancer-related pain.
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InTRODuCTIOn
Chronic pain places a significant burden on patients, affecting many activities of daily liv-
ing as well as resulting in loss of independence, anxiety and depression1,2. Moderate-to-
severe chronic pain has a prevalence of approximately 20% in Europe, and is even more 
common in patients with cancer, affecting most individuals with advanced disease 1,3,4. 
Opioid analgesics are effective treatments for moderate to severe cancer-related and 
non-cancer pain and are recommended in this setting5–8. However, as a therapeutic 
class, opioids are associated with side effects, including opioid-induced bowel dysfunc-
tion (OIBD). OIBD arises from the interaction of exogenous opioids with enteric µ-opioid 
receptors located throughout the gastrointestinal tract. This can result in inhibited gas-
tric emptying, decreased peristalsis, decreased secretion of intestinal fluids, increased 
absorption of water as well as dysfunction of esophageal and anal sphincters. These 
effects can result in gastro-esophageal reflux, nausea and vomiting, and symptoms of 
opioid-induced constipation (OIC) including abdominal pain and distension, hard stools 
which are difficult to pass, hemorrhoids and incomplete evacuation9–12. OIC affects up 
to 80% of patients treated with opioid analgesia and is frequently reported to be the 
most bothersome side effect associated with this therapy13–15. OIC has a negative impact 
on patients’ quality of life, and has also been shown to be associated with lower work 
productivity, absenteeism and significant utilization of healthcare resources13,15–17. 
Treatment guidelines recommend that laxatives should be used in conjunction with 
opioid analgesics in patients with cancer-related and non-cancer pain7,8,18. However, 
evidence is lacking regarding the type, dosage and timing of laxative therapy19,20. Many 
patients report that laxatives fail to relieve symptoms of OIC. For example, a large-scale 
study of patients taking opioid analgesia revealed that over half reported fewer than 
three bowel movements per week despite taking laxatives13. In this study, 44% of patients 
reported using two or more different types of laxatives in the preceding 3 months, and a 
similar proportion reported using laxatives on at least 5 days of the week13. Furthermore, 
despite taking laxatives, one-third of patients reduce the dosage or stop taking opioids 
in order to make it easier to have a bowel movement, thereby sacrificing effective pain 
relief13. 
Given the nature of chronic pain, effective management often requires prolonged opi-
oid therapy. However, as well as the financial cost, bloating, flatulence and abdominal 
cramps associated with laxative treatments, it is noteworthy that continuous, long-term 
use of laxatives may lead to electrolyte imbalances as well as having a negative impact 
on daily activities due to loss of bowel control and unpredictable timing of laxation17,21–24.
The opioid analgesic oxycodone (Oxy) has proven efficacy for the management of 
moderate-to-severe cancer related and non-cancer-related pain25,26. In order to address 
the opioid class-effect symptoms of OIC, Oxy was combined with the opioid-receptor 
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antagonist, naloxone in a prolonged-release formulation (OXN PR). Following oral 
administration, naloxone has ≤2% systemic availability due to extensive first-pass 
hepatic metabolism, and consequently acts on opioid receptors in the gastrointestinal 
tract where it has greater affinity than Oxy27. Importantly, the addition of naloxone to 
oxycodone was shown to be capable of counterbalancing oxycodone-induced delay of 
colonic transit, as measured with 99mTc-labelled tablets28. 
Clinical trials have demonstrated that OXN PR is associated with analgesia comparable 
with Oxy PR while providing significantly superior bowel function in patients with non-
cancer-related pain and in those with cancer related pain29–32. These beneficial effects of 
OXN PR were associated with improvements in quality of life compared with previous 
analgesic therapy33, and were prolonged, being observed during long-term treatment 
for up to 52 weeks34,35. Furthermore, the efficacy and safety of OXN PR in real-world 
treatment settings has been demonstrated in non-interventional studies involving over 
10,500 patients with cancer-related pain and non-cancer related pain36,37. 
However, little is known about the effect of OXN in patients who have OIC which is par-
ticularly difficult to treat. This includes patients experiencing no relief from OIC despite 
taking several different types of laxatives. Therefore a pooled analysis of randomized, 
controlled trials was conducted, focused on patients with moderate to severe pain who 
were randomized to OXN PR and had OIC at screening, despite the use of two or more 
laxatives with different modes of action.
PaTIenTs anD meThODs
Patients and study design
This pooled analysis comprised patients aged ≥18 years with moderate-to-severe, 
chronic pain that required round-the-clock opioid therapy, and had received OXN PR 
in prior double-blind, multicenter, randomized studies, designed to assess the efficacy 
and safety of OXN PR. At study entry, all patients included in this pooled analysis had 
OIC. Their OIC was associated with prior, non-study opioid therapy and persisted de-
spite the use of at least two laxatives with different mechanisms of action (Anatomical 
Therapeutic Chemical [ATC] 4). The design of these studies has been described previ-
ously. In brief, Study OXN9001 was a pooled analysis of two Phase III studies of similar 
design (OXN3001; EudraCT: 2005-002398-57; and OXN3006; EudraCT: 2005-003510-15). 
Patients with non-cancer pain were randomized to 12 weeks of OXN PR or Oxy PR at 
doses equivalent to 20–50 mg/day (OXN3001)32, or 60–120 mg/day of Oxy (OXN3006)30, 
following a run-in period (7–28 days), in which patients were titrated to an effective 
analgesic dose of Oxy PR30–32. Study OXN2001 was a Phase II study of patients with 
moderate-to-severe cancer-related pain (ClinicalTrials. gov: NCT00513656). Following 
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a screening period (3–10 days), patients were switched from their pre-study opioid to 
treatment with OXN PR or Oxy PR for 4 weeks at doses of 20–120 mg/day (a run-in, 
dose-titration period was not included)29.
In all studies, oral bisacodyl (10 mg/day) was permitted as rescue laxative medication 
(OXN9001: 72 hours after a bowel movement but could be taken sooner if patients exhib-
ited discomfort; OXN2001: maximum of five doses in seven consecutive days). The studies 
were conducted in accordance with the Declaration of Helsinki and the International 
Conference on Harmonization Guidelines for Good Clinical Practice, were approved by lo-
cal ethics committees, and all patients gave informed, written consent prior to enrolment.
Outcomes and assessments
The primary objective of this pooled analysis was to evaluate bowel function in patients 
randomized to OXN PR who had OIC at study entry, despite the use of two different 
classes of laxatives. This was performed using the validated Bowel Function Index (BFI; 
Copyright for the Bowel Function Index is owned by Mundipharma GmbH, Switzerland, 
2002; the BFI is subject of European Patent Application Publication No. EP 1,860,988 
and corresponding patents and applications in other countries)38,39. BFI score comprised 
the arithmetic mean score of three items rated on a numerical analogue scale (NAS) of 
0–100: ease of defecation (0=easy/no difficulty to 100=severe difficulty), feeling of in-
complete bowel evacuation (0=not at all to 100=very strong), and personal judgment of 
constipation (0=not at all to 100=very strong). BFI score was assessed at screening, start 
of double-blind treatment and end of double-blind treatment. Laxative use (bisacodyl 
and non-study laxatives) throughout the studies was
documented. Analgesic efficacy was monitored using the Brief Pain Inventory Short 
Form (BPI-SF) to assess average pain over the last 24 hours (single question on NAS; 
0=no pain to 10=worse pain ever). Use of oxycodone immediate release tablets (Oxy 
IR) as analgesic rescue medication throughout the studies was recorded. Safety was 
monitored via the documentation of adverse events (AEs, classified by system organ 
class and Medical Dictionary for Regulatory Activities [MedDRA] preferred terms) and 
serious adverse events (SAEs); monitoring of vital signs, hematology, blood chemistry, 
and electrocardiograms.
statistical methods
Analyses were performed in the intention-to-treat population. The change in BFI score 
from the start to end of study treatment was analyzed using paired t-tests, with a 
change of ≥12 points being considered clinically meaningful38. Change in BPI-SF score 
and frequency of analgesic rescue medication use (Oxy IR) during study treatment were 
assessed using signed-rank tests, while change in laxative use was assessed using a 
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McNemar test. All statistical analyses were performed using SAS version 9.1.3 software 
(SAS Institute Inc., Cary, NC, USA).
ResulTs
Patient characteristics and study treatment 
In total 75 patients with chronic, moderate-to-severe pain and OIC at study entry despite 
the use of at least two laxatives with differing mechanisms of action had been random-
ized to double-blind treatment with OXN PR. Just over half the patients (n=40, 53.3%) had 
cancer related pain (OXN2001) and 46.7% (n=35) had non-cancer pain (OXN9001). There 
were no significant differences in the demographic characteristics of the two groups. 
Median (range) age was 62.0 (40, 80) years (OXN2001:61.5 [40, 80]; OXN9001: 62.0 [40, 
77]) and approximately two-thirds of patients (69.3%) were ≤65 years (OXN2001: 65.0%; 
OXN9001: 74.3%). There was a trend for more women with non-cancer pain (71.4%) ver-
sus cancer pain (47.5%). OXN PR dosage remained relatively stable throughout the trials. 
Across the studies, the mean daily dose of OXN PR at the start of treatment (28.5 mg/
day) increased by 6.0 mg/day at the end of the double-blind treatment. Mean changes 
in OXN PR dosage during treatment were similar in patients with cancer-related pain 
and non-cancer pain (OXN2001: 7.0 mg/day, OXN9001: 4.9 mg/day).
bowel function index
Overall, the mean (SD) BFI score at screening was 62.5 (18.7) and was comparable in 
patients with cancer-related pain and non-cancer pain (OXN2001: 62.8 [17.4], OXN9001: 
62.1 [20.4]). At the start of the double-blind treatment phase, high BFI scores were 
recorded (OXN2001: 66.4 [15.9], OXN9001: 61.3 [23.2]). Improvements in bowel func-
tion, indicated by a decrease in BFI score, were observed at the end of the double-blind 
treatment with OXN PR. Overall, BFI score decreased by a mean (SD) of 21.2 (28.8) to 
43.0 (31.1). Patients with cancer-related pain had a decrease of 19.0 (28.9) after a mean 
of 24.7 days of treatment, while patients with non-cancer related pain experienced a 
decrease in BFI score of 23.3 (29.0) following 69.5 days of treatment. The reductions in 
BFI score were clinically and statistically significant in both groups of patients (P≤0.0002; 
Figure 1). 
The shorter mean duration of treatment with OXN PR in patients with cancer-related pain 
compared with non-cancer related pain reflected differences in the treatment durations 
defined in the study protocols (4 weeks versus 12 weeks). In addition to the significant 
improvements in BFI scores associated with OXN PR, an increase in the proportion of pa-
tients who had a BFI score within the normal range (validated as≤28.8 in non-constipated 
patients with chronic pain39) was observed within the first 2 weeks of treatment. 
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Prior to randomization, 9.5% of patients had a BFI score ≤28.8 (5.1% in OXN2001 and 
14.3% in OXN9001). At Day 8 of OXN PR, this increased to 31.9% (27.8% in OXN2001 
and 36.4% in OXN9001), and at Day 15 of OXN PR, 43.1% (36.4% OXN2001 and 50.0% 
OXN9001) had a normal BFI score (Table 1).
laxative use
All patients in this analysis had been using at least two laxatives of different mechanistic 
classes at study entry without success. Contact laxatives (n=72, 96.0%) and osmotically 
 
0
10
20
30
40
50
60
70
80
90
100
Screening Start of  treatment End of treatment
Me
an
 BF
I Sc
ore
Timepoint
OXN2001
OXN9001
Total
*
Figure 1. Bowel Function Index during treatment.
Mean ± confidence interval. BFI score 0–28.8 is the reference range for non-constipated patients with 
chronic pain39. 
*BFI score at end of double-blind treatment minus score at start of double-blind treatment, assessed using 
paired t-test: OXN2001 P=0.0002; OXN9001<.0001; and Total P<0.0001. OXN2001: patients with cancer-
related pain randomized to OXN PR for 4 weeks. OXN9001: patients with non-cancer-related pain random-
ized to OXN PR for 12 weeks.
Table 1: Patients with normal Bowel Function Index score.
Duration of treatment with OXN PR
BFI score ≤28.8 Screening 
% (n/N)
Day 1 
% (n/N)
Day 8 
% (n/N)
Day 15 
% (n/N)
Day 29 
% (n/N)
Day 57 
% (n/N)
Day 85 
% (n/N)
OXN2001 5.1 (2/39) 0 (0/40) 27.8 (10/36) 36.4 (12/33) 22.2 (8/36) – –
OXN9001 14.3 (5/35) 8.6 (3/35) 36.4 (12/33) 50.0 (16/32) 44.8 (13/29) 48.1 (13/27) 40.0 (14/35)
Total 9.5 (7/74) 4.0 (3/75) 31.9 (22/69) 43.1 (28/65) 32.3 (21/65) – –
BFI score 0–28.8 is the reference range for non-constipated patients with chronic pain.
OXN2001: 40 patients with cancer-related pain randomized to OXN PR for 4 weeks
OXN9001: 35 patients with non-cancer-related pain randomized to OXN PR for 12 weeks
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acting laxatives (n=67, 89.3%) were most commonly used, while enemas, stool softeners/
emollients and other laxatives were used by 8 (10.7%), 4 (5.3%) and 12 (16.0%) patients, 
respectively. In total, 64.0% (n=48) required the study laxative (bisacodyl) during study 
treatment. Four patients (5.3%) used non-study laxatives in addition to bisacodyl: one 
patient in OXN9001 (polyethylene glycol and lactulose) and three patients in OXN2001 
(lactulose [n=2], polyethylene glycol [n=1]). During study treatment, no patients started 
using laxatives while 36.0% stopped using laxatives (McNemar test, P<0.001). As ex-
pected, use of the study laxative was more frequent in patients with cancer-related pain 
(82.5%; median [range] 6.0 [1–20] tablets) than in those with non-cancer-related pain 
(42.9%; 10 [1–36] tablets). Mean daily doses of study laxative were 2.1 mg for patients in 
OXN2001 and 4.3 mg for those in OXN9001. Data indicate that study laxative was used as 
needed; for patients with non-cancer pain, the mean number of days with study laxative 
use (4.2 days) was less than the mean number of days receiving study medication (69 
days) (Table 2).
This is in contrast to the period prior to receiving double-blind treatment with OXN PR 
in which all patients used at least two laxatives of different ATC class. At this time, 67% of 
patients used at least one laxative on a daily basis (70% of patients with cancer-related 
pain and 63% of patients with non-cancer pain).
Table 2: Use of study laxative (bisacodyl) during double-blind treatment with OXN PR.
bFI score OXn2001 
(n=40)
OXn9001 
(n=35)
Any study laxative used % (n/N) 82.5 (33/40) 42.9 (15/35)
Any non-study laxative used % (n/N) NR 2.9 (1/35)
Number of days study laxative used n NR 15
Mean (SD) NR 4.2 (2.8)
Median NR 5.0
Min, max NR 1, 8
Duration of study treatment (days) n 33 15
Mean (SD) 24 (7.5) 69 (33)
Median 28 77
Min, max 1, 34 7, 146
Daily dose of bisacodyl (mg/day) n 33 15
Mean (SD) 2.1 (1.7) 4.3 (4.0)
Median 1.82 3.1
Min, max 0.2, 8.3 0.3, 11.3
OXN2001: 40 patients with cancer-related pain randomized to OXN PR for 4 weeks
OXN9001: 35 patients with non-cancer-related pain randomized to OXN PR for 12 weeks
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analgesic efficacy and safety
Overall, there was no significant difference in ‘average pain over the last 24 hours’ scores 
from the start to end of double-blind treatment with OXN PR. While pain response re-
mained stable in patients with non-cancer related pain (OXN9001: mean change in score 
0.1, P=0.481), there was a non-significant trend for improvement in pain scores reported 
by patients with cancer related pain (OXN2001: mean change in score -0.4, P=0.311). Use 
of Oxy IR analgesic rescue medication decreased following double-blind treatment with 
OXN PR. In patients with cancer-related pain (OXN2001) there was a significant decrease 
in the median dose of rescue medication (Oxy IR) from the start of study treatment 
(Days 1–7: 3.93 mg) to the end of study treatment (Days 29–35: 1.25 mg; P¼0.0018). 
Similarly, in patients with non-cancer related pain median dose of rescue medication 
(Oxy IR) in the run-in period (5.0 mg) was significantly greater than that at the end of 
study treatment (Days 57–84; 0.3 mg; P=0.006). The percentage of patients who used 
Oxy IR remained stable throughout double blind treatment with OXN PR in both studies.
AEs related (definitely, probably or possibly) to study medication were reported in 
one-third of patients
(OXN2001: 27.5%, OXN9001: 40.0%). SAEs were more common in patients with 
cancer-related pain (OXN2001: 25.0%, OXN9001: 2.9%). All four deaths during the study 
occurred in patients with cancer-related pain but none were considered related to study 
medication. During double-blind treatment with OXN PR, the most common AEs were 
nausea (9.3%), constipation (9.3%) and vomiting (8.0%; Table 3).
Table 3: All causality adverse events occurring during double-blind treatment with OXN PR (≥2 patients).
system organ class and medDRa preferred term
Total (n=75) 
n (%)
blood and lymphatic system disorders 2 (2.7)
Anaemia 2 (2.7)
Lymphopenia 2 (2.7)
gastrointestinal disorders 27 (36.0)
Abdominal pain 2 (2.7)
Abdominal pain upper 4 (5.3)
Constipation 7 (9.3)
Diarrhoea 2 (2.7)
Dry mouth 2 (2.7)
Nausea 7 (9.3)
Vomiting 6 (8.0)
general disorders and administrative site conditions 21 (28.0)
Asthenia 5 (5.3)
Drug withdrawal syndrome 2 (2.7)
Fatigue 3 (4.0)
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DIsCussIOn
This pooled analysis of randomized clinical trials demonstrates that OXN PR is associ-
ated with significantly improved bowel function in patients with moderate-to-severe 
pain and OIC that is refractory to at least two different ATC class 4 laxatives. Switching 
from opioid analgesic plus multiple laxatives to OXN PR was associated with statistically 
significant and clinically relevant improvements in BFI scores as well as significant reduc-
tions in the use of laxatives.
Table 3: All causality adverse events occurring during double-blind treatment with OXN PR (≥2 patients). 
(continued)
system organ class and medDRa preferred term
Total (n=75) 
n (%)
Odema peripheral 4 (5.3)
Pain 4 (5.3)
Pyrexia 2 (2.7)
Investigations 16 (21.3)
Blood glucose increased 2 (2.7)
Haemoglobin decreased 3 (4.0)
Neutrophil count increased 2 (2.7)
metabolism and nutritional disorders 9 (12.0)
Anorexia 3 (4.0)
Hyperkalaemia 3 (4.0)
Hyperuricaemia 2 (2.7)
Hypoalbuminaemia 3 (4.0)
Hypocalcaemia 2 (2.7)
neoplasms (benign, malignant, unspecified) 9 (12.0)
Cancer pain 4 (5.3)
Malignant neoplasm progression 4 (5.3)
nervous system disorders 12 (16.0)
Dizziness 2 (2.7)
Headache 4 (5.3)
Respiratory, thoracic and mediastinal disorders 6 (8.0)
Dyspnoea 3 (4.0)
skin and subcutaneous disorders 6 (8.0)
Hyperhidrosis 3 (4.0)
Pruritis 2 (2.7)
Adverse events reported documented in only one patient are not shown
OXN2001: 40 patients with cancer-related pain randomized to OXN PR for 4 weeks
OXN9001: 35 patients with non-cancer-related pain randomized to OXN PR for 12 weeks
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Apart from the underlying cause of pain, there were no notable differences between 
patients with cancer-related pain and non-cancer-related pain in terms of demographic 
factors and dose of OXN PR received during the studies. At screening, when patients 
were receiving opioid analgesia of any type and at least two different types of laxatives, 
high BFI scores were observed in both groups (mean score 62.5), indicating these pa-
tients were suffering with constipation. While BFI scores at the start of treatment were 
greater in patients with cancer-related pain (66.4), statistically significant and clinically 
relevant improvements in OIC were observed in both groups of patients at the end of 
double-blind treatment with OXN PR (mean reductions in BFI scores of 19.0 and 23.3 
points, respectively, P≤0.002). It is noteworthy that individuals with cancer-related 
pain received OXN PR for a shorter duration than those with non-cancer-related pain (4 
weeks versus 12 weeks), since the design of the OXN2001 trial reflected the limited life 
expectancy of these patients. The positive effect of OXN PR on bowel function is further 
emphasized by the finding that the proportion of patients who had a BFI score within 
the normal range (≤28.8) increased by over four-fold from screening (9.5%) to Day 15 of 
OXN PR (43.1%).
In addition to the significant improvements in bowel function, OXN PR was also 
associated with reduced use of laxatives. While all patients were using at least two dif-
ferent classes of laxatives at screening, not all patients required laxatives during study 
treatment; 36.0% of patients stopped using laxatives and no patients started using laxa-
tives during double-blind treatment with OXN PR (P<0.001). Furthermore, for patients 
with nonmalignant pain (OXN9001), the mean number of days with study laxative use 
(4.2 days) was approximately two-thirds less than the mean number of days receiving 
study medication (15.4 days). More patients with cancer-related pain (82.5%) used study 
laxative during study treatment compared with those with pain of a non-cancer origin 
(42.9%). This difference may be due to the other etiologies of constipation in patients 
with cancer in addition to opioid medication, including the malignancy itself, general 
debility, less mobility, other medications such as chemotherapeutic agents and con-
comitant diseases40,41. 
While treatment guidelines recommend laxatives are prescribed to be used in conjunc-
tion with opioid analgesics in patients with cancer-related and non-cancer pain, many 
patients report that laxatives fail to relieve symptoms of OIC and/or are associated with 
unpleasant complications7,8,13,15,18,22,23. Given the unique etiology of OIC and the effects 
of opioids on neural activity, motility and secretion throughout the entire gastrointes-
tinal tract11, it is unsurprising that laxatives frequently fail to counteract the symptoms 
of OIC13,15. Instead, treatment of OIC should target the etiology of this condition via a 
µ-opioid receptor mediated approach such as that of naloxone (a non-selective opioid 
antagonist), rather than just focus on symptomatic management10,11. 
Chapter 4
88
As demonstrated in previous studies, OXN PR can significantly improve bowel func-
tion without affecting the pain relief observed with Oxy PR in patients with moderate-
to-severe chronic pain29–32. This pooled analysis demonstrates that these effects are also 
valid for patients with persisting OIC despite the use of at least two different types of 
laxatives, and provides further confirmation that naloxone addresses OIC from a patho-
physiological point of view rather than merely a symptomatic standpoint. In this pooled 
analysis, OXN PR provided effective analgesia for patients with moderate-to-severe pain 
with OIC that is refractory to at least two different classes of laxatives. The stable average 
pain scores during study treatment were comparable to observations in the patients 
randomized to Oxy PR in the primary studies for OXN2001 and OXN900129,31. These find-
ings add to the substantial body of evidence that addition of naloxone to Oxy PR (in the 
combination of OXN PR) can prevent symptoms of OIC while not interfering with the 
pain relief obtained with Oxy PR42,43.
COnClusIOn
In summary, the results of this pooled analysis add to the body of evidence for the unique 
mechanism of action and therapeutic value of OXN PR. In patients with persisting OIC 
despite the use of two different classes of laxatives, OXN PR resulted in a significant and 
clinically relevant improved bowel function, significantly reduced the use of laxatives, 
and provided effective analgesia for patients with moderate-to-severe cancer-related 
pain and non-cancer related pain.
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absTRaCT
Purpose 
Laxative-refractory OIC (defined as opioid-induced constipation despite using 2 laxatives 
with a different mechanism of action (based on the Anatomical Therapeutic Chemical 
(ATC) Classification System level 4 term, e.g. contact laxatives, osmotically acting laxa-
tives, softeners/emollients, enema’s and others))  has a great impact on the treatment 
and quality of life (QoL) of patients with severe chronic pain. This non-interventional 
observational, real-life study in Belgium investigates the efficacy of prolonged release 
oxycodone/naloxone combination (PR OXN) treatment regarding pain relief and OIC, 
compared to previous prolonged release oxycodone (PR OXY) treatment for laxative-
refractory OIC patients in daily clinical practice. 
methods 
Laxative-refractory OIC patients with severe chronic pain were treated with PR OXN for 
12 weeks (3 visits). Pain relief (numerical rating scale [NRS]) and OIC (Bowel Function 
Index [BFI]) were evaluated at each visit. A responder was defined as a patient who had 
a) no worsening of pain at last visit compared to visit 1, or an NRS ≤ 4 at visit 3/last visit, 
as well as b) a reduction in BFI ≥ 12 units at visit3/last visit compared to visit 1, or c) a BFI 
≤28.8 at visit 3/last visit. 
Findings 
68 laxative-refractory OIC patients  with severe chronic pain were treated during  91 days 
with PR OXN (median daily dose 20 mg). Treatment with PR OXN resulted in a significant 
and clinically relevant decrease of pain with  2.1 units (p<0.001, 95% CI: 1.66, 2.54) and of 
BFI with 48.5 units (p<00.001; 95% CI: 44.4, 52.7) compared to PR OXY treatment, while 
use of laxatives was significantly reduced (p<0.001). 95.1% of patients was a responder 
and QoL  (EQ-5D) improved significantly. Adverse events were opioid related and  PR 
OXN treatment was well tolerated. 
Implications
Treatment with PR OXN results in a significant and clinically relevant reduction of OIC 
compared to previous PR OXY treatment for patients with severe chronic pain and 
laxative-refractory OIC. Treatment with PR OXN also resulted in a significant improve-
ment in pain relief and quality of life.
Clinical Trial Registry number
ClinicalTrials.gov identifier: NCT01710917
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InTRODuCTIOn 
Opioids are widely used for treatment of patients with severe chronic pain. However, 
adverse drug reactions associated with the use of opioids, particularly opioid-induced 
bowel dysfunction (OIBD), can be very problematic and severely affect quality of life1. 
Opioid-induced constipation (OIC) is the most distressing lead symptom of OIBD and 
occurs in approximately 40% of opioid-treated patients2, 3. In contrast to opioid-related 
adverse effects mediated through the central opioid receptors, occurring at the start 
of the treatment and usually decreasing rapidly, OIC is mediated through intestinal 
opioid receptors, often persisting throughout opioid treatment without diminishing in 
intensity4. OIC is the most troublesome opioid-related side effect reported by patients, 
resulting in reduction or discontinuation of opioid treatment in a third of opioid-treated 
patients1. Laxatives are the most common drugs used for relieving OIC. However, since 
laxatives do not address the underlying mechanisms of OIC they are insufficiently ef-
fective in the majority of patients suffering from OIC5, 6 . Moreover, there are no direct 
comparative data on different laxatives in the prevention or treatment of OIC, resulting 
in a lack of generally accepted guidelines on laxative use in OIC6.
A strategy to minimize or prevent OIC while maintaining analgesic efficacy is blocking 
intestinal opioid receptors while allowing the activation of central opioid receptors6. To 
this end, a prolonged release  tablet consisting of oxycodone and naloxone (PR OXN) in 
a 2:1 ratio has been developed. Oxycodone has been shown to be an effective analgesic 
in different types of pain7. Naloxone is an opioid receptor antagonist with low systemic 
bioavailability (<3%) primarily used as an injectable solution for treatment of opioid 
overdose by its antagonizing effect on central opioid receptors. When administered 
orally, naloxone antagonizes the opioid receptors in the gut wall, thereby counteracting 
OIC, while its extensive first pass hepatic metabolism ensures the lack of antagonist 
effect on the central analgesic effect of oxycodone8.  
Several randomized controlled studies demonstrated comparable analgesic efficacy 
of PR OXN and prolonged release oxycodone (PR OXY) with a significant and clinically 
relevant improvement in OIC of PR OXN compared to PR OXY in different types of pain 
even after long-term treatment9-15. The frequency of adverse events was similar between 
PR OXN and PR OXY treatment. This has been confirmed in a daily clinical practice in 
Germany for patients with a wide variety of pain etiologies16. 
PR OXN is indicated for the treatment of severe pain which can only be adequately 
managed with opioid analgesics. In Belgium reimbursement for PR OXN is strictly limited 
to patients who have been treated with PR OXY for at least the last 30 days prior to PR 
OXN treatment and who suffer from laxative-refractory OIC (defined as OIC despite the 
use of at least 2 laxatives with different mechanisms of action  (based on the Anatomical 
Therapeutic Chemical (ATC) Classification System level 4 term, e.g. contact laxatives, 
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osmotically acting laxatives, softeners/emollients, enema’s and others; level 4 ATC term) 
during previous PR OXY treatment. 
This study was requested by the Belgian reimbursement authorities to investigate 
PR OXN efficacy regarding both pain relief and OIC in chronic pain patients eligible for 
PR OXN reimbursement in Belgium in real-life. Besides evaluation  of efficacy regarding 
pain relief and OIC use of laxatives and analgesic rescue medication, quality of life and 
safety during PR OXN treatment compared to the previous PR OXY treatment were also 
evaluated.
meThODs
study design
This non-interventional, observational, real-life study was designed to evaluate the pain 
relief and OIC of the PR OXN treatment in daily practice in patients with chronic severe 
pain compared to previous PR OXY treatment. PR OXN treatment started at visit 1. The 
study was performed with electronic Case Record Forms (eCRF). All parameters collected 
at visit 1 reflected the PR OXY treatment.  Evaluations were performed during 2 follow 
up visits. Visit 2 was scheduled after PR OXN dose titration and visit 3 was scheduled at 
least 12 weeks after visit 1. 
This study was conducted in accordance with Belgian and European health law and 
controlled drug regulations. 
Patients
Patients enrolled in this study met the reimbursement conditions for PR OXN in Belgium 
as well as the summary of product characteristics (SPC) for PR OXN. In Belgium  patients 
are eligible for reimbursement if they meet the following conditions: 
a) all patients had to be  ≥ 18 years, with a documented history of severe pain requir-
ing around-the-clock opioid therapy,  treated with PR OXY during at least 30 days  with 
insufficient pain relief and/or unacceptable side effects  AND  b) all patients had to be 
suffering from OIC (Bowel Function Index [BFI] ≥ 28.8, see section methods) despite the 
use of at least 2 laxatives with different mechanisms of action (level 4 ATC term) during 
the previous PR OXY treatment.
Patients were excluded from the study if any of the following criteria based on the SPC 
were met: any history of hypersensitivity to oxycodone, naloxone, related products or 
other ingredients; active alcohol or drug abuse and/or history of opioid abuse; patients 
who participated in a clinical research study involving a new chemical entity or an ex-
perimental drug within 30 days of study entry; surgery completed prior to the start of 
the study, or planned surgery during the study that would influence pain or bowel func-
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tion; patients who had taken naloxone £30 days prior to the start of the study; patients 
suffering from diarrhoea and/or opioid withdrawal; patients with any situation in which 
opioids were contra-indicated; patients suffering from severe respiratory depression 
with hypoxia and/or hypercapnia, severe obstructive pulmonary disease, cor pulmonale, 
severe bronchial asthma, non-opioid induced paralytic ileus, moderate to severe liver 
function impairments, and pregnant or breastfeeding women. Written informed con-
sent was obtained from patients for the anonymous use of the data.
medication
PR OXN is available in 5mg/2,5mg; 10mg/5mg; 20mg/10mg and 40mg/20mg (oxyco-
done/naloxone) tablets and was prescribed to the patients according to the SPC.Patients 
were switched immediately from PR OXY to PR OXN with equal oxycodone doses. After 
switch to PR OXN the PR OXN dose could be titrated as needed,   Use of laxatives and 
analgesic rescue medication as well as other co-medication was allowed during PR OXN 
treatment as in daily clinical practice and documented (yes/no was mandatory, type and 
dosage was optional). 
study assessments
Primary parameter
The primary parameter was the percentage of responders after 12 weeks of PR OXN 
treatment. The response was based on the parameters pain and OIC as described below.
Pain 
Pain was assessed at each visit by the physician on a numerical rating scale (NRS) from 0 
(no pain) to 10 (worst pain). 
OIC
OIC was evaluated by the physician using the validated BFI** 17,18. This index uses a nu-
merical scale  from 0 (easy/no difficulty) to 100 (severe difficulty/very strong) to record a 
patients’ subjective assessment of three items related to OIC: ease of defecation, feeling 
of incomplete bowel evacuation and personal judgement of OIC. The BFI is calculated as 
the arithmetic mean of the scores for these three items. A lower score indicates a better 
bowel function. A score of ≤28.8 is considered a normal bowel function with respect to 
OIC and a BFI change of ≥12 points is considered a clinically relevant change17,18,19.
*  Copyright for the BFI is owned by Mundipharma Laboratories GmbH, Switzerland 2002; the BFI is subject 
of European Patent Application Publication No. EP 1 860 988 and corresponding patents and applications 
in other countries.
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Responders
A patient was defined as a responder if the patient had:
•	 no	worsening	of	pain	(NRS	increase	≤	1	unit	at	visit	3/last	visit	compared	to	visit	
1 or a NRS ≤ 4 at visit3 /last visit AND 
•	 had	a	reduction	in	BFI	of	≥	12	units	at	the	last	visit	compared	to	visit	1	or a BFI 
≤ 28.8 at visit 3/last visit. 
Secondary parameters
Secondary parameters included the use of laxatives and analgesic rescue medication, 
evaluation of the quality of life and safety assessment during PR OXN treatment com-
pared to the previous PR OXY treatment.
Use of laxatives
Laxative use was assessed by asking if the patient had used laxatives in the last 7 days 
prior to the each study visit (yes or no) and whether laxative use had increased/de-
creased or remained constant compared to previous visit was also registered (decrease/
constant/increase). If laxatives were used in the last seven days prior to the study visit, 
notation of type, dose and frequency of the used laxatives were optional due to the 
non-interventional character of the study. The percentage of patients using laxatives in 
the last 7 days before each visit and the percentages of patients reporting increased/
decreased/stable laxative use at visits 2 and 3  compared to visit 1 were calculated. 
Use of analgesic rescue medication
The assessment of the use of analgesic rescue medication was similar to the assessment 
of laxative use as described above.
Quality of Life
The patient’s quality of life was evaluated via the standardized EQ-5D questionnaire. The 
EQ-5D score and EQ-5D VAS health score was recorded at visit 1 and at the last visit. A 
derived EQ-5D score was calculated from the 5 items (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) as well as the absolute change in EQ-5D score 
and EQ-5D VAS health score  between the last visit and visit 1. 
Safety 
Safety assessments consisted of monitoring and recording all (Serious) Adverse Events 
((S)AEs) and adverse reactions (ARs) at all visits. 
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statistical analysis
For the efficacy parameters the analyses were performed for all patients meeting the in-
clusion criteria who received at least one dose of PR OXN treatment and who had at least 
one post-dose efficacy evaluation (full analysis population). Patients using laxatives dur-
ing the 30 days PR OXY treatment  were included in this full analysis. Since patients were 
not asked pro-actively about the laxative treatment before start, and since the laxative 
use during last 7 days was evaluated at the consecutive visits, it was decided to analyze 
the primary parameter also for patients who used laxatives in the last 7 instead of 30 
days before study inclusion (per protocol population). The safety analysis was performed 
for all patients who had received at least one dose of study medication and had at least 
one safety assessment after the last dose (safety population). Descriptive statistics of all 
demographic, baseline variables and study parameters were provided overall. Continu-
ous data were summarized by their mean, standard deviation, 95% confidence interval 
of the mean, median, minimum and maximum. Categorical and ordinal data were sum-
marized by frequency and percentages. No imputation of missing data was performed. 
A paired t-test was used to test if there was a change in mean pain NRS, BFI and EQ- 5D 
score between the first and last visit. The McNemar test for paired data was used to test 
if there was a change in use of laxatives or use of analgesic rescue medication between 
the first and the last visit. The effect of the treatment time on changes in mean BFI scores 
was studied in more detail using linear mixed effect models. All statistical tests were 
performed using a two-sided significance level of 5%.
ResulTs
A total of 68 patients were included in the full analysis population (Figure 1). 91.2% of 
the patients (62 out of 68) completed the study. Three patients (4.4%) discontinued the 
study on their own choice, one patient stopped due to an adverse event and 2 patients 
(2.9%) for other reasons ( Figure 1).  For 3 subjects no laxative intake for the last 7 days 
was documented and therefore 65 patients were included in the per protocol analysis 
(Figure 1). 
Table 1 shows age, gender and diagnosis of pain for enrolled patients. The median study 
duration was 91 days (7 - 127 days), with 37.5 days (3-85) for visit 2 (dose titration) and 
91 day for visit 3 (39-127). These variations in study durations were due to the non-
interventional set-up of the study. The median (range) dose of PR OXY treatment used 
before start of the study (visit 1) was 20 (5-360) mg. The median (range) prescribed dose 
of PR OXN at  visit 1 was similar to that of PR OXY, 20 (10-360) mg.  At visit 2 and visit 3 
the median (range) dose of PR OXN remained stable at 20 (10-360) mg.
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Figure 1: Patient diagram 
The full analysis population included all patients meeting the inclusion criteria who received at least one 
dose of PR OXN treatment during the study and who had at least one post-dose efficacy evaluation. The 
per protocol population included all patients meeting the inclusion criteria who took laxatives in the last 7 
days before study inclusion.
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efficacy of PR OXn treatment with regard to pain relief
The pain NRS reduced significantly (p<0.001) with on average 2.1 units (95% CI: 1.66, 
2.54) between visit 1 (mean(SD)  6.8±1.5) and visit 3 (mean(SD) 4.6±1.5) (Figure 2). The 
average pain NRS was also significantly decreased over time during PR OXN treatment 
to 3.8 after 18 weeks.
Table 1: Baseline characteristics of the patients (n=68, full analysis population)
Characteristic Value
Age (years), Mean (SD) 59.8 (13.3)
Sex, no. (%)
Male 22 (32.4)
Female 46 (67.6)
Pain diagnosis, no. (%)
Malignant 4 (5.9)
Non-malignant* 62 (91.2)
Osteoarthritis 19 (30.6)
Arthritis 1 (1.6)
Low back pain 26 (41.9)
Neuropathic pain 22 (35.5)
Osteoporosis 2 (3.2)
Post-operative pain 6 (9.7)
Other 9 (14.5)
Unknown 2 (2.9)
*For patients with non-malignant pain, multiple diagnoses were possible
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Figure 2: Average pain score (NRS) with standard deviation per visit  (FA population). 
Number of patients at visit 1 n=60, visit 2 n=59 and visit 3 n=54. * Indicate a significant reduction in pain 
NRS in comparison with visit 1 (p<0.001, linear mixed effect model).
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efficacy of PR OXn treatment with regard to OIC
The BFI reduced significantly (p<0.001) with on average 48.5 units (95% CI: 44.4, 52.7) 
between visit 1 (mean(SD) 70.8±16.2) and visit 3 (mean(SD) 21.3±13.2) (Figure 3).
The BFI improved significantly (p<0.001) with on average 3.4 units (95% CI: -3.8, -3.0) 
per week during PR OXN treatment. This improvement of BFI was clinically relevant with 
an average of 13.6 units (95% CI: 12, 15.2) after already 4 weeks of PR OXN treatment. 
After 6 weeks of PR OXN treatment, the average BFI was <28.8 and thus patients were 
considered not constipated anymore.
efficacy of PR OXn treatment in terms of responders
The efficacy of PR OXN regarding pain relief and OIC was expressed as the percentage 
of responders following 12 weeks PR OXN treatment compared to the previous PR OXY 
treatment. Data for 1 and 2 patients were missing for the full analysis and per protocol 
populations respectively (Figure 1, primary parameter). Among the full analysis popula-
tion, 58 out of 61 patients were qualified as responders (95.1%, 95% CI: 86.0%; 98.9%) 
and for the per protocol population 55 out of 58 patients (94.8%, 95% CI: 85.3%; 98.8%) 
were qualified as responders.
use of laxatives
The number of patients using laxatives in the last 7 days before each visit decreased 
significantly from 65 patients (95.6%) at start to 24 patients (38.7%) at visit 3 (McNemar 
test χ²(1) = 37.0, p<0.001)(Table 2). 
The optional field for type of laxative was registered for  32  out of 65 patients  at visit 
1; the majority of these patients (73%) used polyethylene glycol (PEG), 30% bisacodyl, 
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Figure 3: Average bowel function index (BFI) with standard deviations per visit (FA population). 
Number of patients at visit 1 n=67, visit 2 n=66 and visit 3 n=61. * Indicate a significant reduction in BFI in 
comparison with visit 1 p,.001,  linear mixed effect model).
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17% sodium picosulphate, 17% senna, 8% lactulose and 8% rectal laxatives. Since more 
than one laxative could be registered the sum of these percentages is >100%. 
Within the group of 41 patients using laxatives at visit 2, 37 patients (90.2%) reported 
a decreased use of laxatives in the last 7 days compared to the preceding PR OXY treat-
ment. Of the 24 patients using laxatives at visit 3, 20 patients (83.3%) reported a de-
creased use of laxatives in the last 7 days compared to the preceding PR OXY treatment. 
use of analgesic rescue medication
The number of patients using analgesic rescue medication in the last 7 days before 
each study visit decreased significantly from 44 patients (64.7%) at start  to 26 patients 
(41.9%) at visit 3 (McNemar test χ²(1) = 13.1, p<0.001). The optional field for type of 
rescue medication was registered for 28 out of 44, 19 out of 37  and 15 out of 26 patients 
at visit 1,2 and 3 respectively.  The majority of these patients (V1 68%, V2 63% and V3 
66%) used oxycodone as rescue medication. 
Quality of life
The EQ-5D score increased significantly with on average 0.275 units (95% CI: 0.202; 
0.347) between visit 1 (mean(SD) 0.247±0.233) and the last visit (mean 0.522±0.275) 
(p<0.001) . The EQ-5D VAS health score increased significantly with on average 25.2 
units (95% CI: 20.1; 30.3) between visit 1 (mean(SD) 33.0±13.0) and the last visit (mean 
58.2±16.8) (p<0.001). 
safety analysis
Only two patients (2.9%) reported an adverse event. One patient reported euphoria and 
drowsiness at visit 2. The other patient had an epileptic seizure after visit 2, however, this 
Table 2: Laxative use in the 7 days before the study visit. Data are given as no. (%).
laxative use
Visit 1 a
n
(%)
Visit 2 b
n
(%)
Visit 3 b
n
(%)
last visit b
n
(%)
Yes / No 65 / 3 (95.6 / 4.4) 41 / 26 (60.3 / 38.2) 24 / 38 (38.7 / 61.3) 26 / 42 (38.2 / 61.8)
Decrease / Constant 
/ Increased C
NA
37 / 3 / 1 (90.2 / 7.3 
/ 2.4)
20 / 4 / 0 (83.3 / 16.7 
/ 0)
21 / 5 / 0 (80.8 / 19.2 
/ 0)
Missing data 0 1 (1.5) 0 0
NA = not available
A Laxative used in last 7 days before study inclusion. These data are considered data for laxative use during 
the previous PR OXY treatment.  
B Laxative used in last 7 days before study visit: yes/no and increased, decreased or constant laxative use 
during PR OXN treatment compared to the preceding PR OXY treatment.
C Decrease / Constant / Increased laxative use for patients who used laxatives during the preceding PR OXY 
treatment 
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was considered to be unrelated to PR OXN treatment. AEs were of average intensity and 
were pharmacologically treated, leading to disappearance of the AE. No serious adverse 
event (SAE) was reported throughout the study.
DIsCussIOn
This study, requested by the Belgian reimbursement authorities evaluated the efficacy of 
PR OXN regarding pain relief and OIC in 68 patients with chronic pain who were treated 
with PR OXY during at least the last 30 days before PR OXN treatment and who suffered 
from OIC despite the use of at least 2 laxatives with different mechanisms of action (level 
4 ATC term). To the best of our knowledge, this is the only non-interventional study of 
opioid treatment where laxative use is documented before and during opioid treatment.
This study shows that PR OXN was superior to PR OXY regarding pain relief, OIC and 
quality of life in chronic pain patients previously treated with PR OXY and suffering 
from OIC despite the use of at least 2 different laxatives. The mean pain NRS reduced 
significantly with on average 2.1 units during treatment with PR OXN, comparable to 
other studies previously demonstrating similar analgesic efficacy of PR OXN and PR OXY 
even after long-term treatment with PR OXN4, 9, 12-15. The median PR OXN daily dose of 
20 mg remained constant throughout the study and was equal to the PR OXY dose dur-
ing the preceding PR OXY treatment. Moreover, the use of analgesic rescue medication 
decreased significantly during PR OXN treatment compared to the preceding PR OXY 
treatment. The observed improved pain relief during PR OXN treatment can therefore 
not be explained by an increased dose or increased use of analgesic rescue medication 
and is probably related to the improved OIC during PR OXN treatment. 
This is the first non-interventional study in which the effect of PR OXN on OIC was 
evaluated using two parameters, i.e. the BFI and laxative use. The BFI showed a statis-
tically significant and clinically relevant improvement of 49 points from visit 1 to the 
last visit. A change in BFI of ≥ 12 points is proven to be related to clinically meaningful 
changes of bowel habits in patients with OIC18.This study confirms that after 4 weeks of 
treatment with PR OXN a clinically relevant improvement of OIC is attained in patients 
suffering from laxative-refractory OIC. The average BFI was below 28.8 after 6 weeks of 
PR OXN treatment, indicating that patients were on average not constipated anymore 
despite the opioid treatment19. 
In addition to the BFI, PR OXN efficacy regarding OIC was investigated by comparing 
the use of laxatives between the previous PR OXY treatment and PR OXN treatment. 
The number of patients using laxatives declined significantly during PR OXN treatment 
compared to PR OXY. If laxatives were needed, the vast majority of patients using laxa-
tives during PR OXN treatment indicated decreased laxative use during PR OXY treat-
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ment. Therefore, the improvement in OIC observed during PR OXN treatment cannot 
be explained by an increased use of laxatives. This supports the rationale that PR OXN 
treatment counteracts OIC through other mechanisms than laxatives do and that PR 
OXN addresses the underlying mechanism of OIC. The results of this non-interventional 
study are in line with results of a pooled analysis of laxative-refractory OIC patients from 
studies with PR OXN with respect to BFI and laxative use20. This pooled analysis showed 
that PR OXN significantly improved bowel function and reduced the use of laxatives in 
patients with OIC, previously unresponsive to at least two different classes of laxatives. 
PR OXN also provided effective analgesia for patients with moderated-to-severe 
cancer-related pain and non-cancer-related pain. The efficacy of PR OXN regarding pain 
relief and OIC was expressed as the percentage responders following PR OXN treatment 
compared to the previous analgesic treatment with PR OXY. The percentage of respond-
ers was 95.1% after 12 weeks of PR OXN treatment, indicating that almost all patients 
experienced a pain NRS score ≤ 4 or improved pain relief in the absence of OIC (BFI ≤ 
28.8) or with a clinical improvement in OIC (BFI improvement ≥ 12 units) compared to 
the preceding PR OXY treatment.
Quality of life improved significantly during PR OXN  treatment. The overall EQ-5D 
score and EQ-5D VAS health score increased significantly with on average 0.275 units 
and 25.2 units resp. after 12 weeks of PR OXN treatment compared to PR OXY. This im-
proved quality of life probably reflects the improved pain relief and OIC during PR OXN 
treatment and is in line with previous studies4, 16, 21.
PR OXN treatment was well tolerated in this study. No SAEs were reported during 
this study. The frequency of AEs was lower compared to other studies, which can be 
explained by the observational design of this study. 
Remarkably, in this study one patient was directly switched from a daily dose of 
360 mg oxycodone to an equivalent dose of 360 mg/180 mg oxycodone/naloxone. 
In current literature daily doses of up to 240 mg/120 mg oxycodone/naloxone have 
been described using a stepwise switch from oxycodone to oxycodone/naloxone with 
different outcomes14,22. Close review of the patient’s records revealed that the patient 
responded well to the direct switch. Pain relief on oxycodone was comparable to pain 
relief on oxycodone/naloxone (pain NRS score was 3 throughout the 87 days treatment 
period). Moreover, no adverse events were reported, the patient did not require any 
analgesic rescue medication or other concomitant medication and a decrease in laxa-
tive medication was reported alongside an improvement in bowel function after switch 
from oxycodone to oxycodone/naloxone (BFI decreased from 46.7 to 0). 
Of course a non-interventional study has limitations, one of them being that we could 
not ensure that  all data were documented in the database. This limitation was tackled 
by marking important parameters (e.g. BFI, pain relief, laxative use yes/no and rescue 
Chapter 5
108
medication yes/no) as mandatory fields in the electronic CRF, as a result there were 
hardly any missing data for these mandatory fields. 
Whilst keeping the inherent limitations of a  non-interventional study in mind  the 
effects of PR OXN in real-life clinical practice in Belgium for those patients who were 
eligible for reimbursement, demonstrated significant reduction of OIC during treatment 
of PR OXN in laxative-refractory OIC patients. The results of this real-life study confirmed 
the improvement seen in a pooled analysis from pivotal studies with PR OXN in a com-
parable patient group20. 
COnClusIOn
In this real-life study in Belgium, patients with chronic severe pain and  OIC despite the 
use of at least 2 laxatives with different mechanisms of action (level 4 ATC term) experi-
enced a significant improved pain relief,  a significant and clinically relevant reduction 
of OIC as well as a significant improvement of quality of life after PR OXN treatment 
compared to previous PR OXY treatment. The percentage of responders was 95.1% after 
12 weeks of PR OXN treatment, indicating that almost all patients experienced no pain 
or improved pain relief in the absence of OIC  or with a clinical improvement in OIC 
compared to the preceding PR OXY treatment.
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absTRaCT 
Objective
Treatment with prolonged-release oxycodone/naloxone (PR OXN) has been shown to 
improve opioid induced constipation (OIC) in constipated patients. This publication re-
ports on a real-life observational study investigating the efficacy of PR OXN with regard 
to bowel function in patients switching to PR OXN from WHO-step 1, step 2 and step 3 
opioids. 
methods
Patients with chronic pain experiencing insufficient pain relief and/or unacceptable side 
effects were switched to PR OXN and monitored in this observational study with respect 
to efficacy regarding bowel function and efficacy regarding pain relief in comparison 
with previous analgesic therapy. A patient was considered responder with respect to 
efficacy if this assessment was ‘slightly better’, ‘better’ or ‘much better’ compared with 
previous therapy. Bowel function index, pain intensity, quality of life, laxative medica-
tion use, and safety analgesic were also evaluated.
Results
1,338 patients  (mean (sd ) age 64.3 (14.9), 63% female) were observed for 43 [3-166] days 
(median [range])  during treatment with PR OXN. Overall response rate regarding bowel 
function efficacy was 82.5%.  Patients with symptoms of constipation at study entry 
obtained a clinically relevant improvement of the bowel function index (BFI) within the 
first 2 weeks of PR OXN treatment.  Non-constipated patients at study entry maintained 
normal bowel function despite switching to treatment with the opioid PR OXN. 
Conclusion
In conclusion, treatment with PR OXN results in a significant and clinically relevant 
improvement of bowel function. During the observation of the treatment with PR OXN 
patients reported an improvement of QoL. More interestingly, non-constipated patients 
maintained a normal bowel function, showing prevention of constipation despite the 
use of an opioid.
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InTRODuCTIOn
The prevalence of chronic pain in adults is about 19% in Europe 1. Chronic severe pain, 
has important implications for the individual’s quality of life and is a major public health 
challenge because of the impact on  work performance and the increased use of health-
care services2.  
Strong opioids are a treatment option for pharmacological management of chronic 
moderate to severe pain of malignant and non-malignant origin3-6. However, 30% of 
the patients with malignant pain and 12% with non-malignant pains treated with an 
opioid do not achieve an adequate level of analgesia and/or suffer from intolerable or 
dose-limiting adverse effects7. Opioid-induced constipation (OIC) is the most common 
and most dominant adverse effect of opioid treatment8 affecting up to 80% of patients 
treated with opioids9-11. Opioids contribute to OIC by activation of opioid receptors in 
the gastrointestinal wall leading to reduced motility of the gut and opioids can increase 
circular muscle activity (hence causing cramping pain) at the expense of longitudinal 
muscle. In addition, opioids contribute to OIC by increasing water withdrawal from 
the bowel8-11. OIC negatively impacts the patient’s quality of life12, resulting in a lack of 
compliance in up to one third of the patients10 potentially leading to insufficient pain 
relief. Moreover, OIC can in itself also be a cause for pain; the majority of patients with 
OIC report pain caused by OIC. Pain caused by OIC may result in more discomfort than 
pain caused by the underlying condition 10, 13, 14. In contrast to other opioid-related side 
effects OIC is unlikely to improve over time and most patients do not develop tolerance 
to OIC10, 15-17.
Treatment of OIC comprises general non-pharmacological measures, like dietary 
advices and excercise,  and the treatment with non-specific laxatives like bisacodyl, poly 
ethylene glycol with electrolytes and lactulose. However, about half of all opioid treated 
patients requiring laxatives do not achieve satisfactory relief from OIC, as most used 
laxative treatments for OIC are non-specific and do not target the underlying cause of 
OIC17, 18. Furthermore, laxatives themselves may lead to gastrointestinal adverse events 
and complications17.
Prolonged release oxycodone/naloxone (PR OXN) is a fixed combination of  oxyco-
done/naloxone. When co-administered orally with oxycodone, naloxone counteracts 
OIC by antagonizing opioid receptors in the gastrointestinal wall, while its limited avail-
ability following first pass metabolism ensures its lack of interference on the analgesic 
effect of oxycodone mediated by activation of opioid receptors in the central nervous 
system19. In several randomized controlled trials PR OXN has shown to provide effective 
pain relief, while effectively counteracting OIC20-27. Several prospective, observational 
studies confirmed the efficacy of PR OXN in real-life studies28-30.
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In this real-life observational study, the efficacy of PR OXN regarding bowel function 
was evaluated in patients with severe pain switching from WHO-step 1, step 2 and/or 
step 3 medication to PR OXN due to insufficient pain relief and/or unacceptable side ef-
fects in daily clinical practice in Belgium, taking into account previous used medication 
and constipation status at study entry. 
meThODs
study design and patient population
This publication describes the results of a phase IV, open label, multicenter, prospective, 
observational, real-life study conducted in Belgium between April and December 2011 
approved by the ethical committees of the participating centers. 
The decision to switch to open-label PR OXN preceded the decision to participate in 
the study and written informed consent was obtained before study entry.Adult patients 
with severe pain previously treated with WHO-step1, step 2 and/or step 3 (excluding 
PR OXN) analgesics that had been switched to PR OXN because of insufficient pain 
relief and/or unacceptable side effects on their previous medication were consecutively 
included and treatment with open-label PR OXN as in daily clinical practice was moni-
tored. Unacceptable side effects were defined as side effects that could not be tolerated 
by the patient. Patients were excluded in case of alcohol abuse, a history of active drug 
abuse, use of hypnotics or CNS depressants that might pose a risk of additional CNS 
depression, opioid therapy for opioid addiction, confirmed diagnosis of irritable bowel 
syndrome, evidence of clinically significant GI disease, and abnormalities of the GI tract 
or suffering from diarrhea and/or opioid withdrawal.
At the first baseline visit, patients were switched from their previous analgesic medi-
cation to the most appropriate twice-daily PR OXN dose (5 mg/2.5 mg, 10 mg/5 mg, 20 
mg/10 mg or 40 mg/20 mg) according to the physician’s judgment, taking into account 
that PR OXN is as effective for pain relief as oxycodone. Pain intensity and bowel func-
tion were recorded at the first baseline visit (visit 1) and at two follow-up visits (visit 2 
and 3) during PR OXN treatment as in daily clinical practice. 
Due to the observational real-life study design follow-up of patients was performed 
as in daily practice. In daily practice follow-up of patients during treatment differs per 
physician, therefore no fixed time points were set for the follow-up visits (visit 2 and 
3). For efficacy analyses over time (efficacy regarding pain relief and efficacy regarding 
bowel function) the following intervals were defined; a) 2 ±2 weeks (visits on day 1 -28 
after first visit) b) 6±2 weeks(visits on day 29- 56 after first visit); c) 11±3 weeks(visits day 
57-98) and d) 17±3 weeks(visits day 98-140). For patients with more than one visit in one 
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time period, only the last visit in that period was considered for analysis of the efficacy 
endpoints.
BFI was analyzed at baseline (visit 1) and follow-up visits (visit 2 and 3) as well as over 
time (baseline, 2±2 weeks, 6±2 weeks, 11±3 weeks and 17±3 weeks). Data on laxative 
use, and adverse drug reactions were recorded over the period between visit 1 and 2 at 
visit 2, and over the period between visit 2 and 3, at visit 3. Quality of life was evaluated 
at the first and last study visit per patient (see supplementary table 1 for an overview of 
the study and study schedule). 
Outcome measurements
Outcome measurements included efficacy of PR OXN regarding bowel function com-
pared to the previous analgesic treatment as evaluated by the physician using a 7-point 
ordinal scale (much worse, worse, slightly worse, same, slightly better, better and much 
better) and bowel function was also evaluated with the (Bowel Function Index ([BFI]31, 32; 
Copyright for the BFI is owned by Mundipharma Laboratories GmbH, Switzerland 2002; 
the BFI is subject of European Patent Application Publication No. EP 1 860 988 and cor-
responding patents and applications in other countries). 
For analysis, the 7-point physician evaluation scale was converted to a binary scale, 
where patients were considered responder if their bowel function during PR OXN treat-
ment was evaluated as ‘slightly better’, ‘better’, or ‘much better’.  
The BFI is the arithmetic mean value of the patients’ evaluation on the difficulty of 
bowel movement, feeling of incomplete bowel evacuation and personal judgment of 
constipation during the last 7 days, each scored from 0 (no problem/no difficulty) to 100 
(severe difficulty/problem). A BFI <28,8 is validated as a normal bowel function33 and a 
change in BFI≥ 12  is considered as a clinically relevant change in bowel function31. 
Outcome measurements for pain relief  included the efficacy of PR OXN regarding 
pain relief compared to the previous analgesic treatment as evaluated by the physician 
using a 7-point ordinal scale (much worse, worse, slightly worse, same, slightly better, 
better and much better). Pain relief was also evaluated with the Numeric Rating Scale 
([NRS] from 0 to 10.
For analysis, the 7-point physician evaluation scale was converted to a binary scale, 
where patients were considered responder if their pain relief during PR OXN treatment 
was evaluated as ‘slightly better’, ‘better’, or ‘much better’.  The percentages of patients 
using laxatives or analgesic rescue medication at the follow-up visits were calculated. 
The quality of life of patients was evaluated via the standardized EuroQol (EQ-5D) 
questionnaire with 5 dimensions: mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression. The total EQ-5D score was calculated using Belgian population 
based tariffs that could range between -0.158 (all criteria scored a value of 3) and 1 
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(perfectly healthy). Additionally, patients assessed their QoL using the EQ-5D VAS (from 
0  to 100, worst to best possible health status), indicating the patient’s self-rated health. 
ethical considerations
The study was registered with the Federal Agency for Medicinal Products and Health 
Products in Belgium (study code OXN9510) and was registered on clinicaltrials.gov with 
the identifier NCT01983137. The study was conducted in accordance with all applicable 
ethical guidelines and legislations. All patients provided written informed consent 
before inclusion. 
statistics
All data were analyzed by descriptive statistics and statistical comparisons for all study 
parameters over time and between previous analgesic WHO-step treatments groups 
were performed. Patients were categorized by the previous WHO step group based on 
the highest WHO step group. All efficacy endpoints were analyzed for the full analysis 
(FA) population, defined as all eligible patients who received at least one dose of PR 
OXN and had at least one post-dose evaluation; safety endpoints were analyzed for the 
safety population, defined as all patients who received at least one dose of PR OXN and 
for whom at least one post dose safety assessment was recorded. Additionally, post 
hoc analyses on all efficacy parameters were performed on patients with symptoms of 
constipation (BFI≥28.8, constipated patients) and without symptoms of constipation 
(BFI<28.8, non-constipated patients) at study entry. 
ANOVA and two-sample t-tests were used to compare subgroups at baseline and to 
compare changes from study entry and at last visit in  bowel function (BFI), pain inten-
sity (NRS) and QoL (EQ-5D) between the different subgroups. Categorical variables were 
compared using the Fisher’s exact test. 
ResulTs
Patient population and demographic characteristics
229 general practitioners and 55 specialists screened 1,429 patients experiencing se-
vere pain (272 patients were screened by specialists and 1,157 by GPs),  of whom 1,369 
patients were treated with PR OXN. The safety population consisted of 1,367 patients of 
whom safety evaluations were available. 31 patients were excluded from the full analysis 
population (FA-population) because there were no data available on previous analgesic 
treatment (n=27) or pain NRS score was “0” at study entry (n=2) or follow up data were 
unavailable (n=2), rendering 1,338 patients in the full analysis (FA)-population (Figure 1). 
The vast majority of patients (84.0%) terminated the study conforming to the protocol. 
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Reasons for early study discontinuation were adverse drug reactions (2.1%), insufficient 
effectiveness (1.3%), patients choice (3.4%), other reasons, such as planned surgical 
procedures and interventions (2.8%) and due to the observational nature of the study 
lost to follow-up (6.5%).
Patient demographics and characteristics for the overall population and the analyzed 
subgroups are summarized in Table 1. The mean age of the overall population was 
64.3±14.9 years, and 63% were female. Significantly more constipated patients (defined 
by a BFI>28.8 at study entry) were  older (p<0.001) and of female gender (p=0.039). 
The majority of patients suffered from non-malignant pain (77%), mainly caused by 
osteoarthritis (53%), low back pain (49%) and neuropathic pain (34%) (multiple pain 
indications could be chosen for one patient resulting in a sum >100%). Nearly a quarter 
of the patients (23%) suffered from malignant pain, mainly caused by cancer of lung 
(16%), breast (16%), colon (16%) and prostate (10%). For patients with pain of malignant 
origin the majority suffered pain due to metastatic disease (n=127), 41 suffered from 
advancing disease and 20 suffered from post-treatment/post-operative pain. For 121 
patients no specifications were given. Most malignant as well as non-malignant pain 
patients were treated by their GP (242 and 861 patients, respectively). 
 
Subjects treated (n=1369) 
Excluded from analysis (n=31): 
- No reported history on previous pain 
medication (n=27) 
- Pain NRS score of “0” at study entry (n=2) 
- No efficacy measurement after visit 1 (n=2) 
Safety-population (n=1367) 
2 patients excluded due to 
lack of safety evaluation 
Full Analysis-population  (n=1338) 
- Termination conform protocol (n=1124, 84.0%) 
- Patients’choice (n=45, 3.4%) 
- Other reasons (n=37, 2.8%) 
- Adverse drug reactions (n=28, 2.1%) 
- Insufficient effectiveness (n=17, 1.3%) 
- Lost to follow-up (n= 87, 6.5%) 
Figure 1. Flow diagram of the patients’ disposition
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At the start of PR OXN treatment, 10.6% of patients were previously treated with WHO 
step 1, 46.7% with WHO step 2 and 42.7% with WHO step 3 analgesics. Patients with ma-
lignant pain were more often treated with WHO-step 3 analgesics  than with WHO-step 
1 and WHO-step 2 analgesics (p<0.001). At study entry, the pain score was significantly 
lower in the WHO-step 3 group compared to the other WHO-step groups (p<0.001) and 
pain score of constipated patients was significantly (but not clinically relevant) lower 
compared to non-constipated patients (p=0.002). 
Mean BFI at study entry was high (53.5± 27.9), with significant differences between 
the WHO-step groups (p<0.001). Interestingly, the percentage of constipated patients 
at study entry (BFI>28.8) in the WHO-step 1 group was already 50.4% and this was 
even higher in the WHO-step 2 group and in the WHO-step 3 group (72.8% and 91.4% 
respectively). The overall mean EQ-5D total score at study entry was low 0.26±0.25, 
with statistically significant differences between the WHO-step groups, with the lowest 
scores for the WHO step 2 and WHO step 3 group (0.25 and 0.26 respectively (p=0.005).
Table 1. Demographics and baseline characteristics of patients  (Full Analysis-population)
Previous WhO step analgesic bowel function Total
step 1
n = 142
step 2
n = 625
step 3
n = 571
non-constipated
n=289
Constipated
n=1,048 n = 1,338
age in years 
 Mean ± SD 63.0±15.6 63.8±14.9 65.0±14.7 60.8±15.2 65.2±14.7 64.3±14.9
 gender: %Female  
   (n/N)
57.7%
(82/142)
62.2%
(389/625)
65.3%
(373/571)
57.8%
(167/289)
64.5%
(676/1048)
63.1%
(844/1338)
Type of pain
Malignant %
(n/N)
Non-malignant %
(n/N)
16.4%
(23/140)
83.6%
(117/140)
19.6%
(122/621)
80.4%
(499/621)
28.8%
(164/570)
71.2
(406/570)
17.8%
(51/287)
82.2%
(236/287)
24.7%
(258/1043)
75.3%
(785/1043)
23.2%
(309/1331)
76.8%
(1021/1331)
bowel Function Index 
(bFI)
Mean ± SD 31.8±26.4 47.7±27.6 65.3±23.0 10.4±9.3 65.4±17.8 53.5±27.9
Pain intensity (nRs)
Mean ± sd 7.3±1.3 7.7±1.1 6.7±2.0 7.6±1.3 7.2±1.7 7.2±1.7
bowel function 
BFI ≥28.8, %
 (n/N)
50.4%
(71/141)
72.8%
(455/625)
91.4%
(522/571)
n.a n.a.
78.4%
(1048/1337)
eQ-5D Total score 
Mean ± SD 0.32±0.26 0.25±0.23 0.26±0.26 0.27±0.24 0.26±0.25 0.26±0.25
Reasons for switch
Insufficient effectiveness
Unacceptable side effects
94.5%
17.9%
94.9%
56.9%
50.1%
86.2%
93.8%
33.4%
73.9%
67.7%
78.9%
65.4%
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PR OXn treatment
Overall, patients were followed in the study for mean ± sd 47.8±25.2 days (N=1338) and 
45.5%were followed between 4 to 8 weeks with no significant differences between the 
subgroups.  The mean daily dose of PR OXN increased from 11.6 mg at visit 1 to 15.2 mg 
at last visit in the total group (Table 2). 
The highest dose was prescribed in WHO-step 3 pretreated patients and the mean 
dose of PR OXN was numerically higher for constipated patients at study entry. However, 
there were no statistically significant differences in mean PR OXN dose between the 
three WHO-step subgroups and the two bowel function subgroups. 
efficacy regarding bowel function
The mean BFI at study entry was 53.5± 27.9 for the overall population (Table 3).  As 
expected BFI at study entry was significantly higher in patients pre-treated with WHO-
step 3 medication (65.3± 23.0, n=571)   compared with WHO-step 1 (31.8± 26.4, n=141) 
and WHO-step 2 (47.7± 27.7, n=625) medication (p<0.001). 
The response rate with respect to bowel function during PR OXN treatment was 82.5% 
at last visit, indicating that bowel function during PR OXN treatment was evaluated as 
‘slightly better’ to ‘much better’ for the majority of patients. Highest response was seen 
in the WHO-step 3 group (89.0%) and lower responses were seen in the WHO-step 2 and 
WHO-step 1 group (81.0% and 63.1% respectively). 
In line with the response rate a significant and clinically relevant decrease (Δ BFI 
(mean± sd)  -28.39 ± 26.45; p<0.0001) in BFI was observed during PR OXN treatment 
compared to previous analgesic treatment between visit 1 and last visit for the overall 
group, with the largest (and clinically relevant) decrease in the WHO-step 3 subgroup 
and the lowest non clinically relevant decrease of 10.5 points in the WHO-step 1 sub-
group (Δ BFI (mean ± sd) -10.5 ± 20.86 for WHO-step 1 group; -24.6 ± 26.20 for WHO-step 
2 group and -36.87 ± 24.78 for WHO-step 3 group). After 6 weeks of PR OXN treatment, 
the mean± sd  BFI values for the overall population, WHO-step 1 and WHO-step 2 groups 
Table 2. Daily dose of the oxycodone component of PR OXN
Previous WHO step analgesic Bowel function Total
Step 1 Step 2 Step 3 Non-constipated Constipated
Daily Oxycodone Dose (mg) Visit 1
Mean ± SD 
(N) 
7.5±5.2
(141)
8.8±7.2 
(622)
15.8±13.3
(565)
8.7±6.9
(287)
12.5±11.4
(1041)
11.6±10.7
(1328)
Daily Oxycodone Dose (mg) Visit 2 
Mean ± SD 
(N) 
8.4±5.3
(140)
10.8±8.1
(622)
18.4±14.6
(557)
9.9±7.5
(284)
14.8±12.6
(1034)
13.7±11.9
(1319)
Daily Oxycodone Dose (mg) Visit 3 
Mean ± SD 
(N)
8.6±5.7
(125)
12.3±10.4
(573)
20.0±16.8
(527)
11.0±8.6
(249)
16.3±14.8 
(975)
15.2±13.9
(1225)
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were below the constipation threshold of 28.8 and around that threshold for the WHO-
step 3 group (30.33±19.48) (Figure 2). 
For patients with constipation at study entry (N=1048; BFI (mean ± sd) 65.40 ± 17.81) 
a significant and clinically relevant decrease (mean -36.40 ± 22.90; p<0.0001) in BFI was 
observed during PR OXN treatment between visit 1 and last visit. Analysis over time 
showed that already in the first 2 weeks of PR OXN treatment a fast and clinically relevant 
BFI reduction was observed (BFI (mean ± sd)   35.99 ± 18.96 (N=690)). After 11 weeks 
PR OXN treatment, the BFI  (mean ± sd) had further decreased to 28.24±18.97 (N=324) 
(Figure 3A). 
For patients without constipation at study entry  (n=289), the mean BFI remained well 
below 28.8 up to 17 weeks of PR OXN treatment (Figure 3A). Table 3 gives the actual 
BFI-values over time.
laxative use during the study
Despite the high level of constipation at study entry between visit 1 and visit 2 in the 
total population only 31.3% (419/1337 ) of patients used additional laxatives during the 
study and this additional laxative use was significantly higher in patients pretreated 
Table 3. Bowel function (BFI scores) over time per subgroup and overall
Previous WhO step analgesic bowel Function Total
bowel function 
(bFI score)
step 1 
n = 142
step 2 
n = 625
step 3 
n = 571
non-constipated
n=289
Constipated
n=1048
 
n = 1338
study start (visit 1)
     Mean ± SD
     (N)
31.8±26.5 
(141)
47.7±27.6 
(625)
65.3±23.0 
(571)
10.4±9.3 
(289)
65.4±17.8 
(1048)
53.5±27.9
(1337)
Week 2±2
     Mean ± SD 
     (N)
26.1±20.4 
(106)
27.8±20.5 
(426)
34.5±21.0 
(372)
11.9±15.4
(213)
35.9±18.9 
(690)
30.3±20.9 
(903)
Week 6±2
     Mean ± SD 
     (N)
23.3±20.1 
(86)
24.7±19.6 
(427)
30.3±19.5 
(367)
11.6±15.6 
(168)
30.5±18.9 
(711)
26.9±19.8 
(879)
Week 11±3
     Mean ± SD 
     (N)
22.4±16.5 
(31)
21.2±17.0 
(198)
28.8±20.9 
(173)
9.3±9.6 
(78)
28.2±18.9 
(324)
24.6±19.1 
(402)
Week 17±3
     Mean ± SD 
     (N)
11.3±14.9 
(5)
26.9±26.2 
(22)
31.7±23.1 
(26)
13.6±29.5 
(11)
31.5±21.5 
(42)
27.8±24.2 
(53)
study end (last visit)
     Mean ± SD 
     (N)
21.6±18.9 
(141) 
23.0±19.0 
(625)
28.4±19.9 
(571)
10.7±16.7
(288)
28.2±19.7 
(1048)
25.2±19.6 
(1337)
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with WHO-step 3 medication (41.7%, 238/571) compared with patients pretreated with 
WHO-step 1 medication (20.4%, 29/241) and WHO-step 2 medication (24.3% 152/625; 
p<0.001). The percentage of patients using laxatives did not change significantly during 
the study for the WHO-step groups. 
Looking at constipated patients versus non-constipated patients at study entry laxa-
tive use during the study was significantly higher in constipated than non-constipated 
patients (36.9% (387/1048) vs. 11.1% (32/289) respectively, p<0.001). Despite treatment 
with PR OXN, laxative use between visit 1 and visit 2 versus laxative use between visit 
2 and visit 3 did not change significantly for non-constipated patients at study entry 
(10.1% to 9.1%), which is in line with the stable BFI. For patients with  constipation  at 
study entry a numerical but not statistically significant decrease in laxative use was seen 
(35.5% to 28.6%), which is in line with the improvement seen in the BFI (Figure 3B).
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Figure 2. Bowel function measured by  BFI over time for patients in WHO-step 1, WHO-step 2 and the WHO-
step 3 groups (Full analysis-population)
Dashed line and closed diamonds represent the WHO-step 1 group, solid line and open squares represent 
the WHO-step 2 group and the dotted line  and open triangles represent the WHO-step 3 group. The dotted 
line at BFI 28,8 represents the cut-off for constipation. Error bars represent the 95% confidence interval of 
the mean BFI. Patient numbers at weeks 0, 2, 6 and 11 are listed below the graph. 
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Figure 3a. Bowel function measured by  BFI over time for constipated and non-constipated patients (FA 
population)
Dotted line and closed diamonds represent non-constipated patients (BFI<28.8) and the solid line and 
open squares represent constipated patients (BFI≥28.8). The line at BFI 28,8 represents the cut-off value 
between constipated and non-constipated patients. Error bars represent the 95% confidence interval of 
the mean BFI. Patient numbers at weeks 0, 2, 6 and 11 are listed below the graph.
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Figure 3b. Bowel function measured by  BFI per visit and laxative use for constipated patients and non-
constipated patients (Full analysis population)
Dotted line and closed diamonds represents non-constipated patients (BFI<28.8) and the solid line and 
open squares represents constipated patients (BFI≥28.8). The line at BFI 28 represents the cut-off value 
between constipated and non-constipated patients. Error bars represent the 95% confidence interval of 
the mean BFI. Solid filled black bars represent the percentage of non-constipated patients using laxatives 
between visit 1 and 2 (29/288 (10.1%)) and between visit 2 and 3 (23/253 (9.1%)). Open bars represent the 
percentage of constipated patients using laxatives between visit 1 and 2 (372/1,048 (35.5%)) and between 
visit 2 and 3 (281/981 (28.6%)). Patient numbers at visit 1, 2 and 3 are listed below the graph.
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efficacy regarding pain relief
The response rate regarding pain relief at last visit after PR OXN treatment was 84.5%, 
indicating that analgesic efficacy of PR OXN treatment was evaluated as ‘slightly better’, 
‘better’ or ‘much better’ compared to the previous analgesic medication for the majority 
of patients. As expected responses were high in all groups, with a significantly lower 
response rate in the  WHO-step 3 group (77.1%, p<0.001) compared with response rates 
of 91.5% and 89.8% in the WHO-step 1 and WHO-step 2 groups respectively. Looking 
more closely at subjects with and without constipation, at visit 2 and visit 3, response 
was significantly higher in the non-constipated subgroup (85.8% at visit 2 and 92.1% at 
visit 3) than in the constipated subgroup at visit 2 and visit 3 (80.2 (p=0.033) and 85.7% 
(p=0.006) respectively).
Table 4 gives the actual pain intensity scores over time. 
Quality of life 
Patients reported that during treatment with PR OXN all aspects of quality of life (QoL) 
improved, resulting in a significant increase of 0.31± 0.26 (95% CI [0.30,0.32]) in the EQ-
D5  score from first to last visit. QoL improved significantly in all three WHO-step groups 
Table 4. Pain intensity scores over time per subgroup and overall.
Previous WhO step analgesic bowel Function Total
Pain intensity score 
(nRs)
step 1 
n = 142
step 2 
n = 625
step 3 
n = 571
non-constipated
n=289
Constipated
n=1048
 
n = 1338
study start (visit 1)
     Mean ± SD
     (N)
7.3±1.3
(141)
7.7±1.1
(625)
6.7±2.0
(571)
7.6±1.3
(289)
7.2±1.7
(1048)
7.2±1.7
(1337)
Week 2±2
     Mean ± SD 
     (N)
4.3±2.1
(106)
4.7±1.9
(426)
4.7±2.0
(372)
4.2±2.1
(213)
4.8±1.8
(690)
4.7±1.9
(904)
Week 6±2
     Mean ± SD 
     (N)
3.9±2.1
(86)
4.0±1.9
(427)
4.2±1.7
(368)
3.7±2.0
(168)
4.2±1.8
(712)
4.1±1.8
(881)
Week 11±3
     Mean ± SD 
     (N)
4.2±2.4
(31)
3.5±1.6
(198)
4.3±1.9
(173)
3.4±1.8
(78)
4.0±1.8
(324)
3.9±1.8
(402)
Week 17±3
     Mean ± SD 
     (N)
5.4±0.9
(5)
3.4±1.5
(22)
4.3±1.6
(26)
4.5±1.6
(11)
4.0±1.6
(42)
4.1±1.6
(53)
study end (last visit)
     Mean ± SD 
     (N)
3.8±2.2
(141)
3.7±1.9
(625)
4.1±1.9
(571)
3.5±2.1
(288)
4.0±1.9
(1048)
3.9±1.9
(1337)
Chapter 6
126
with a significantly larger increase in both WHO-step 1 and WHO-step 2 groups (both 
0.34±0.26) compared to the WHO-step 3 group (0.27±0.26; p< 0.0001). 
Similarly, the self-reported EQ-5D VAS health scores showed an increase of 16.5 ± 26.8 
(95% CI 15.0,18.0) between the first (41.2±22.0) and last visit (58.2±21.7). The improve-
ment was significantly larger for the WHO-step 2 group (19.6 ± 27.5) compared to the 
WHO-step 1 group (17.4 ± 27.0) and the WHO-step 3 group (13.0 ± 25.5; p = 0.0002). 
QoL also improved significantly in both bowel function  groups, with a statistically 
significant larger increase in non-constipated patients (0.38±0.27) versus constipated 
patients (0.29±0.25; p<0.0001). No statistically significant differences are seen in changes 
from baseline to last visit in EQ-5D Vas health scores between non-constipated (18.2 ± 
32.0) and constipated groups (16.1 ± 25.3).
safety
Overall, 4.8% of the patients in the safety population reported at least one adverse drug 
reaction (ADR) during OXN treatment (77 ADRs reported by 66 out of 1369 patients). 
The most frequently reported ADRs were nausea (1.2%), constipation (0.9%), drowsiness 
(0.5%), vertigo/dizziness (0.5%) and somnolence (0.3%). Most ADRs documented as 
mild (36.9%) or moderate (44.6%) mainly affecting the gastrointestinal system and the 
central nervous system (Table 5). 
Twelve ADR (18.5%) were severe and mainly affected the gastrointestinal system 
(nausea and constipation). No additional ADR compared to the ADR mentioned in the 
Table 5.  Number of patients with at least one adverse drug reaction, severity and relation to study medica-
tion of reported adverse drug reactions (safety population)
Total 
n = 1369
Any Adverse Drug Reaction        4.8%  (66/1369)
Maximal ADR Severity Reported, % (n/N)
   Mild 36.9%  (24/65)
   Moderate 44.6%  (29/65)
   Severe 18.5%  (12/65)
   Missing 1
Maximal ADR Relation Reported, % (n/N)
   Not related 3.3%   (2/60)
   Possibly related 28.3%  (17/60)
   Probably related 51.7%  (31/60)
   Definitely related 16.7%  (10/60)
   Missing 6
ADR, adverse drug reaction
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SmPC were reported. No serious ADRs were documented. Twenty-eight patients (2.2 
%) reported stopping the study because of an adverse drug reaction. The incidence of 
drug related adverse events was comparable between analgesic pretreatment-groups 
(WHO-step 1, WHO-step 2 and WHO-step 3) as well as between constipated and non-
constipated patients.
DIsCussIOn
The present study showed that the majority of patients in the total population (78.4%) 
and in all WHO-step groups experienced symptoms of constipation as defined by a 
BFI≥28.8 (50.4%, 72.8% and 91.4% for WHO-step 1, WHO-step 2 and WHO-step 3 respec-
tively)33. It was shown that significantly more patients with symptoms of constipation at 
study entry were older and of female gender, both factors that are known to be associated 
with constipation and patients with pain are less mobile which could also have contrib-
uted to constipation9-11. Moreover, it is possible that there is a bias in the percentage of 
constipated patients in this observation as in Belgium PR OXN was marketed especially 
for patients with a BFI above 30. Also in literature it has been demonstrated that treat-
ment with  WHO-step 1 and WHO-step 2 analgesics, like NSAIDs, codeine and tramadol 
are strongly associated with occurrence of constipation. This might have contributed to 
the high percentage of constipated patients in the WHO-step 1 and WHO-step 2 groups, 
together with the other factors that are associated with constipation that are present in 
the study population34-37. 
Already after 2 weeks of PR OXN treatment a clinically relevant improvement of bowel 
function (defined by a reduction in BFI of 12 points or more) was observed in the overall 
population and in the WHO-step 2 and WHO-step 3 groups. Mean BFI dropped below 
28.8 after 6 weeks of PR OXN treatment for the overall population and the WHO-step 1 
and WHO-step 2 groups. In the WHO-step 3 group mean BFI reached 28.8 after 11 weeks 
of PR OXN treatment. The observed reduction in BFI for all groups was maintained over 
time. These results indicate that during the observation bowel function can restore over 
time irrespective of the previous analgesic treatment, despite initiation of the opioid PR 
OXN. The reduction in BFI is in line with reduction of BFI reported in previous observa-
tional studies with PR OXN for patients with neuropathic pain28, constipated patients 
with non-malignant pain29 and patients with severe pain30.  In this observation also 
patients switching from WHO-step 1 and WHO-step 2 medication, as well as patients 
without constipation at start of the observation were included, which is in contrast 
to previous studies, in which patients already experienced OIC or were switched from 
WHO-step 3 medication to PR OXN.
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When looking more closely at constipated patients at study entry (irrespective of pre-
vious analgesic treatment), it was shown that treatment with PR OXN led to a clinically 
relevant improved bowel function already in the first two weeks of PR OXN treatment 
and the improvement was maintained  over time. After 17 weeks, BFI was close to the 
threshold of 28.8 showing that bowel function was almost restored to normal values de-
spite the treatment with the opioid PR OXN. Interestingly, for patients not constipated at 
study entry the BFI remained below 28.8 even during PR OXN treatment up to 17 weeks. 
This indicates that treating pain adequately with strong opioids in non-constipated 
patients normal bowel function is maintained despite the initiation of the opioid PR 
OXN, even in patients stepping-up from non-opioid treatment. This study adds to the 
evidence found in previous studies with PR OXN which have also shown that switch-
ing non-constipated patients to PR OXN maintained their bowel function in a more 
controlled study setting (one clinical trial and one prospective open-label study with a 
blinded endpoint)38, 39. 
Importantly, the reduction in BFI cannot be explained by increased use of laxatives. 
The percentage of patients using laxatives at subsequent visits in the overall population 
and all subgroups remains stable indicating that the clinically relevant improvement in 
bowel function during PR OXN treatment cannot be attributed to an increased use of 
laxatives. This adds to the evidence that PR OXN is a pathophysiological treatment  for 
OIC targeting the underlying cause of OIC and not a symptomatic treatment for OIC as 
is the case with laxatives40, 41. These results suggest that for patients with pre-existing 
risk-factors for constipation (like older age, female gender and immobility) as well as 
for patients with pre-existing symptoms of constipation, PR OXN might be a valuable 
option to treat severe pain, whilst maintaining or even restoring normal bowel function.
In Belgium patients have a co-payment for laxatives which could have led to a lower 
level of patients using laxatives at start of the observation. The percentage of patients 
using laxatives during the observation is also low, 31.3% of patients used laxatives 
during the observation. PR OXN has been shown to improve and prevent symptoms of 
constipation with reduced laxative use compared with prolonged release oxycodone. 
Treatment with PR OXN and co-payment for laxatives in Belgium might have led to the 
low level of laxative use in this observation.   
This study also showed that pain relief during PR OXN treatment was “slightly better”, 
“better” or “much better” for the vast majority of patients with severe pain as compared 
to the previous analgesic treatment. Response rate with respect to pain relief (propor-
tion of patients with pain relief that was “slightly better”, “better” or “much better”) was 
significantly lower in WHO-step 3 pretreated patients (77.1%) compared with WHO-step 
1 and WHO-step 2 pretreated patients (91.5% and 89.9%, respectively). This was as 
expected since treatment was stepped-up for patients pretreated with WHO-step 1 and 
or WHO-step 2 analgesics to a WHO-step 3 analgesic. Counter-intuitively, there were no 
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significant differences in mean PR OXN dose between the subgroups, which might con-
tribute to a lower efficacy for pain relief in the WHO-step 3 subgroup. Patients pretreated 
with WHO-step 3 analgesics treatment were switched to another WHO-step 3 analgesic 
with the addition of naloxone and all randomized clinical trials and observational trials so 
far have shown that the addition of naloxone to oxycodone did not influence pain relief 
compared with oxycodone 20-27. As the majority of patients in the WHO-step 3 pretreated 
group were switched to PR OXN due to side effects of the WHO-step 3 pretreatment 
(86.2%), physicians might have been more conservative in titrating the PR OXN dose. 
We observed that there was a small but significant difference in pain relief during PR 
OXN treatment when looking at constipated versus non-constipated patients at study 
entry favoring non-constipated patients. This might be explained by the fact that 49.8% 
of constipated patients were pretreated with WHO-step 3 medication and these WHO-
step 3 pretreated patients had a significantly lower response rate with respect to pain 
relief (77.1%) compared with WHO-step 1 and WHO-step 2 pretreated patients (91.5% 
and 89.8% respectively). Logistic regression analyses with adjustment for age, gender, 
type of pain and constipation level, showed that the previously used WHO step analgesic 
is a statistically significant predictor for response to pain relief at last visit. 
In the present observational study, patients reported a significant increase in their 
self-perception of quality of life compared to previous analgesic treatment. The im-
provement in QoL was significantly higher in patients previously treated with WHO-step 
1 and 2 analgesics. This might be expected taking into account that patients previously 
treated with WHO-step 3 analgesics had significantly less pain relief during the study 
compared to the other WHO-step subgroups. Improvement in QoL also significantly 
improved in constipated patients and non-constipated patients, with the improvement 
being significantly higher in non-constipated patients compared with constipated 
patients. 
However, both the significant increase in pain relief and the significant decrease in 
OIC could have contributed to the increase in QoL in this study. It has been consistently 
reported that pain has an inverse correlation between the extent of its relief and the 
associated QoL42 and that OIC has a negative impacts on QoL too1, 10, 12. 
Unfortunately, with the current study design it is not possible to distinguish between 
the contribution of improved bowel function and pain relief to the improvement of QoL. 
Further studies are warranted to investigate the impact of OIC on QoL of pain patients 
taking into account their level of pain control as well as pain medication used. 
The nature of the adverse drug reactions reported during the study are among those 
documented for oxycodone/naloxone as outlined in the SmPC. The incidence of drug 
related adverse events was comparable between subgroups of patients. The frequency 
of ADR reported in this study are lower than reported in the SmPC. Despite the fact 
that at each study visit the physicians had to actively answer a question about the oc-
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currence of adverse drug reactions in the period before the study visit as a reminder to 
report all ADRs, we suspect that there is under reporting of ADRs. Unfortunately, this 
is a well-known and common problem, especially in observational studies43. Moreover, 
the adverse drug reaction profile seen with oxycodone/naloxone is very similar to the 
profile of oxycodone and oxycodone is a well-known compound to physicians. Therefore 
the expectations of the physician regarding ADRs with oxycodone/naloxone might have 
also led to underreporting of ADRs in this observation.  
Limitations of the present study include its prospective observational open-label de-
sign and the lack of a control arm not using PR OXN. However, the strict in- and exclusion 
criteria seen in randomized controlled clinical trials were not used in this real-life non-
interventional prospective observational study, resulting in findings that are applicable 
to real-life patient populations.
COnClusIOns
The results of this real-life non-interventional prospective observational study per-
formed in daily clinical practice in Belgium show thatpatients with severe pain report a 
significant and clinically relevant improvement of bowel function as well as an improve-
ment of QoL compared to the previous WHO analgesic treatment during PR OXN treat-
ment. The majority of patients (84.5%) with severe pain switching from their preceding 
analgesic treatment to PR OXN indicate the efficacy of PR OXN regarding pain relief as 
‘slightly better’, ‘better’ or ‘much better’ compared to the previous analgesic medication 
at last visit. 
More interesting, constipated subjects showed a significant and clinically relevant im-
provement in bowel function(BFI) over time, while laxative use numerically decreased. 
In non-constipated subjects, the BFI remains well below the threshold value for nor-
mal bowel function (28.8) whilst laxative use remains low (~10%), showing a prevention 
of constipation despite the use of an opioid. This confirms that treatment with PR OXN 
improves bowel function in constipated subjects and might maintain bowel function in 
non-constipated patients even during treatment with opioid analgesics, reflecting the 
local action of opioids in the gut and the pathophysiological action of naloxone (in PR 
OXN) on bowel function. 
All adverse drug reactions observed were well-known opioid-related AEs raising no 
additional safety concerns. 
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Objective
To compare the cost effectiveness of prolonged release (PR) oxycodone/naloxone (OXN) 
and prolonged release oxycodone (PR OXY) in patients with moderate-to-severe pain 
of non-malignant origin suffering from laxative-refractory opioid induced constipation 
(OIC) from the perspective of the Dutch healthcare system.
methods
The pharmaco-economic model was a cohort cost-utility model with constipated and 
non-constipated health states. It was adapted from a model which was previously used 
in non-malignant chronic pain in the UK context and published in 2012 by Dunlop et 
al.1. Data from a pooled analysis of two phase III randomized, controlled trials (RCTs) 
focusing on patients with non-malignant chronic moderate to severe pain and laxa-
tive refractory OIC under PR OXY treatment were used. Dutch costs data were used to 
calculate the cost difference between treatments in the model by combining the costs 
of pain therapy, costs of laxative use, costs of additional constipation treatments as well 
as costs of other resources used to manage constipation. The base case analysis was 
from a societal perspective, including societal costs. EuroQol-5 dimensions (EQ-5D) 
utility values for constipation were derived from a study performed in the Netherlands 
by Penning-van Beest et al.2. EQ-5D utility and disutility due to constipation were used 
to calculate the quality adjusted life year (QALY) gains. Deterministic and probabilistic 
sensitivity analyses were performed.
Results
The incremental cost of PR OXN versus PR OXY was €763 for the average treatment 
duration of 52 weeks per patient. PR OXN gave an incremental QALY gain of 0.110 per 
patient. The estimated incremental cost-effectiveness ratio (ICER) was €6,924 per QALY 
gained. Sensitivity and scenario analyses gave a maximum ICER of € 21,284 per QALY 
gained when increasing the probability of constipation in the PR OXN arm by 25%. Key 
drivers of the model are the utility value for non-constipated patients, the probability of 
constipation in the PR OXN arm and the mean daily dose of opioid per day. Probabilistic 
sensitivity analysis showed that PR OXN had approximately 96% probability of being 
cost effective at the €20,000 threshold.
limitations
The main limitations of the analysis were the limited data of costs of constipation. These 
were obtained from a 2-round Delphi panel of 12 Dutch GPs and were therefore based 
on the perceptions of primary care physicians3. As indicated by Dunlop et al.1, other 
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groups of healthcare professionals, like nurses and secondary care specialists treating 
constipation, may report different resource use and costs. A second limitation might 
be a possible lack of power of the Penning-van Beest study providing the utility scores 
and disutility2. Moreover, the health states were based on constipation, the most com-
mon side-effect of opioid treatment. However, PR OXN may counteract other aspects 
of opioid-induced bowel disorders (such as abdominal pain, cramping and bloating) 
that may require additional healthcare resources. It is therefore possible that a model 
examining these aspects on top of OIC may show a greater incremental QALY gain from 
PR OXN compared with PR OXY.
Conclusions
The present pharmaco-economic study demonstrated PR OXN was estimated to be a 
cost-effective option for treating patients with non-malignant moderate to severe pain 
and laxative-refractory OIC. Several sensitivity and scenario analyses show the robust-
ness of the model. 
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InTRODuCTIOn
Opioids are an effective analgesic therapy recommended by the World Health Organiza-
tion for a specific group of patients4. The WHO three-step analgesic ladder is used as a 
reference in several international guidelines, including the European Society for Medical 
Oncology (ESMO5), and the European Association for Palliative Care (EAPC6). Besides 
treatment of malignant pain opioids are also used in the treatment of severe nociceptive 
non-malignant pain7. 
Side effects of opioids are well known and often require a dose limitation, and some-
times a treatment discontinuation8. Constipation, nausea, somnolence/dizziness, dry 
mouth and respiratory depression remain commonly reported adverse events of opioid 
usage9. 
Opioid induced constipation (OIC) is defined as “a change when initiating opioid 
therapy from baseline bowel habits that is characterized by any of the following: reduced 
bowel movement frequency, development or worsening of straining to pass bowel 
movements, a sense of incomplete rectal evacuation, or harder stool consistency”10. On 
top of impacting the correct intake of the opioid treatment, OIC has a major impact on 
patient’s quality of life (QoL)2,9,11-13 and can eventually lead to debilitating complications 
like external peri-anal thrombosis, anal fissures or rectum prolapse14. Therefore OIC is 
an additional burden especially for patients with chronic moderate-to-severe pain, a 
vulnerable group of patients 15-18. 
In current practice the advice is to treat patients on opioid analgesics prophylactically 
with a laxative regime.  In Dutch clinical practice this laxative regime consists of treat-
ment with at least one laxative in an adequate dosage (e.g. macrogol plus electrolytes 
or lactulose) and if needed addition of a second laxative of a different therapeutic class 
(e.g. bisacodyl)19. However, some patients still experience OIC despite the use of this 
laxative regime and/or do not tolerate the adverse events of the laxative regime; i.e. 
patients with laxative-refractory OIC20,21. Current management of OIC episodes includes 
the symptomatic treatment with oral laxatives (osmotic laxatives, stimulant laxatives 
and stool softeners), rectal laxatives and lavements. Laxatives have been found to be 
ineffective to treat OIC19,22. Moreover, treatment with laxatives causes side effects and 
complications10,23. Opioid receptor antagonists like methylnaltrexone, naloxegol and 
naloxone are used for the pathophysiological treatment of OIC 24-26.  They inhibit binding 
of opioids to the opioid receptors in the gut, thereby preventing OIC10,22.
PR OXN combines the strong opioid receptor agonist oxycodone and the opioid re-
ceptor antagonist naloxone. When administered orally, a reduction of constipation can 
be achieved due to a local action of naloxone in the gut without affecting pain relief 
by oxycodone27-29. PR OXN has proven equivalent analgesic efficacy to PR OXY with 
significant improvements in bowel function in chronic non-malignant pain30-35 as well 
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as in moderate/severe malignant pain36,37. It is important to assess cost utility of PR OXN 
treatment for laxative-refractory patients, as treatment with PR OXN is more expensive 
than treatment with PR OXY. 
The present publication describes the methodology and findings of a Dutch cost-
utility analysis for PR OXN for patients with non-malignant moderate-to-severe pain who 
need treatment with an opioid to obtain adequate analgesia and laxative-refractory OIC.
meThODs
Patients and treatments
The model used data from a pooled analysis of two randomized, controlled, double-blind, 
parallel-group studies in non-malignant pain patients published in 2014 by Koopmans 
et al.21. This pooled analysis included 35 patients with non-malignant pain with OIC at 
study entry that was refractory to at least two laxatives with different modes of action 
(at least two laxatives of a different ATC-level 4 class). Patients completed randomized, 
double-blind treatment with PR OXN 20–120 mg/day for 12 weeks with an extension 
phase of up to 52 weeks. The primary objective of this pooled analysis was to evaluate 
bowel function in patients randomized to PR OXN who had OIC at study entry, despite 
the use of at least two different classes of laxatives. Assessment of bowel function was 
performed using the validated Bowel Function Index (BFI* (*Copyright for the BFI is 
owned by Mundipharma Laboratories GmbH, Switzerland 2002; the BFI is the subject 
of European Patent Application Publication No.EP1860988 and corresponding patents 
and applications in other countries)38-40. BFI score comprised the arithmetic mean score 
of three items rated on a numerical analogue scale (NAS) of 0–100: ease of defecation 
(0=easy/no difficulty to 100=severe difficulty), feeling of incomplete bowel evacuation 
(0=not at all to 100=very strong), and personal judgment of constipation (0=not at all 
to 100=very strong). Normal bowel function is defined as a score of ≤28.8; this was de-
termined in a study that reported that 95% of non-constipated patients had a BFI score 
≤28.8. BFI score was assessed at screening, start of double-blind treatment and end of 
double-blind treatment. Laxative use (bisacodyl and non-study laxatives) throughout 
the studies was documented. Full details of the study populations have been previ-
ously described21,30-35. The study showed statistically significant and clinically relevant 
improvements in bowel function following double-blind treatment with PR OXN. Mean 
(SD) reduction in BFI score was 23.3 [29.0] (P≤0.0002). Furthermore, the proportion of 
patients with a BFI score within normal range (≤28.8) increased from 8.6% at screening 
to 50.0% at Day 15 of PR OXN. While all patients used ≥2 laxatives of different classes 
at screening, during study treatment 36% stopped using laxatives (P<0.001). PR OXN 
provided effective analgesia, evidence by stable pain scores during study treatment, 
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and there were no unanticipated adverse events. The mean (sd) dose of oxycodone used 
was 54.5 (29.5) mg and was relatively stable, changing with 4.9 (12.5) mg from start of 
treatment to end of treatment. 
model structure and overview
A cohort cost-utility model was developed in Microsoft Excel 2007 (Microsoft Corpo-
ration, Redmond, WA, USA) with constipated and non-constipated health states. The 
model calculated the incremental cost-effectiveness ratio (ICER) defined as Δcost/
Δeffectiveness, where effectiveness was defined in terms of quality adjusted life-years 
(QALY) gained1. Utility values were derived from an article by Penning-van Beest de-
scribing the impact of OIC on QoL, using the EQ-5D score2. Pain control was not included 
as a health state as based on the study data, it was assumed to be equal between treat-
ments. The model included laxative use as patients treated with opioids require laxative 
treatment to prevent OIC. For this subpopulation of laxative-refractory OIC patients all 
patients in the oxycodone arm (PR OXY) are per definition treated with two laxatives of 
a different Anatomical Therapeutic Chemical (ATC) level 4 class (e.g. the ATC level 4 code 
of macrogol is A 06 AD 15) and for the PR OXN arm laxative use was based on the use of 
rescue laxative in the study by Koopmans et al. 201421. Figure 1 shows the structure of 
the model. 
Most patients started in a constipated health state to mimic laxative-refractory OIC 
as well as the data from the pooled analysis. Over time patient movement occurred 
between the constipated and non-constipated health states, with the constipated 
health state incurring an additional cost. The model had weekly time intervals. The time 
horizon used in the base case analysis was 365 days, according to the average duration 
of treatment with PR OXY tablets in patients with non-malignant chronic pain. Cost and 
effects were not discounted owing to the time horizon being less than 1 year.
The following equations were used in the model:
 
Patients with non‐
malignant pain and 
laxative refractory 
OIC 
Prolonged‐release 
oxycodone/prolonged‐
release naloxone tablets 
(Targinact; OXN) 
Prolonged‐release 
oxycodone tablets 
(OXY) 
Constipated 
Non‐constipated 
Non‐constipated 
Constipated 
Weighted cost of additional resources 
Weighted cost of additional resources 
Figure 1: Model structure.
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Total cost of drug (laxative and pain treatment)
COXN=total cost of drug in treatment group over the treatment period for patients 
treated with PR OXN and COXY= total cost of drug in treatment group over the treatment 
period for patients treated with OXY. K=the expected duration of each treatment, which 
is estimated at 52 weeks, hence K=52.
DOXN is the average weekly cost of PR OXN and DOXY is the average weekly cost of PR OXY. 
Therefore, DOXN=cost per mg of PR OXN x average (mean) dose (mg) PR OXN per day x 7 
(days) and DOXY=cost per mg of PR OXY x average (mean) dose (mg) PR OXY per day x 7 
(days).
LOXN is the average weekly cost of as needed bisacodyl use in the OXN treatment 
group. LOXN=cost per mg bisacodyl x average (mean) dose (mg) bisacodyl per day x 7 
(days). LOXY is the average weekly cost of optimal laxative use in the OXY treatment group 
LOXY=average cost of optimal laxative use per day x 7 days.
Hence, COXN = K(DOXN+ LOXN) and COXY=K(DOXY+LOXY)
Resource use costs
PiOXN is the proportion of patients with constipation in the PR OXN treatment group at 
each week (i, i=week 1,2….,52) and PiOXY is the proportion of patients with constipation 
in the PR OXY treatment group at each week. 
The total average weekly cost per patient of additional resource use is V, where 
V=average cost of additional resource use per constipated patient per week. Costs of 
additional resource use do not differ between patients in the PR OXN and PR OXY group. 
Therefore, using a half-cycle correction, the additional healthcare costs  in the PR OXN 
treatment group (ZOXN* ) is given by: 
(P0OXN+P1OXN)/2*V+(P1OXN +P2OXN)/2*V+(P2OXN +P3OXN)/2*V+….+(P51OXN +P52OXN)/2*V
And the additional healthcare costs  in the PR OXY treatment group (ZOXY* ), using a 
half-cycle correction is given by: 
(P0OXY+P1OXY)/2*V+(P1OXY +P2OXY)/2*V+(P2OXY +P3 OXY)/2*V+….+(P51OXY +P52OXY)/2*V
The incremental cost is therefore (COXN-COXY)+(ZOXN*-ZOXY*)
Utilities
If the utilities for the constipated patients in the PR OXN treatment group at each week 
are denoted 
UOIC, OXNi then, the total QALY gain across all 52 weeks for the constipated patients in 
the PR OXN treatment group can be defined as UOIC, OXN is:
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UOIC, OXN =((P0OXN+P1 OXN )/2*( UOIC, OXN0+ UOIC, OXN1)/2)+(P1 OXN+P2 OXN)/2*( UOIC, OXN1+ UOIC, 
OXN2)/2+(P2 OXN+P3 OXN)/2*( UOIC, OXN2+ UOIC, OXN3)/2+….+(P51OXN+P52OXN)/2*( UOIC, OXN51+ 
UOIC, OXN52)/2).
If the utilities for the non-constipated patients in the PR OXN treatment group at each 
week are denoted 
Unon-OIC, OXNi then, the total QALY gain across all 52 weeks for the non-constipated 
patients in the PR OXN treatment group defined as Unon-OIC, OXN is:
Unon-OIC, OXN =(1-(P0OXN+P1 OXN )/2)*( Unon-OIC, OXN0+ Unon-OIC, OXN1)/2)+(1-(P1 OXN+P2 OXN)/2)*( 
Unon-OIC, OXN1+ Unon-OIC, OXN2)/2+(1-(P2 OXN+P3 OXN)/2)*( Unon-OIC, OXN2+ Unon-OIC, OXN3)/2+….+(1-
(P51OXN+P52OXN)/2)*( Unon-OIC, OXN51+ Unon-OIC, OXN52)/2).
UOXN*= UOIC, OXN + Unon-OIC, OXN
If the utilities for the constipated patients in the PR OXY treatment group at each week 
are denoted 
UOIC, OXYi then, the total QALY gain across all 52 weeks for the constipated patients in 
the PR OXN treatment group defined as UOIC, OXY is:
UOIC, OXY =((P0OXY+P1 OXY )/2*( UOIC, OXY0+ UOIC, OXY1)/2)+(P1 OXY+P2 OXY)/2*( UOIC, OXY1+ UOIC, 
OXY2)/2+(P2 OXY+P3 OXY)/2*( UOIC, OXY2+ UOIC, OXY3)/2+….+(P51OXY+P52OXY)/2*( UOIC, OXY51+ 
UOIC, OXY52)/2).
If the utilities for the non-constipated patients in the PR OXN treatment group at each 
week are denoted 
Unon-OIC, OXYi then, the total QALY gain across all 52 weeks for the non-constipated 
patients in the PR OXN treatment group defined as Unon-OIC, OXY is:
Unon-OIC, OXY =(1-(P0OXY+P1 OXY )/2)*( Unon-OIC, OXY0+ Unon-OIC, OXY1)/2)+(1-(P1 OXY+P2 OXY)/2)*( 
Unon-OIC, OXY1+ Unon-OIC, OXY2)/2+(1-(P2 OXY+P3 OXY)/2)*( Unon-OIC, OXY2+ Unon-OIC, OXY3)/2+….+(1-
(P51OXY+P52OXY)/2)*( Unon-OIC, OXY51+ Unon-OIC, OXY52)/2).
UOXY*= UOIC, OXY + Unon-OIC, OXY
The ICER is therefore given by
((COXN-COXY)+(ZOXN*-ZOXY*))/UOXN*-UOXY*
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model inputs
Cost inputs
Unit costs were based on the pharmacy purchase price (AIP) of each strength of 
PR OXN and PR OXY and were retrieved from the Dutch national list prices database 
(source:www.z-index.nl, January 2015)). The pack costs for PR OXN were €78.63 (90 
tablets 5 mg), €106.50 (90 tablets 10 mg), €197.52 (90 tablets 20 mg) and €388.54 (90 
tablets 40 mg).
The cost of PR OXY was a weighted average of the different available presentations 
(OxyContin® and its generic versions). The weight was based on the actual dispensed 
units of the different oxycodone strengths from the different manufacturers (source: 
www.farminform.nl). The weighted average pack costs for PR OXY were €3.73 (30 tablets 
5 mg), €5.31 (30 tablets 10 mg), €9.09 (30 tablets 20 mg) and €40.87 (30 tablets 40 mg). 
The model used dispensed unit data for PR OXN and PR OXY to calculate a weighting 
that was then used to estimate cost per mg. The weightings applied were 29.7% (5 mg), 
49.8% (10 mg), 17% (20 mg) and 3.5% (40 mg). It yielded average costs per mg of € 0.12 
for OXN and € 0.02 for OXY (Table 1). 
The average daily dose of opioid during treatment of laxative-refractory patients was 
54.5 mg (Koopmans et al.)21,. As opioid antagonist treatment does not interfere with pain 
relief this dose was used in both arms. The dose was multiplied with the average cost 
per mg of each drug to estimate the cost of opioid treatment in each arm of the model. 
The weighted cost per week of OXY was €7.62; the weighted cost per week of PR OXN 
was €46.69.
The average costs of laxative use for patients on PR OXN treatment was based on laxa-
tive costs derived from the Dutch national list prices database (Table 2; source:www.z-
index.nl, January 2015) as well as laxative use from patient data (Koopmans et al.)21. 
42.9% of laxative-refractory patients received ‘as needed’ bisacodyl, with an average 
daily dose of 4.32mg21. 
Table 1: Information for  PR OXN and PR OXY weighted average price calculation used in the model
strength sales OXn OXY
mg opioid % Pack size aIP/pack €/mg Pack size aIP/pack €/mg
5 29.7% 98 €78.63 € 0.16 30 € 3.73 € 0.02
10 49.8% 98 €106.50 € 0.11 30 € 5.31 € 0.02
20 17.0% 98 €197.52 € 0.10 30 € 9.09 € 0.02
40 3.5% 98 €388.54 € 0.10 30 € 40.87 € 0.03
Total 100% € 0.12 € 0.02
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For patients on PR OXY treatment the average costs of laxative use were based on cur-
rent Dutch practice and guidelines which recommend laxative treatment during opioid 
treatment for all patients. It was therefore assumed that 100% of patients were receiv-
ing the laxative treatment, being a combination of lactulose/movicolon+ bisacodyl 
on a daily basis19,41. The national public claims database user information showed that 
11% of patients are using lactulose and 89% macrogol plus electrolytes (source: www.
gipdatabank.nl). The average cost of optimal laxative use per day in the PR OXY arm was 
estimated using the weighted average cost of lactulose/macrogol combinations based 
on number of users derived from the national public claims database (GIP-databank) 
and medication costs from the national list prices database (Z-index ) (Table 2). The cor-
responding weekly cost of laxatives in addition to opioid treatment were calculated was 
estimated at €0.09 with PR OXN and €2.11 with PR OXY. 
A two-round Delphi panel including 24 Dutch GPs in first round and 12 Dutch GPs in 
second round showed that patients with laxative-refractory OIC regularly require treat-
ments in addition to a laxative regime to temporarily obtain relief from OIC over time3. 
Moreover, patients with laxative-refractory OIC can suffer from complications caused 
by OIC. The medical resources, including additional laxatives, visits, diagnostic tests and 
procedures required to temporarily relieve OIC and to treat OIC complications as well 
as the frequency of additional required OIC treatment and the percentage of patients 
suffering from complications during an additional treatment for OIC were also collected 
in the Delphi panel. Costs for productivity losses and costs for transportation during 
periods with additional OIC treatments were also collected in the Delphi panel. Each 
item was multiplied with its unit cost to obtain the average total cost per additional 
OIC treatment. The costs of complications are linked with the number of additional OIC 
treatments needed and the average total cost for OIC complications. 
Table 2: Average costs of laxative use per week for patients using OXN and OXY.
OXn % of patients 
using laxative
average daily dose Cost/unit
(€) 
Cost/day
(€)
Costs of Bisacodyl per day 42.9% 4.32mg 0.0073/mg € 0.0135
Total laxative  cost with OXn per week € 0.09
OXY % of patients 
using laxative
mDD* Cost/unit
(€) 
Cost/day
(€)
Costs of Lactulose per day 11% 1 bag, 15 ml 
(12 g granules)
0.0146/ml € 0.024
Macrogol plus electrolytes per day 89% 1 bag, 25 ml 0.0092/ml € 0.205
Bisacodyl per day 100% 10mg 0.0073/mg € 0.073
Total laxative cost with OXY per day € 0.302
Total laxative  cost with OXY per week € 2.11
*MDD=minimal daily dosage as per SmPC.
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As the Dutch national guidelines on opioid treatment and OIC prevention have not 
changed significantly since 2008, the type and frequency of medical resources used 
obtained from the Delphi panel performed in 2008 were not updated19,41. The corre-
sponding unit costs for visits and treatments in different settings were retrieved from 
the 2010 costing manual (2009 costs) and were inflated to 2014 using the evolution of 
the consumer price index (CPI), Health compound, between 2009 (102.55) and the most 
recent year available (2014: 105.88, factor 1.03) as per national guidelines. A further as-
sumption was required in order to estimate the additional total cost of OIC on average 
per year. 
Delphi-panel outcomes
On average, in the Delphi panel the experts reported that additional OIC treatment 
to temporarily relief OIC in laxative-refractory OIC patients was needed on average 6 
(range 3.0-10.0) times over a 12 month period3. Most frequently reported resources for 
additional OIC treatment in laxative-refractory patients within the Delphi-panel were 
medications (up to 64%), GP (home) visits (up to 53%) and in hospital treatments (up 
to 30%). The corresponding cost of one additional OIC treatment course in constipated 
patients was estimated at €171.67 per additional OIC treatment; or €19.81 per week 
(Table 3)3.
The most frequently reported complications of OIC reported in the Delphi-panel were 
fecal impaction, overflow diarrhea, anal fissures and hemorrhoids, resulting in drug 
costs, GP (home visits), tests and in-hospital procedures. The corresponding cost of 
Table 3: Costs for additional OIC treatments, costs for OIC complications, costs of productivity loss and 
transport costs.
Cost item € / OIC per additional 
OIC treatment course
95% CI € / week* 95% CI
Total additional OIC treatment 171.67 [129-215] 19.81 [15-25]
Total OIC complications 318.90 [204-434] 36.80 [24-50]
average cost of productivity loss caused by OIC, 
per additional OIC treatment
107.32 [19-195] 12.38 [2-23]
average transport costs home-hospital, per 
additional OIC treatment (due to additional OIC 
treatments and treatment of OIC complications)
2.04 [1-3] 0.24
*assuming 6 courses of additional OIC treatment per year in the base case analysis.
95% confidence intervals (CI) were estimated based on the certainty scores provided by the experts from 
the panel during the second round. 1-certain, low risk of the figure being wrong (± 10% relative divergence 
possible); 2-reliable, some risk of being wrong (± 20%); 3-risky, substantial risk of being wrong (± 40%); or 
4-unreliable, great risk of being wrong (more than 40%). Based on these results, average, lower and upper 
limit of resources used were calculated, and then multiplied with the unit cost of that item of resource use 
in order to obtain, respectively, the average, lower and upper limit of costs.
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treating OIC complications in constipated patients was estimated at €318.90 or €36.80 
per week (Table 3)3.
The average cost of productivity loss was also estimated based on the Delphi panel 
outcomes. The Dutch GPs estimated that on average 23% range 17-29%] of the chronic 
pain patients who are receiving opioids are professionally active. Of these patients, on 
average 30% [range 22-38%] was unable to work due to constipation or due to com-
plications of constipation. In these patients with prescribed sick leaves, there were on 
average 6.2 [range 4.6-7.8] working days absent per additional OIC treatment course. 
The hourly rate was estimated from the most recent manual of cost research (2010). 
In 2009, the average salary was €30.02 per hour, which was inflated to € 31.50 in 2014 
based on the evolution of the prices of the collective labour agreement as per national 
guidelines (“Collectieve Arbeidsovereenkomst” (CAO), index varied from 125.4 in 2009 
to 131.6 in 2013 –latest yearly value available at the time of the analysis). Assuming an 
average working day of 8 hours, the average cost of a working day loss was estimated 
at € 252.03.  Combined with the Delphi panel data, the resulting indirect cost of OIC per 
patient was €107.32 per additional OIC treatment course (=252.0 x 0.23 x 0.30 x6.2). The 
corresponding cost of productivity losses caused by OIC in constipated patients was 
estimated at on average €107.32 [range 19-195] per additional OIC treatment course 
and on average €12.38 [range 2-23] per week (Table 3).
The direct costs not related to health care were estimated as the cost of transport from 
the patient’s home to the hospital and back, including a parking cost. The 2009 unit 
costs per km with a personal car (€0.22/km) and the average parking cost (€3.36) were 
obtained from the 2010 costing manual values, inflated to 2014 using the Dutch CPI 
index. The transport cost for each treatment performed in the hospital (day clinic or in-
hospital) was calculated as follows: (7km (as per national guidance) x €0.22) x 2 + €3.36 = 
€6.30. It was then multiplied with the proportion of patients requiring the treatment. The 
total transport costs remained marginal given the relative small proportion of patients 
going to the hospital for additional OIC treatment and treatment of OIC complications. 
The corresponding cost of transport related to additional OIC treatment and treatment 
of OIC complications in the hospital (day-care or in-hospital stay) or out-patient hospital 
visits was estimated at €2.04 per intervention and €0.24 per week (Table 3).
Inputs for health states 
The treatment effect was modeled according to the analysis performed by Koopmans et 
al. 21, for the laxative-refractory OIC population, which is a sub-group of patients in the 
OXN9001 trial. Patients were considered laxative-refractory when their BFI was above 
28.8 despite the use of at least 2 laxatives of a different ATC level 4 class. A switch from 
opioids plus laxative treatment to PR OXN was associated with a reduction in the propor-
tion of constipated patients over time21. The weekly rates of OIC are presented in Table 
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4. In the PR OXY arm, the baseline rate of constipated patients (91.4%; not all patients 
were constipated some patients did not tolerate the laxative treatment) was assumed 
unchanged until the end of the model horizon. The rational for the latter assumption 
was the absence of other treatments in this specific patient population treated with 
opioids and suffering from laxative-refractory OIC. The patients need a treatment with 
opioids and are unresponsive to laxatives. So in clinical practice these patients will be 
kept on an optimal laxative schedule and they will receive additional OIC treatment to 
temporarily relieve OIC when needed19 (Table 4). 
To allow modelling beyond 12 weeks, it was assumed that the BFI values achieved at 
the end of 12-week treatment period would remain constant for both treatment groups 
until the end of the model (52 weeks). This was a conservative assumption given long-
term extension phase study results, showing sustained benefit of PR OXN relative to PR 
OXY over a 12-month period42. 
Quality of life inputs (utility values)
For laxative-refractory patients no utility values were available in the pooled analysis, 
since there were a limited number of non-constipated patients in the trial21. To obtain 
utilities specifically related to constipation status a literature search was performed 
which revealed three publications in which impact QoL was measured in relation to 
constipation in the Netherlands2. The article by Penning-van Beest was the only article 
describing the impact of OIC on QoL, using the EQ-5D score. In this publication the OIC-
specific impact on QoL of patients treated with opioids for pain was measured in terms 
of disutility, applied to constipated vs. non-constipated patients with non-advanced 
disease2. The utility level was determined by the presence or absence of OIC. In a 
population with non-advanced disease (assumed to represent a non-malignant-pain 
population), the average EQ-5D utility was 0.65 [0.22-0.78] without OIC (=Unon-OIC) and 
0.31 [0.17-0.73] with OIC (UOIC), i.e. a disutility of 0.34 [0.32-0.36] due to OIC.
Table 4. Weekly proportions of OXN patients in “constipated” and “non-constipated” health states
Week non constipated (« normal bFI score ») Constipated (bFI  score >28.8) 95% CI
n/N (%) n/N (%)
Week 0 (Day 1) 3/35 (8.6%) 32/35 (91.4%) [82-100]
Week 1 (Day 8) 12/33 (36.4%) 21/33 (63.6%) [47-80]
Week 2 (Day 15) 16/32 (50.0%) 16/32 (50.0%) [33-67]
Week 4 (Day 29) 13/29 (44.8%) 16/29 (55.2%) [37-73]
Week 8 (Day 57 ) 13/27 (48.1%) 14/27 (51.9%) [33-71]
Week 12 (Day 85) 14/35 (40.0%) 21/35 (60.0%) [44-76]
95% confidence intervals (CI) around each proportion p were estimated as follows: p +/- sqrt(p*(1-p)/N)
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Deterministic sensitivity analyses 
It was important to determine which inputs had the most significant impact on model 
results and whether particular inputs increased or decreased the ICER. The variations of a 
number of variables were tested separately and their impact on the ICER was presented 
in a Tornado diagram. Table 5 represents the variables that were tested separately in-
cluding the range tested as well as the method used.
Probabilistic sensitivity analysis
The model conducted probabilistic sensitivity analysis (PSA) on the following major 
model inputs: utility values; probability of constipation over time; average oxycodone 
dose; unit costs of additional OIC treatment in constipated patients; cost of laxatives. 
A second order Monte-Carlo simulation i.e. probabilistic sensitivity analysis (PSA) was 
undertaken based on 3000 simulations.
Beta distributions were used for probabilities and disutility score, gamma distributions 
for costs, and normal distributions for other continuous variables (dosages, durations). 
The details on the distributions used in the PSA are presented in Table 6.
A cost-effectiveness plane representing the outcome of each simulation as a dot with 
QALYs gained with OXN vs. OXY on the x-axis and incremental costs on the y-axis and 
an acceptability curve showing the probability for OXN to be cost-effective compared to 
OXY depending on the willingness-to-pay (WTP) of the health care payer were derived 
Table 5. Parameter limits used in the univariate sensitivity analysis
model parameter mean
base case
Range
(lower limit-
upper limit
source
scenario 1, base case 
% of patients with OIC, OXN arm cf Table 1 +/- 25% Koopmans 2014, as per 95% confidence intervals
% of patients with OIC, OXY arm Cf Table 1 +/- 25% Koopmans 2014, as per 95% confidence intervals
N opioid mg/day, OXN 54.5mg +/- 25% Koopmans 2014
Model duration 52 wks 12 wks Koopmans 2014 
Blagden 2014
Treatment duration 100% of 
time
25-80% Assumption
Utility constipated state 0.65 0.22-0.78 Penning van Beest 2010, as per published 95% CI 
Disutility due to OIC 0.34 +/-25% Penning van Beest 2010, as per 95% CI around the 
disutility
Cost of resources use 
(incl. complications), per week
€56.60 +/-33% Delphi NL (updated 2014), as per certainty scores* 
(Table 7 and Table 10)
Cost of productivity loss 
caused by OIC, per week
€12.38 +/-80% Delphi NL (updated 2014) as per certainty scores*
StdErr: standard error; 
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from the PSA. To ease the interpretation of the PSA results a range of WTP thresholds 
was used: from 20,000 €/QALY, which is the threshold mentioned in The Netherlands for 
diseases with a low burden of disease to 50,000 €/QALY, as can be encountered when 
the burden of disease is higher. 
scenario analyses
Besides deterministic and probabilistic sensitivity analyses also a set of different sce-
narios were analyzed, based on feedback from real-life studies43,44. First scenario a sce-
nario in which 3 OIC interventions per year were assumed based on low value obtained 
in the Delphi panel (base case 6 interventions). Other scenario’s involved excluding 
costs of constipation-related complications and excluding indirect costs. A last scenario 
involved a scenario in which costs were derived from Dik et al. 201444 who investigated 
constipation-related direct medical costs in 16 887 patients newly diagnosed with 
chronic constipation in the Netherlands.
ResulTs
base case
Table 7 shows the base case results. Patients treated with PR OXN had higher analgesia 
costs (€2,032) compared to PR OXY. Compared to OXY, patients treated with PR OXN 
Table 6. Distribution and parameter limits used in the probabilistic sensitivity analysis
model parameter mean Distri.
Psa
Distri. Param.
% of pts with OIC, OXY (week 0) 91.4% Beta 718-68
% of pts with OIC, OXN, week 1 64% Beta 20-12
% of pts with OIC, OXN, week 2 50% Beta 16-16
% of pts with OIC, OXN, week 4 55% Beta 15-13
% of pts with OIC, OXN, week 8 52% Beta 13-13
% of pts with OIC, OXN, week >=12 60% Beta 20-14
N opioid mg/day 54.5mg Normal 54.5, 0.60
Laxative cost with OXY per day €2.11 Gamma 1, 2.11
Laxative cost with OXN, per day €0.09 Gamma 1, 0.24
Utility non constipated 0.65 Beta 7-4
Disutility due to OIC 0.34 Beta 531-1031
Costs additional OIC treatment, € 19.75 Gamma 1, 19.75
Costs of OIC complications cost, € 36.70 Gamma 1, 36.70
costs of OIC-related transport costs, € 0.24 Gamma 1, 0.24
Costs of OIC-related productivity loss € 12.38 Gamma 1, 12.38
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had lower laxative treatment costs, lower additional OIC treatment costs and lower OIC 
complication costs as well as lower costs for OIC-related productivity loss and lower 
OIC-related transport costs (total savings amounted to €1269 over 52 weeks). The incre-
mental cost of PR OXN versus PR OXY was € 762.90 over 52 weeks. Relative to PR OXY, PR 
OXN gave an incremental QALY gain of 0.1102. Resulting in an ICER of € 6,924 per QALY 
gained. This value is deemed cost-effective, assuming a willingness-to-pay threshold of 
€20,000 per QALY gained.
univariate (deterministic) sensitivity analyses 
The results of the univariate sensitivity analysis testing relative variations around the 
base case values as described in table 5 are presented in the Tornado diagram in Figure 2.
The utility level of the “non-constipated” patients resulted in an ICER variation chang-
ing the value to PR OXN dominated (lower costs and more QALYs gained relative to PR 
OXY)  and € 5,009 per QALY gained when the utility in the “non-constipated” health state 
was changed to from 0.22 and 0.78, respectively (base case = 0.65). Increasing the utility 
level of non-constipated patients results in a lower ICER. 
The variations of -25% to +25% around the base case OIC rate of the weekly propor-
tions of patients with OIC in the PR OXN arm resulted in a higher ICER to  €1,470 and 
21,284 per QALY gained. As expected the proportion of patients with OIC in the PR OXN 
arm has an impact on the ICER. 
Varying the mean daily dose of opioid received in the PR OXN and PR OXY arms, with 
variations from 41 to 68mg/day resulted in an ICER change to € 2,318 and  11,535 QALY 
gained. However, the average dispensed daily dose of PR OXY per patient has been 
stable during the years 2009-2013 at approximately 35 mg per day (www.gipdatabank.
Table 7: Incremental and total costs in the base case analysis
Cost item OXN OXY Incremental 
OXN vs. OXY
Opioid costs (pain therapy) € 2,427.88 € 396.24 € 2,031.64
Laxative treatment costs (concomitant to opioid) € 4.92 € 109.77 -€ 104.84
Additional OIC treatment costs € 606.00 € 938.88 -€ 332.88
OIC complications costs € 1,125.71 € 1,744.07 -€ 618.36
OIC-related transport costs for in-hospital additional OIC treatment 
and treatment of OIC complications
€ 7.36 € 11.41 -€ 4.04
OIC-related costs for productivity losses € 379.78 € 588.40 -€ 208.62
Total cost (societal) € 4,551.66 € 3,788.75 € 762.90
QalY 0.4494 0.3392 0.1102
Results are undiscounted (time horizon < 1 year).
ICER base case analysis (societal perspective):€6,924, ICER base case analysis (without societal costs):€8,853
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nl). An increase to an average daily dose of 68 mg is not expected as PR OXN results in 
comparable pain relief compared to PR OXY. When costs of OIC complications or costs 
of additional OIC treatment course are varied from -36% to +36% around the base case 
value, ICER changed to €8,945 and €4,904 per QALY gained. Varying the disutility associ-
ated with the “constipated” state to 0.26 and 0.43 results in a change in ICER to € 9,232 
and € 5,539 per QALY gained. The ICER increases when the impact of OIC on patients’ 
QoL increases. When the mean indirect costs (costs of OIC-related productivity losses) 
are varied from -80% to +80% around the base case value during additional OIC treat-
ment courses the ICER changes to €8,439 and €5,409 per QALY gained.
Probabilistic sensitivity analysis
The PSA outcomes are described in Table 8. 
On average over 3000 simulations, the mean (SD) QALYs gained with PR OXN vs. PR 
OXY were 0.11 (0.022) and the mean (SD) incremental costs were € 765 (822) per patient, 
resulting in an ICER of €6,953 per QALY gained. This result is in line with the base case 
deterministic conclusion. The cost-effectiveness plane (scatter plot) is shown in Figure 3. 
Each dot represents the outcome of a simulation. There were 15% in the South-East 
quadrant (lower costs, higher QALYs i.e. dominant situation of PR OXN vs. PR OXY).At a 
threshold of €20,000 per QALY gained a total of 96% simulations are cost-effective and 
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Laxative Cost concomitant to opioid, per week [‐10% ; +10%]
Resource Cost/wk ‐ Constipated, additional OIC treatments [14.82 ; 24.69]
Model duration (weeks) [12 ; 52]
Indirect costs ‐ Constipated, per week [2.48 ; 22.28]
Disutility constipated [0.26 ; 0.43]
Resource Cost/wk ‐ Constipated, OIC complications [23.49 ; 49.91]
Mean daily opioid dose (mg) [40.87 ; 68.12]
Constipation status, OXN [‐25% ; +25%]
Utility non‐constipated [0.22 ; 0.78]
ICER (€ / QALY)
Tornado diagram
Figure 2: Tornado diagram, ICER of OXN vs. OXY, societal perspective (univariate sensitivity analysis).
In blue: ICER obtained with the low value of the parameter; in red: ICER with the high value parameter. ICER 
base case analysis: €6,924 per QALY gained.
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100% at a €50,000 per QALY gained threshold. The acceptability curve is shown in Figure 
4 and confirms the findings above.
Other scenario analyses
Scenario assuming 3 additional OIC treatment courses per year (base case 6 courses per year)
This scenario demonstrates that decreasing the number of additional OIC treatment 
courses results in an increase of the ICER to €11,241 per QALY gained. 
Scenario excluding indirect costs (OIC-related productivity costs) 
This scenario shows that there is an impact of OIC-related productivity loss on the ICER. 
As expected exclusion of these costs led to a higher ICER of €8,818 per QALY gained. 
Table 8: PSA outcomes OXN vs. OXY, 3000 simulations
strategy
mean (sD)
Cost
mean (sD)
ΔCosts
mean (sD)
QalYs
mean (sD)
ΔQalYs
OXY (ref ) 3,754.4 (2,112.6) 0.343 (0.116)
OXN 4,519.2 (1,371.9) 764.8 (821.6) 0.453 (0.118) 0.11 (0.022)
ΔCosts: difference in cost per patient treated with OXN vs. OXY
ΔQALYs: difference in QALYs gained per patient treated with OXN vs. OXY
SD: standard deviation.
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Figure 3: Cost-effectiveness plane.
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Scenario excluding costs OIC complications 
As expected costs of OIC complications have an impact on the ICER increasing it to 
€12,536. 
Scenario using Chronic constipation related costs from Dutch Health Insurance Claims 
database (Dik et al.).
When using chronic constipation related costs in patients with persistent constipation 
from the Dutch health care insurance claims database the ICER increases to €14,761. 
In this publication all costs in the claims database related to chronic constipation were 
included from secondary care. 
The results of the base case analysis, deterministic and probabilistic sensitivity analy-
ses as well as the scenario analyses are depicted in table 9.
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Figure 4: Acceptability curve PR OXN vs. PR OXY, PSA
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DIsCussIOn
PR OXN combines the strong opioid receptor agonist oxycodone and the opioid recep-
tor antagonist naloxone. PR OXN has proven equivalent analgesic efficacy to PR OXY 
with significant improvements in bowel function in chronic non-malignant pain30-35 as 
well as in moderate/severe malignant pain36,37. It is important to assess cost utility of 
PR OXN treatment for laxative-refractory patients, as treatment with PR OXN is more 
expensive than treatment with PR OXY. 
This cost-utility analysis demonstrates that treatment with PR OXN generates an ICER 
well below the commonly applied thresholds in the Netherlands. The ICER is similar 
Table 9: Results of univariate sensitivity & scenario analyses
subject Δcosts ΔQalYs ICeR (€/QalY)
base case 762.9 0.1102 6,924
univariate sensitivity analyses LOW HIGH
Δcosts ΔQalYs ICeR 
(€/QalY)
Δcosts ΔQalYs ICeR 
(€/QalY)
Model duration (weeks) [12 ; 52] 148.3 0.028 5,285 762.9 0.110 6,924
Mean daily opioid dose (mg) [40.875 ; 68.125] 255.4 0.110 2,318 1270.9 0.110 11,535
Resource Cost/wk - Constipated, additional OIC 
treatments [14.82 ; 24.69] 846.1 0.110 7,679 679.7 0.110 6,169
Resource Cost/wk - Constipated, OIC 
complications [23.49 ; 49.91] 985.5 0.110 8,945 540.3 0.110 4,904
Resource Cost/wk - Constipated, transport 
home-hosp [0.18 ; 0.3] 763.9 0.110 6,933 761.9 0.110 6,915
Laxative Cost concomitant to opioid, per week 
[-10% ; +10%] 789.1 0.110 7,162 736.7 0.110 6,686
Indirect costs - Constipated, per week [2.476 ; 
22.284] 929.8 0.110 8,439 596.0 0.110 5,409
Disutility constipated [0.255 ; 0.425] 762.9 0.083 9,232 762.9 0.138 5,539
Utility non-constipated [0.221 ; 0.78] 762.9 -0.029
OXN 
Dominated 762.9 0.152 5,009
Constipation status, OXN [-25% ; +25%] 235.4 0.160 1,470 1287.7 0.061 21,284
Δcosts ΔQalYs ICeR (€/QalY)
scenario analyses
3 additional OIC treatment courses/year 1,238.5 0.1102 11,241
Excluding OIC indirect costs (OIC-related 
productivity loss)
971.5 0.1102 8,818
Excluding costs of OIC complications 1,381.2 0.1102 12,536
Costs from Health insurance claims database 
(secondary care, Dik 2014)
1,626.34 0.1102 14,761
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to that generated in a previous cost-utility model of PR OXN compared with PR OXY1. 
Under a conservative approach taking into account the optimal laxative schedule and 
assuming a continuous opioid treatment, it demonstrated cost-effectiveness of PR OXN 
plus rescue bisacodyl for opioid-treated patients with non-malignant pain suffering 
from laxative-refractory OIC compared to OXY plus a laxative regime with an ICER of 
€6,924 per QALY gained. 
Several sensitivity and scenario analyses show the robustness of the model (ICERs be-
tween €1,470 and €21,284 per QALY gained; the latter in patient who are unresponsive 
to treatment with PR OXN). The probability of being cost-effective for PR OXN vs. PR 
OXY was 96% and 100% at a WTP threshold of €20,000 to €50,000 per QALY gained, 
respectively. 
The univariate sensitivity analysis in which the proportion of constipated patients in 
the OXN-arm was increased with 25% resulted in the highest ICER €21,284 per QALY 
gained. In general, it can be discussed that patients with OIC unresponsive to treatment 
with PR OXN most probably  suffer from constipation caused by other factors than con-
stipation . For these patients other more invasive pain management methods could be 
explored in real-life.
A scenario analyzing the impact of decreasing the number of additional OIC courses 
per year from 6 to 3 resulted in increase of the ICER to €11,241 per QALY gained. How-
ever, in this specific patient population patients on opioids who are suffering from 
laxative-refractory OIC it is not expected that the number of additional OIC treatment 
courses will decrease. Actually in the Delphi panel it was shown that in this specific pa-
tient population the number might increase to 1 additional OIC treatment course every 
month i.e. 12 per year, implying a conservative base case.
 Also a scenario was analyzed in which the costs of complications were excluded. This 
is in line with the pharmaco-economic report of subcutaneous (sc) methylnaltrexone 
that was submitted to obtain reimbursement in the Netherlands, in which also no 
costs for complications were added45. As expected costs of OIC complications have an 
impact on the ICER increasing it to €12,536 per QALY gained. However, this ICER is still 
lower than the national threshold of €20,000 per QALY gained. In comparison the ICER 
obtained with sc methylnaltrexone was €33,464  per QALY gained. Both patient popula-
tions consisted of laxative refractory OIC patients. Difference between the population 
is the palliative care setting for sc methylnaltrexone compared with the non-malignant 
patients in our analysis. 
Finally, a scenario was analyzed using chronic constipation related costs in patients 
with persistent constipation from the Dutch health care insurance claims database. In 
this scenario the ICER increased to €14,76142. However, according to the authors of the 
publication there might be an underestimation of costs as laxatives and treatments for 
constipation might also have been prescribed as part of the treatment for the underly-
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ing disease. In those cases, diagnostic related groups (DRGs) for chronic constipation 
might not be claimed, leading to an underestimation of the actual chronic constipation 
related direct medical costs. Also GP-related care (primary care) was not included in the 
costs. According to the Delphi panel a substantial proportion of costs of additional OIC 
management OIC complications originated from GP-care (primary care).
In current guidelines a laxative regime is advised for the prevention and treatment 
of OIC19,41. Despite the use of this laxative regime, a group of patients will suffer from 
laxative-refractory OIC19,41. Recently, for these patients besides  PR OXN, subcutaneous 
(sc) methylnaltrexone and naloxegol have also become available in the Netherlands for 
non-malignant pain patients. These options have not been taken into account in this 
model. However, medication costs of PR OXN are the lowest with current list-prices of 
these medications; sc methylnaltrexone approximately €178,- per week (assuming 4 
flacons with 0.6 ml 20 mg/ml methylnaltrexone per week), naloxegol  approximately 
€36,75 per week (assuming 1 tablet of 25 mg per day) and PR OXN approximately €16,13 
per week (assuming 14 tablets of 10 mg per week) and assuming a comparable clinical 
benefit of PR OXN, sc methylnaltrexone and naloxegol on OIC, (source: www.medici-
jnkosten.nl; last accessed: april 29th 2018).  However, until now there are no data available 
that compare the clinical benefit between the different peripherally acting mu-opioid 
receptor antagonists (PAMORA’s) and the comparability found in systematic reviews still 
needs to be confirmed. Moreover, also side effects and ease of administration should be 
taken into account in establishing the clinical benefit from a societal perspective.
No utility values were available in the pooled analysis for this specific sub-population 
of patients, since there were a limited number of non-constipated patients in the trial21 
There is no doubt that constipation contributes to the QoL in chronic pain patients1,2. In 
this economic evaluation the utility level corresponding to the health states “constipat-
ed” and “non-constipated” in a Dutch population treated with opioids for pain caused by 
a non-advanced disease was taken from the article by Penning-van Beest et al. (2010)2. 
These utilities were also used in the economic evaluation of sc methylnaltrexone45. 
Moreover, several observational studies in the real-world treatment setting support 
improvements in quality of life for patients with chronic pain receiving PR OXN43,46-49.
limitations 
The main limitations of the analysis are pertaining to: (1) the economic data inputs, 
which were obtained from a Delphi panel of 12 Dutch GPs so that the outcomes are 
based on the perceptions of primary care physicians. As indicated in Dunlop et al. 2012, 
other groups of healthcare professionals, like nurses and secondary care specialists 
treating constipation, may report different resource use and costs1. To address this prob-
lem also a scenario analysis was performed and discussed using the costs in secondary 
care from the Dutch Health Insurance Claims Database as described by Dik et al. 201444.; 
159
      
(2) Model and cost inputs were from 2015.  Since 2015 drug prices might have changed 
as also generic macrogol plus electrolytes has entered the market. Moreover, also costs 
of PR OXN have dropped whereas costs for PR OXY have not dropped further. However, 
costs for additional OIC treatments and costs of treating OIC complications had a far 
greater impact on the cost-difference than laxative costs. Besides generic entry also 
other PAMORA’s like sc methylnaltrexone, oral naloxegol and naldemedine will and/
or have become available to patients with laxative-refractory OIC which could impact 
the model. As described above PR OXN seems to be a cheaper treatment option than 
sc methylnaltrexone and naloxegol for patients using oxycodone, but the impact of all 
PAMORA’s on cost-utility of OIC treatments from a societal perspective remains to be 
elucidated; (3) a possible lack of power of the Penning-van Beest study2 providing the 
utility scores and disutility. Although the  difference in utility level between OIC and 
non-OIC patients was significant in the non-advanced disease population (p<0.01) the 
confidence intervals around the utility scores were wide. This is reflected by the univari-
ate sensitivity analysis which showed the sensitivity of the model to the utility level of 
non-OIC patients; (4) the rate of OIC was based on trial data until week 12 and extrapo-
lated based on extension trial data until week 52. A potential area for future research is to 
develop parametric survival curves to more accurately estimate the treatment benefits 
beyond 12 weeks; (5) constipation status was based on relatively low patient numbers in 
the analysis. However, real-life observational studies in larger patient populations sug-
gest similar response rates43,49.  (6) finally, the health states were based on constipation, 
the most common side-effect of opioid treatment. However, PR OXN may counteract 
other aspects of opioid-induced bowel disorders (such as abdominal pain, cramping 
and bloating) that may require additional healthcare resources. It is therefore possible 
that a model examining these aspects on top of OIC may show a greater incremental 
QALY gain from PR OXN compared with OXY1.
appropriateness comparator
In order to have an appropriate comparison the model should reflect treatment in real-
life practice. In this model PR OXN was compared to its opioid component PR OXY, as 
the addition of naloxone does not affect pain relief of oxycodone nor the safety-profile 
(with the exception of constipation). Furthermore oxycodone is the most prescribed oral 
strong opioid in the Netherlands50. In current guidelines a laxative regime is advised for 
the prevention and treatment of OIC19,41. Therefore patients in the PR OXY-arm received 
laxative therapy on top of their opioid treatment and for patients with PR OXN as needed 
bisacodyl was used in the model, as was the case in the clinical trials. Other peripherally 
acting mu-opioid receptor antagonists like sc methylnaltrexone and naloxegol, were 
not used as a comparator since at time of model preparation they were not licensed in 
the Netherlands for the treatment of OIC in non-malignant pain patients.  
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COnClusIOns 
The present pharmaco-economic study is based on available evidence in non-malignant 
pain patients treated with opioids and suffering from laxative-refractory OIC, using piv-
otal trial data. It demonstrated cost-effectiveness of PR OXN for opioid-treated patients 
with non-malignant pain suffering from laxative-refractory OIC with an ICER of € 6,924 
per QALY gained. Several sensitivity and scenario analyses show the robustness of the 
model. The overall conclusion is that PR OXN has a probability of being cost-effective 
compared to PR OXY of 96% and 100% at WTP thresholds of respectively € 20,000 to 
€50,000 per QALY.
TRansPaRenCY
Declaration of funding
This study was designed by Mundipharma Pharmaceuticals BV There is no financial 
interest linked to the preparation, scientific advice and authorship of the article for the 
authors. No grants, equipment or drugs were supplied by the sponsor. F.J.P.M. Huygen 
and M. Dirckx provided scientific advice to Mundipharma Pharmaceuticals BV.  All au-
thors were involved in the development, writing, critical reviewing and approval of this 
manuscript.
Declaration of financial/other relationships 
M. Dirckx and F.J.P.M. Huygen have nothing to disclose. 
Y.J.B. van Megen, and G. Koopmans-Klein report personal fees from Mundipharma 
Pharmaceuticals BV, during the conduct of the study and personal fees from Mundip-
harma Pharmaceuticals BV,  outside the submitted work. W. Dunlop reports personal 
fees from Mundipharma International at time of study conduct and article drafting and 
personal fees from Mundipharma International outside the submitted work.
acknowledgments
The authors would like to thank L.Gerlier, IMS Health Belgium, for providing pharmaco-
economical services and advice. The corresponding author takes responsibility for the 
integrity and the accuracy of the data analysis, and also had final responsibility for the 
decision to submit for publication. The authors would also like to thank all physicians 
and their patients who have participated in the Delphi panel.
161
      
ReFeRenCes
 1. Dunlop, W., Uhl, R., Khan, I., Taylor, A. & Barton, G. Quality of life benefits and cost impact of 
prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with 
moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility 
analysis. J Med Econ 15, 564-575 (2012).
 2. Penning-van Beest, F.J.A., et al. Quality of life in relation to constipation among opioid users. J Med 
Econ 13, 129-135 (2010).
 3. Caekelbergh, K., Lamotte, M. & Megen=van, Y. Management of opioid induced constipation (OIC) 
in pain patients: a costs of illness study in Belgium and the Netherlands. ISPOR (2009).
 4. WHO. Cancer pain relief, with a guide to opioid availibility. WHO guideline second edition, 13-15 
(1996).
 5. Ripamonti, C.I., Santini, D., Maranzano, E., Berti, M. & Roila, F. Management of cancer pain: ESMO 
Clinical Practice Guidelines. Annals of Oncology 23, 139-154 (2012).
 6. Caraceni, A., et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based 
recommendations from the EAPC. Lancet 13, 58-68 (2012).
 7. Coluzzi, F., Pappagallo, M. & National Initiative on Pain, C. Opioid therapy for chronic noncancer 
pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 71, 425-
433 (2005).
 8. Annemans, L. Pharmacoeconomic Impact of Adverse Events of Long-Term Opioid Treatment for 
the Management of Persistent Pain. Clin Drug Investig 31, 73-86 (2011).
 9. Panchal, S.J., Muller-Schwefe, P. & Wurzelmann, J.I. Opioid-induced bowel dysfunction: preva-
lence, pathophysiology and burden. Int J Clin Pract 61, 1181-1187 (2007).
 10. Camilleri, M., et al. Emerging treatments in neurogastroenterology: a multidisciplinary working 
group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 26, 1386-
1395 (2014).
 11. Abramowitz, L., et al. Prevalence and impact of constipation and bowel dysfunction induced by 
strong opioids: a cross-sectional survey of 520 patients with cancer pain: DYONISOS study. J Med 
Econ 16, 1423-1433 (2013).
 12. Coyne, K.S., et al. Opioid-induced constipation in patients with chronic noncancer pain in the 
USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes 
and retrospective chart review. ClinicoEconomics and outcomes research : CEOR 6, 269-281 (2014).
 13. Coyne, K.S., et al. Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain 
in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and 
Symptom Burden Over Time. Pain Med 16, 1551-1565 (2015).
 14. Benyamin, R., et al. Opioid complications and side effects. Pain Physician 11, S105-120 (2008).
 15. Jubb, A.M. Palliative care research: trading ethics for an evidence. J Med Ethics 28, 342-346 (2002).
 16. Laneader, A., et al. Ethical issues in research to improve the management of malignant bowel 
obstruction: Challenges and recommendations. Journal of Pain and Symptom Management 34, 
20-27 (2007).
 17. Leppert, W. The role of opioid receptor antagonists in the treatment of opioid-induced constipa-
tion: a review. Adv Ther 27, 714-730 (2010).
 18. Leppert, W. New treatment possibilities for opioid-induced bowel dysfunction. Pain 154, 1491-
1492 (2013).
 19. Koopmans-Klein, G., Wagemans, M.F., Wartenberg, H.C., Van Megen, Y.J. & Huygen, F.J. The efficacy 
of standard laxative use for the prevention and treatment of opioid induced constipation dur-
Chapter 7
162
ing oxycodone use: a small Dutch observational pilot study. Expert review of gastroenterology & 
hepatology 10, 547-553 (2016).
 20. Kress, H.G., et al. Managing chronic pain in elderly patients requires a CHANGE of approach. Curr 
Med Res Opin 30, 1153-1164 (2014).
 21. Koopmans, G., et al. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination 
improves bowel function in patients with moderate-to-severe pain and opioid-induced constipa-
tion refractory to at least two classes of laxatives. Curr Med Res Opin 30, 2389-2396 (2014).
 22. Pergolizzi, J.V., Jr., et al. Peripherally acting mu-opioid receptor antagonists as treatment options 
for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence 
11, 107-119 (2017).
 23. Leppert, W. The place of oxycodone/naloxone in chronic pain management. Wspolczesna Onkol 
17, 128-133 (2013).
 24. Groot=de, J.W.B., Peters, F.T.M. & Reyners, A.K.L. Behandeling van obstipatie in de palliatieve fase. 
NTvG 154, 1-6 (2010).
 25. Holzer, P. Non-analgesic effects of opioids: management of opioid-induced constipation by 
peripheral opioid receptor antagonists: prevention or withdrawal? Curr Pharm Des 18, 6010-6020 
(2012).
 26. Leppert, W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunc-
tion. Drug Des Devel.Ther 9, 2215-2231 (2015).
 27. Smith, K., et al. Naloxone as part of a prolonged release oxycodone/naloxone combination re-
duces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin 
Investig Drugs 20, 427-439 (2011).
 28. Smith, K., et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharma-
col Ther 50, 360-367 (2012).
 29. Leppert, W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmaco-
logical Reports 62, 578-591 (2010).
 30. Nadstawek, J., et al. Patient assessment of a novel therapeutic approach for the treatment of 
severe, chronic pain. Int J Clin Pract 62, 1159-1167 (2008).
 31. Simpson, K., et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone 
for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res 
Opin 24, 3503-3512 (2008).
 32. Vondrackova, D., et al. Analgesic efficacy and safety of oxycodone in combination with naloxone 
as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9, 1144-1154 
(2008).
 33. Meissner, W., et al. Long-term efficacy and safety of oxycodone and naloxone in a prolonged 
release fixed combination tablet in patients with moderate to severe chronic pain. Pain Practice 
9(2009).
 34. Lowenstein, O., et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone 
in the management of moderate/severe chronic non-malignant pain: results of a prospectively 
designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 10, 
12 (2010).
 35. Gatti, A., et al. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study 
in patients with constipation. Adv Ther 30, 41-59 (2013).
 36. Ahmedzai, S.H., et al. A randomized, double-blind, active-controlled, double-dummy, parallel-
group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release 
tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 26, 50-60 (2012).
163
      
 37. Ahmedzai, S.H., et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release 
tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer, 1-8 (2014).
 38. Rentz, A.M., Yu, R., Muller-Lissner, S. & Leyendecker, P. Validation of the Bowel Function Index 
to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12, 371-383 
(2009).
 39. Rentz, A.M., van Hanswijck de Jonge, P., Leyendecker, P. & Hopp, M. Observational, noninterven-
tion, multicenter study for validation of the Bowel Function Index for constipation in European 
countries. Curr Med Res Opin 27, 35-44 (2011).
 40. Ueberall, M.A., Muller-Lissner, S., Buschmann-Kramm, C. & Bosse, B. The Bowel Function Index for 
evaluating constipation in pain patients: definition of a reference range for a non-constipated 
population of pain patients. J Int Med Res 39, 41-50 (2011).
 41. Neefjes, E.C., et al. Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation 
induced by different opioid subtypes combined with laboratory analysis of immunomodulatory 
and antiangiogenic effects of methylnaltrexone. BMC Palliat Care 13, 42 (2014).
 42. Blagden, M., Hafer, J., Duerr, H., Hopp, M. & Bosse, B. Long-term evaluation of combined 
prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: 
pooled analysis of extension phases of two Phase III trials. Neurogastroenterol.Motil. 26, 1792-
1801 (2014).
 43. Poelaert, J., et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief 
and opioid-induced constipation compared with prolonged-release oxycodone in patients with 
chronic severe pain and laxative-refractory constipation. Clin Ther 37, 784-792 (2015).
 44. Dik, V.K., et al. Constipation-related direct medical costs in 16 887 patients newly diagnosed with 
chronic constipation. Eur J Gastroenterol Hepatol 26, 1260-1266 (2014).
 45. CVZ. CFH rapport methylnaltrexon (Relistor). www.cvz.nl (2008).
 46. Schutter, U., Grunert, S., Meyer, C., Schmidt, T. & Nolte, T. Innovative pain therapy with a fixed 
combination of prolonged-release oxycodone/naloxone: a large observational study under 
conditions of daily practice. Curr Med Res Opin 26, 1377-1387 (2010).
 47. Rychlik, R., Viehmann, K., Daniel, D., Kiencke, P. & Kresimon, J. Pain Management and costs of a 
combination of oxycodone + naloxone in low back pain patients. in Pain Management - Current 
Issues and Opinions (eds. Racz, G.B. & Noe, C.E.) 307-320 (2012).
 48. Ueberall, M.A. & Mueller-Schwefe, G.H. Safety and efficacy of oxycodone/naloxone vs. oxycodone 
vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, ran-
domized, open-label blinded endpoint streamlined study with prolonged-release preparations. 
Curr Med Res Opin 31, 1413-1429 (2015).
 49. Koopmans-Klein, G., et al. Prolonged release oxycodone and naloxone treatment counteracts 
opioid-induced constipation in patients with severe pain compared to previous analgesic treat-
ment. Curr Med Res Opin 33, 2217-2227 (2017).
 50. SFK. Gebruik opioïden neemt sterk toe. Pharmaceutisch Weekblad 45, 9 (2013).

Chapter 8 
General Discussion
167
      
geneRal DIsCussIOn
Binding of opioids to µ-receptors within the gastrointestinal (GI) tract can lead to im-
pairment of motility and secretion and induce a variety of symptoms, including nausea, 
gastro-paresis, secondary pseudo-obstruction and constipation1. This complex of im-
pairment and symptoms is called Opioid Induced Bowel Dysfunction (OIBD)1-3. Opioid 
Induced Constipation (OIC) is the most common symptom of OIBD2-7 and in contrast to 
other side effects of opioid treatment patients do not develop a tolerance to constipa-
tion2-7.  OIC develops predominantly as a result of activation of enteric µ-opioid recep-
tors which are distributed throughout the GI tract1,2. They mediate a number of effects 
that influence the function of the GI-tract when activated by opioids1,2. 
In current practice the advice for treatment and prevention of OIC is to treat patients 
on opioid analgesics prophylactically with a laxative regime in addition to lifestyle 
modifications, such as increased exercise, greater fluid intake, and dietary changes1,2. 
In Dutch clinical practice a prophylactic laxative regime is advised consisting of treat-
ment with at least one laxative in an adequate dosage (e.g. macrogol plus electrolytes 
or lactulose) and if needed addition of a second laxative of a different therapeutic class 
(e.g. bisacodyl)8,9. A regime that is comparable with the Belgian laxative regime (source: 
www.bcfi.be). Despite this laxative regimen, literature describes that some patients still 
experience OIC and/or do not tolerate the adverse events of the laxative regime; i.e. 
patients with laxative-refractory OIC10,11. Furthermore, literature describes that laxatives 
are ineffective to treat OIC1,2. Moreover, treatment with laxatives causes side effects and 
complications3,12. 
Over the years opioid receptor antagonists like methylnaltrexone, naloxegol and 
naloxone are increasingly being used for the pathophysiological treatment of OIC13-15. 
Peripherally-acting opioid receptor antagonists (PAMORA’s) and prolonged release 
oxycodone/naloxone (PR OXN) block opioid actions at peripheral opioid receptors that 
mediate decreased intestinal secretion and propulsive colonic motility1,2. By blocking 
μ-opioid receptors in the gut, there is restoration of the function of the enteric nervous 
system, and propulsive motility and secretory functions can be generated by local 
enteric neural circuits in response to physiologic stimuli such as meal ingestion, or 
sensation of a bolus to evoke normal peristalsis1,2.
In the work presented in this thesis the efficacy of treatments for OIC were studies. In a 
pilot study the efficacy of a Dutch laxative regime was studied. The efficacy of PAMORA’s 
and PR OXN were analyzed in a systematic review and meta-analysis. And the treatment 
of OIC with PR OXN has been examined in real-life with a focus on the laxative refractory 
population, to gain more insight in the efficacy of PR OXN in patients with laxative-
refractory OIC in daily practice.
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Although literature on treatment of OIC at time of Dutch guideline development was 
sparse and non-conclusive, based on expert opinion was assumed that the Dutch laxa-
tive regime would be a suitable regime to prevent and treat OIC. To gain more insight 
in the efficacy of a Dutch laxative regimen in daily clinical practice as well as to obtain 
insights for future randomized controlled trials, the laxative regime has been examined 
in a pilot study. Our pilot study indicated that this laxative regime, might not be effective 
and feasible for the prevention and treatment of OIC. Moreover, the results show that a 
larger clinical study is warranted investigating  the efficacy and tolerability of the laxa-
tive regime for the prevention and treatment of OIC. 
A particular challenge for the study is patient recruitment. In our pilot study it already 
became apparent that the majority of physicians expected that an “as needed” laxa-
tive regime would be more appropriate for the treatment and prevention of OIC.  This 
is also reflected by a project started by de Graeff et al.. In this project the aim was to 
assess the efficacy of two laxatives (polyethylene glycol (PEG) with electrolytes versus 
magnesium(hydr)oxide) on the prevention of OIC. This project was terminated early due 
to insufficient patient recruitment (5 patients in 1.5 years) (source: http://www.zonmw.
nl/nl/projecten/project-detail/preventie-van-obstipatie-bij-gebruik-van-opioiden-
magnesiumhydroxide-versus-macrogolelektrolyte/voortgang/).
Given the unique etiology of OIC and the effects of opioids on neural activity, motility 
and secretion throughout the entire gastrointestinal tract1,2, it is unsurprising that laxa-
tives frequently fail to counteract the symptoms of OIC11,13,16. Instead, treatment of OIC 
should target the etiology of this condition via a µ-opioid receptor mediated approach 
such as that of the PAMORA’s and naloxone (a non-selective opioid antagonist), rather 
than just focus on symptomatic management2,14.
To gain insight on the efficacy on OIC between the PAMORA’s and PR OXN a systematic 
review and meta-analysis was performed. A systematic review and consensus article by 
Gaertner et al.17 has suggested that when measuring OIC a combination of outcomes 
should be measured. Therefore the measures evaluated consisted of objective outcome 
measures, patient reported outcome measures and patient-reported global burden 
measures of OIC. Despite significant heterogeneity between studies all identified 
randomized controlled trials showed that the efficacy of opioid antagonist treatment 
was superior to control treatment with respect to the proportion of patients achieving 
normal bowel function, the proportion of patients needing additional laxatives as well 
as the PAC-SYM total score.  The Number Needed to Treat (NNT) to obtain normal bowel 
function was ~5 (~3.5-7; the reciproke of the anticipated absolute risk difference with 
opioid antagonist treatments), which is comparable to the meta-analysis by Nee et al.18. 
Also variables that were not studied for all agents, like (change in) Bowel Function Index 
(BFI) and (change in) number of bowel movements, showed that opioid antagonist 
treatments were superior to control treatment. 
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With respect to pain relief the RCTs showed that treatment with opioid antagonists did 
not significantly interfere with pain relief. The quality of the evidence using the GRADE-
systematic was rated low for alvimopan, moderate for PR OXN, MNTX and naldemedine 
and high for naloxegol. 
An interesting population with respect to OIC is the laxative refractory population. 
Therefore we also included analyses for the subgroup of laxative refractory patients. 
Five RCTs (KODIAC-4, KODIAC-5, OXN2001, OXN3001 and OXN3006) were identified 
that reported on bowel function efficacy in laxative refractory patients or laxative inad-
equate responders. For naloxegol the NNT was ~6.7. For PR OXN the change in BFI was 
less pronounced compared with the total population (MD -8.93 95%CI -16.26 to -1.59; 
n=75). Within the naloxegol and OXN studies no heterogeneity was detected. However, 
a difference between both studies was the definition with respect to laxative refractory 
patients and laxative inadequate responder patients. For PR OXN a patient was con-
sidered laxative refractory if the patients still experienced OIC (defined as a BFI>28.8) 
despite the use of at least 2 laxatives from a different therapeutic class (e.g. macrogol 
and bisacodyl). For naloxegol a patient was considered a laxative inadequate responder 
when the patient took medication from one or more laxative classes for a minimum of 
4 days within 2 weeks before screening and still experienced moderate, severe, or very 
severe symptoms in at least one of four stool-symptom domains of a laxative-response 
questionnaire. There are some limitations to our analyses. Firstly, there is heterogeneity 
in the analyses of the bowel function outcomes, this heterogeneity might be caused 
by differences in the trial populations. Detected differences identified were differences 
with respect to OIC at baseline due to differences in definitions for OIC as well as differ-
ences is the underlying pain conditions (e.g. malignant pain and non-malignant pain). 
To reduce heterogeneity due to trial populations when studying OIC and the efficacy/
effect with respect to OIC, Poulsen et al.19 have developed a model for OIC in healthy 
volunteers, in which these population differences can be ruled out. It will be interesting 
to see whether healthy volunteers can be identified that develop laxative-refractory OIC. 
For this it might be interesting whether predictive factors can be identified that can 
be used to select high-risk populations for laxative-refractory OIC. There has been one 
publication that discussed the elucidation of predictive markers for OIC20. Unfortunately, 
Rosti et al. did not elucidate predictive markers for identification of laxative-refractory 
OIC. Another interesting approach would be head-to-head comparisons of opioid an-
tagonists in patients with laxative-refractory OIC. 
Based on clinical trials of PR OXN and the mechanism of action of PR OXN expectations 
were that PR OXN is a suitable option for the treatment of OIC in patients refractory to at 
least 2 different laxatives (ATC level 4 class) with a different mode of action. A post-hoc 
analysis was performed exploring the efficacy of PR OXN in this patient population. At 
screening, when patients were receiving opioid analgesia of any type and at least two 
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different types of laxatives, patients had a reduced bowel function (BFI>28.8). During 
treatment with PR OXN, statistically significant and clinically relevant improvements in 
bowel function were observed in both groups of patients at the end of double-blind 
treatment with OXN. The positive effect of OXN PR on bowel function is further empha-
sized by the finding that the proportion of patients who had a normal bowel function 
increased by over four-fold from screening with a decrease in laxative use. This post-
hoc analysis suggested that the effects seen in the randomized controlled clinical trial 
program are also valid for patients with persisting OIC despite the use of at least two dif-
ferent types of laxatives, and provides further confirmation that naloxone addresses OIC 
from a pathophysiological point of view rather than merely a symptomatic standpoint.
However, with current guidelines it is likely that patient switched to PR OXN already 
have been extensively treated with laxatives for a prolonged period. Moreover, patients 
included in the clinical trials might not represent the patient population in real-life. 
Therefore,  an observational study was performed that followed laxative-refractory 
patients that were switched to PR OXN in Belgium. The laxative regime in the Benelux is 
very similar and laxatives prescribed in Belgium are similar to the laxatives prescribed 
in the Netherlands (source: www.bcfi.be and www.farmacotherapeutischkompas.nl).  In 
Belgium, patients were eligible for reimbursement of PR OXN if they met the follow-
ing conditions: (1) all patients had to be aged≥18 years, with a documented history of 
severe pain requiring around-the-clock opioid therapy, treated with prolonged release 
oxycodone (PR OXY for at least 30 days with insufficient pain relief and/or unacceptable 
adverse effects; and (2) all patients had to be experiencing OIC (Bowel Function Index 
[BFI]>28.8) despite the use of at least 2 laxatives with different mechanisms of action 
(level 4 ATC term) during the previous PR OXY treatment. The study found that PR OXN 
was superior to PR OXY in terms of pain relief, OIC, and quality of life in patients with 
chronic pain previously treated with PR OXY and experiencing OIC despite the use of 
at least 2 different laxatives. This study confirmed that after 4 weeks of treatment with 
PR OXN, a clinically relevant improvement in OIC was attained in patients experiencing 
laxative-refractory OIC. The average BFI was ≤28.8 after 6 weeks of PR OXN treatment, 
indicating that most patients were no longer constipated despite the opioid treatment. 
Also the number of patients needing additional laxatives declined significantly during 
the study and the majority of patients using laxatives indicated that the laxative use 
had decreased. These results support the rationale that PR OXN treatment counteracts 
OIC through mechanisms other than those of laxatives and that PR OXN addresses the 
underlying mechanism of OIC. However, an observational study has limitations, one of 
them being that we could not ensure that all data were documented. This limitation was 
addressed by marking important parameters (e.g., BFI, pain relief, laxative use yes/no, 
rescue medication yes/no) as mandatory fields in the electronic case record form; as a 
result, few data were missing for these fields.
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As the reimbursement guidelines for laxative-refractory OIC were very strict, also an 
observational study was performed in which patients were followed after switching 
from WHO-step 1, WHO-step 2 or WHO-step 3 medication to PR OXN treatment. Patients 
had been switched to PR OXN because of insufficient pain relief and/or unacceptable 
side effects on their previous medication and the presence of OIC was not an inclusion 
parameter. The present study showed that the majority of patients in the total popula-
tion and in all WHO-step groups experienced symptoms of constipation as defined by a 
BFI≥28.8. It was shown that significantly more patients with symptoms of constipation 
at study entry were older and of female gender, both factors that are known to be as-
sociated with constipation and patients with pain are less mobile which could also have 
contributed to constipation. Moreover, it is possible that there is a bias in the percent-
age of constipated patients in this  observation as in Belgium PR OXN was marketed 
especially for patients with a BFI above 30. Already after 2 weeks of PR OXN treatment 
a clinically relevant improvement of bowel function (defined by a reduction in BFI of 
12 points or more) was observed in the overall population and in the WHO-step 2 and 
WHO-step 3 groups. Mean BFI dropped below 28.8 after 6 weeks of PR OXN treatment 
for the overall population and the WHO-step 1 and WHO-step 2 groups. In the WHO-step 
3 group mean BFI reached 28.8 after 11 weeks of PR OXN treatment. The reduction in BFI 
is in line with reduction of BFI reported in previous observational studies with PR OXN 
for patients with neuropathic pain28, constipated patients with non-malignant pain29 
and patients with severe pain30. When looking more closely at constipated patients at 
study entry (irrespective of previous analgesic treatment), it was shown that treatment 
with PR OXN led to a clinically relevant improved bowel function already in the first two 
weeks of PR OXN treatment and the improvement was maintained  over time. After 17 
weeks, BFI was close to the threshold of 28.8 showing that bowel function was almost 
restored to normal values despite the treatment with the opioid PR OXN. Interestingly, 
for patients not constipated at study entry the BFI remained below 28.8 even during PR 
OXN treatment up to 17 weeks. This indicates that treating pain adequately with strong 
opioids in non-constipated patients normal bowel function is maintained despite the 
initiation of the opioid PR OXN, even in patients stepping-up from non-opioid treat-
ment. This study adds to the evidence found in previous studies with PR OXN which 
have also shown that switching non-constipated patients to PR OXN maintained their 
bowel function in a more controlled study setting (one clinical trial and one prospective 
open-label study with a blinded endpoint)21-23.
To evaluate whether PR OXN is a cost-effective option for the treatment of patients 
with laxative-refractory OIC a cost-utility analysis was performed. This analysis demon-
strated cost-effectiveness of PR OXN for opioid-treated patients with non-malignant 
pain suffering from laxative-refractory OIC with an incremental cost-effectiveness 
ratio (ICER) of € 6,924 per quality adjusted life year (QALY )gained. The model did not 
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include other peripheral opioid antagonists as comparator. However, medication costs 
of PR OXN are the lowest with current list-prices of these medications; subcutaneous 
(sc) methylnaltrexone approximately €178,- per week (assuming 4 flacons with 0.6 ml 
20mg/ml per week), naloxegol  approximately €36,75 per week (assuming 1 tablet of 25 
mg per day) and PR OXN approximately €16,13 per week (assuming 14 tablets of 10 mg 
per week) and assuming a comparable clinical benefit of PR OXN, sc methylnaltrexone 
and naloxegol on OIC, (source: www.medicijnkosten.nl; last accessed: April 29th 2018). 
However, until now there are no data available that compare the clinical benefit be-
tween the different peripherally acting µ-opioid receptor antagonists (PAMORA’s) and 
the comparability found in the systematic reviews still needs to be confirmed. Moreover, 
also side effects and ease of administration should be taken into account in establishing 
the clinical benefit from a societal perspective.
Over the years a lot of evidence has been generated that unravels that effect and 
efficacy of PR OXN treatment. In this thesis also the efficacy of PR OXN treatment in 
laxative-refractory patients has been evaluated. Unfortunately, as of today PR OXN is 
still not reimbursed in the Netherlands, caused by uncertainty of the effect due to low 
patient numbers suffering from laxative-refractory OIC within the clinical studies and 
in the observational studies, as well as the bias introduced by the study designs in this 
specific population and uncertainty on the appropriateness of the comparator. 
In order to know when sufficient patient numbers have been studied the prevalence 
of laxative-refractory OIC needs to be elucidated in daily practice. However, in literature 
already two definitions are being used for the term laxative-refractory. One definition 
is derived from laxative inadequate responder (defined as a patient that took medica-
tion from one or more laxative classes for a minimum of 4 days within 2 weeks before 
screening and still experienced moderate, severe, or very severe symptoms in at least 
one of four stool-symptom domains of a laxative-response questionnaire).The other was 
derived from treatment guidance for OIC ( a patient is laxative-refractory if the patient 
still experienced OIC (defined as a BFI>28.8) despite the use of at least 2 laxatives from a 
different therapeutic class (e.g. macrogol and bisacodyl)). This would most likely result in 
differences in prevalence. Prevalence could also be estimated from insurance data, but 
as laxatives are commonly used for other conditions and a number of laxatives are avail-
able as over the counter medications this is not very promising. Looking at the number 
of users of a peripheral opioid antagonist in the Drug Information System of the National 
Health Care Institute probably underestimates the total number of laxative-refractory 
patients, as only 436 users were registered using in 2016 (source: www.gipdatbank.
nl). Elucidating the prevalence of laxative-refractory OIC in daily practice would be an 
important first step.  
To address study design issues a randomized controlled double-blind trial would 
be the gold standard. However, this would most probably result in ethical issues as 
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comparing PR OXN to PR OXY with a standardized laxative regimen (e.g. macrogol plus 
electrolytes and bisacodyl as needed) as is usual in Dutch practice would be the appro-
priate comparison. This would result in patients that are refractory to laxatives having 
to continue the ineffective treatment with the addition of frequent use of enema’s and 
an increased risk of developing haemorrhoids and anal fissures6. Another option would 
be to perform a prospective open-label blinded-endpoint (PROBE) study in patients 
with laxative-refractory OIC21,23. A similar study was already performed to compare 
the efficacy of PR OXN with PR OXY and PR morphine. Patients could use unblinded 
laxative-treatment as in daily practice and results showed that under the conditions of 
the PROBE design, PR OXN was associated with a significantly better tolerability, a lower 
risk of OIC and a significantly better analgesic efficacy than PR OXY and PR Morphine21,23. 
In the past years the debate on opioid use is increasing, especially when used chroni-
cally and for patients with non-malignant pain. Of course stopping opioid use would 
result in improvement of OIC and this can be seen as an easy option for the treatment of 
OIC. However, we should be careful that we don’t withhold opioid treatment for those 
patients who do benefit from opioid treatment on specific indication, like severe pain 
during short-lived painful events and at the end of life. Opioid treatment should also 
be available for carefully selected patients with chronic pain who can be managed in 
a monitored setting. Within this monitored setting precautions can be taken to avoid 
misuse and diversion and closely monitor adverse events (https://www.iasp-pain.org/
Advocacy/OpioidPositionStatement?navItemNumber=7225). 
This monitored opioid prescribing should in our opinion be accompanied by adequate 
pain education for all health-care professionals in the (chronic) pain patient pathway as 
well as pain education for patients and their caregivers. Moreover, monitored opioid 
prescribing is an opportunity to closely monitor OIC, an adverse event that still results 
in unnecessary hospital admissions (https://www.nivel.nl/sites/default/files/bestanden/
Vervolgonderzoek_Medicatieveiligheid_Eindrapport.pdf ). 
In contrast to guidelines in the Netherlands several European guidance and guidelines 
have already included opioid antagonists (including PR OXN) in the treatment algo-
rithms of OIC1,2,14,15,24.  Unfortunately, despite the wealth of available data from RCTs and 
observational studies, the national healthcare institute did not grant reimbursement for 
PR OXN in the Netherlands and it is unlikely that PR OXN will be reimbursed in the near 
future with the current assessment framework for reimbursement.  
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summaRY
Chapter 1 
The introduction describes the rationale for this thesis. Binding of opioids to µ-receptors 
within the gastrointestinal (GI) tract can lead to impairment of motility and secretion 
and induce a variety of symptoms, including nausea, gastro-paresis, secondary pseudo-
obstruction and constipation. This complex of impairment and symptoms is called Opi-
oid Induced Bowel Dysfunction (OIBD). Opioid Induced Constipation (OIC) is the most 
common symptom of OIBD.  In current practice the advice for treatment and prevention 
of OIC is to treat patients on opioid analgesics prophylactically with a laxative regime in 
addition to lifestyle modifications, such as increased exercise, greater fluid intake, and 
dietary changes. Despite this laxative regimen, literature describes that some patients 
still experience OIC and/or do not tolerate the adverse events of the laxative regime; 
i.e. patients with laxative-refractory OIC. Over the years opioid receptor antagonists like 
methylnaltrexone, naloxegol and naloxone are increasingly being used for the patho-
physiological treatment of OIC. The efficacy of laxative treatment and pathophysiologi-
cal treatment with a prolonged release combination of oxycodone/naloxone (PR OXN) 
in daily practice is not clear. Therefore, the efficacy of the current Dutch laxative regime 
in daily practice was explored. Also the efficacy of PR OXN in daily practice was further 
explored, with a focus on patients with laxative-refractory OIC. 
Chapter 2
In the Netherlands patients on opioids are treated prophylactically with laxatives for the 
prevention of OIC. However, literature on treatment of OIC at time of Dutch guideline 
development was sparse and non-conclusive, based on expert opinion was assumed 
that the Dutch laxative regime would be a suitable regime to prevent and treat OIC. This 
chapter presents the results of an observational pilot study to test the efficacy of the 
laxative regime for the prevention and treatment of OIC in daily practice. The findings 
of the study indicate that the laxative regime might not be effective and feasible for the 
prevention and treatment of OIC and a larger clinical study is warranted investigating 
the efficacy and tolerability of the laxative regime for the prevention and treatment of 
OIC.
Chapter 3 
Given the unique etiology of  OIC and the effects of opioids on neural activity, motility and 
secretion throughout the entire gastrointestinal tract11, treatment of OIC should target 
the etiology of this condition via a µ-opioid receptor mediated approach. PAMORA’s and 
naloxone (a non-selective opioid antagonist), are considered to be pathophysiological 
treatment for OIC. Chapter 3 describes the result on a systematic review and meta-
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analysis performed to gain insight on the efficacy on OIC between the PAMORA’s and 
PR OXN.  Despite significant heterogeneity between studies all identified randomized 
controlled trials showed that the efficacy of opioid antagonist treatment was superior 
to control treatment with respect to the proportion of patients achieving normal bowel 
function, the proportion of patients needing additional laxatives as well as the PAC-SYM 
total score.  The Number Needed to Treat (NNT) to obtain normal bowel function was ~5 
(~3.5-7). An interesting population with respect to opioid induced constipation is the 
laxative refractory population. Therefore we also included analyses for the subgroup of 
laxative refractory patients. For naloxegol the NNT was ~6.7. For PR OXN the change in 
BFI was less pronounced compared with the total population (MD -8.93 95%CI -16.26 to 
-1.59; n=75). Within the naloxegol and PR OXN studies no heterogeneity was detected. 
The results indicate that PAMORA’s and PR OXN are effective treatments for OIC, even 
in patients with laxative-refractory OIC. However, further studies are warranted using 
similar definitions for OIC as well as for laxative-refractory.
Chapter 4 
Based on clinical trials of PR OXN and the mechanism of action of PR OXN expectations 
were that PR OXN is a suitable option for the treatment of OIC in patients refractory 
to at least 2 different laxatives (ATC level 4 class) with a different mode of action. This 
chapter described a post-hoc analysis that was performed exploring the efficacy of PR 
OXN in this patient population. During treatment with PR OXN, statistically significant 
and clinically relevant improvements in bowel function were observed in patients at 
the end of double-blind treatment with OXN. The positive effect of PR OXN on bowel 
function is further emphasized by the finding that the proportion of patients who had 
a normal bowel function increased by over four-fold from screening with a decrease in 
laxative use. This post-hoc analysis suggested that the effects seen in the randomized 
controlled clinical trial program are also valid for patients with persisting OIC despite the 
use of at least two different types of laxatives, and provides further confirmation that 
naloxone addresses OIC from a pathophysiological point of view rather than merely a 
symptomatic standpoint. 
Chapter 5 
In this chapter the results of an observational study that followed laxative-refractory 
patients that were switched to PR OXN in Belgium are presented. The aim of the trail 
was to evaluate the efficacy of PR OXN on bowel function and pain after switching from 
opioids to PR OXN in patients that met the reimbursement-criteria for PR OXN. The study 
found that PR OXN was superior to PR OXY in terms of pain relief, OIC, and quality of 
life in patients with chronic pain previously treated with PR OXY and experiencing OIC 
despite the use of at least 2 different laxatives. This study confirmed that after 4 weeks of 
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treatment with PR OXN, a clinically relevant improvement in OIC was attained in patients 
experiencing laxative-refractory OIC.
Chapter 6 
As the reimbursement guidelines for laxative-refractory OIC were very strict, also an 
observational study was performed in which patients were followed after switching 
from WHO-step 1, WHO-step 2 or WHO-step 3 medication to PR OXN treatment. Patients 
had been switched to PR OXN because of insufficient pain relief and/or unacceptable 
side effects on their previous medication and the presence of OIC was not an inclusion 
parameter. This chapter describes the results of that study. 
Chapter 7 
Chapter 7 describes the results of a cost-utility analysis of PR OXN in patients suffering 
from laxative refractory OIC. This analysis demonstrated cost-effectiveness of PR OXN for 
opioid-treated patients with non-malignant pain suffering from laxative-refractory OIC 
with an ICER of € 6,924 per QALY gained. 
Chapter 8
In the general discussion, the focus of this dissertation is explicated. The findings of 
the studies performed are enumerated and commented. In addition, the current state 
of knowledge and theory concerning opioid induced constipation summarized. It 
discusses the importance of clear definitions for OIC as well as for laxative-refractory 
OIC. And it discusses future research possibilities to investigate the efficacy of PR OXN 
for the treatment of OIC in comparison to the current laxative regime and other opioid 
antagonists. 
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neDeRlanDse samenVaTTIng
hoofdstuk 1 
De introductie beschrijft de achtergrond en aanleiding van deze thesis. De binding van 
opioïden aan µ-receptoren in het gastro-intestinale (GI, maag-darm) stelsel kan leiden 
tot gebreken in de motiliteit en secretie en kan een variëteit aan symptomen veroorza-
ken, waaronder misselijkheid, vertraagde maaglediging, secundaire pseudo-obstructie 
en obstipatie. Dit complex aan gebreken en symptomen wordt opioïd geïnduceerde 
darm dysfunctie genoemd (OIBD). Opioïd geïnduceerde obstipatie (OIC) is het meest 
voorkomende symptoom van OIBD. In de huidige dagelijkse praktijk is het advies voor 
de behandeling en preventie van OIC, een profylactische behandeling met laxantia voor 
alle patiënten die opioïden gebruiken in combinatie met leefstijl aanpassingen, zoals 
beweging, voldoende drinken en aanpassing van het voedingspatroon. Ondanks dit 
laxans regime, wordt er in de literatuur beschreven dat sommige patiënten nog steeds 
OIC ontwikkelen en ervaren en/of dat ze de bijwerkingen van het laxansregime niet 
tolereren; deze patiënten hebben laxans-refractaire OIC. In de afgelopen jaren worden 
opioïd receptor antagonisten, zoals methylnaltrexon, naloxegol en naloxon, steeds 
vaker gebruikt vanwege de pathofysiologische werking op OIC.  De effectiviteit van 
laxansbehandeling, alsook de pathofysiologische behandeling met oxycodon/naloxon 
met verlengde afgifte (PR OXN) in de dagelijkse praktijk is echter nog niet duidelijk. 
Daarom werd de effectiviteit van het huidige Nederlandse laxansregime onderzocht in 
de dagelijkse praktijk. Daarnaast werd de effectiviteit van PR OXN in de dagelijkse prak-
tijk verder onderzocht, met speciale aandacht voor patiënten met laxans-refractaire OIC. 
hoofdstuk 2
In Nederland worden patiënten die met opioïden behandeld worden profylactisch 
behandeld met laxantia om OIC te voorkomen. Echter de literatuur voor de behandeling 
van OIC was op het moment van de ontwikkeling van de Nederlandse richtlijn spaar-
zaam en niet eenduidig, gebaseerd op de opinie van de experts werd aangenomen dat 
het laxans-regime een gepast regime zou zijn voor de preventie en behandeling van 
OIC. Dit hoofdstuk beschrijft de resultaten van een observationele pilot studie naar de 
effectiviteit van dit laxansregime voor de preventie en behandeling van OIC in de dage-
lijkse praktijk. De bevindingen van deze studie tonen dat het huidige laxans-regime mo-
gelijk niet effectief is voor de preventieve en behandeling van OIC. Een grotere klinische 
studie is noodzakelijk waarin de effectiviteit en verdraagbaarheid van het laxans-regime 
voor de preventie en behandeling van OIC wordt onderzocht. 
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hoofdstuk 3 
Gegeven de unieke etiologie van OIC en de effecten van opioïden op neurale activiteit, 
motiliteit en secretie in het maag-darm stelsel, zou de behandeling van OIC gericht 
moeten zijn op deze etiologie via een mu-opioïd receptor gemedieerde aanpak. Perifeer 
werkende mu-opioïd receptor antagonisten (PAMORA’s) en naloxon (een niet selectieve 
opioïd antagonist), worden beschouwd als een pathofysiologische behandeling voor 
OIC. Hoofdstuk 3 beschrijft de resultaten van een systematisch review en meta-analyse 
welke werd uitgevoerd om inzicht te krijgen in de effectiviteit voor de behandeling 
van OIC tussen de PAMORA’s en PR OXN. Hoewel er significante heterogeniteit was 
tussen de studies, toonden alle geïdentificeerde gerandomiseerde gecontroleerd trials 
(RCTs) dat de effectiviteit van de behandeling met opioïd antagonisten superieur was 
aan de controle behandeling, met betrekking tot het proportie patiënten dat een nor-
male darmfunctie bereikte, de proportie patiënten die additionele laxantia gebruikten 
alsook de PAC-SYM totaal score. De Number Needed to Treat (NNT) om een normale 
darmfunctie te verkrijgen was  ~5 (~3.5-7). Een interessante populatie met betrekking 
tot OIC was de laxans-refractaire populatie, wat leidde tot een subgroep analyse van 
deze laxans-refractaire patiënten. De NNT van naloxegol was ~6.7 en voor PR OXN was 
de verandering in BFI minder sterk in vergelijking met de totale populatie  (MD -8.93 
95%BI -16.26 tot -1.59; n=75). Binnen de studies met naloxegol en PR OXN werd geen 
heterogeniteit gedetecteerd. De resultaten suggereren dat  PAMORA’s en PR OXN effec-
tieve behandelingen zijn voor OIC, ook bij patiënten met laxans-refractaire OIC. Echter, 
verdere studies zijn noodzakelijk waarbij vergelijkbare definities gehanteerd worden 
voor OIC, alsook voor laxans-refractaire OIC. 
hoofdstuk 4 
Gebaseerd op klinische studies van PR OXN en het werkingsmechanisme van PR OXN 
was de verwachting dat PR OXN een passende optie is voor de behandeling van OIC bij 
patiënten met laxans-refractaire OIC (waarbij de patiënten refractair zijn aan ten minste 2 
verschillende laxantia (ATC-klasse niveau 4) met een verschillend werkingsmechanisme. 
Dit hoofdstuk beschrijft een post-hoc analyse die werd uitgevoerd om de effectiviteit 
van PR OXN in deze patiëntenpopulatie te onderzoeken. Gedurende de behandeling 
met PR OXN, werden statistisch significante en klinisch relevante verbeteringen van de 
darmfunctie aangetoond aan het eind van de dubbelblinde behandeling met PR OXN. 
Het positieve effect van PR OXN op de darmfunctie werd verder ondersteund door de 
waarneming dat de proportie patiënten met een normale darmfunctie in viervoud 
toenam ten opzichte van de screening, terwijl het laxans-gebruik verminderde.  Deze 
post-hoc analyse suggereert dat de effecten welke gezien werden in het klinische stu-
dieprogramma ook gelden voor patiënten met OIC die persisteert ondanks het gebruik 
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van ten minste 2 verschillende typen laxantia. Het bevestigt het standpunt dat naloxon 
een pathofysiologische behandeling is van OIC. 
hoofdstuk 5 
In dit hoofdstuk worden de resultaten beschreven van een observationele studie in 
België welke patiënten met laxans-refractaire OIC volgde die gestart waren met PR OXN. 
De doelstelling van de studie was om de effectiviteit van de behandeling met PR OXN op 
de darmfunctie en de pijnstilling te analyseren na het overstappen van oxycodon naar 
PR OXN. Alle patiënten voldeden aan de vergoedingscriteria voor PR OXN.  De studie 
toonde dat PR OXN superior was aan oxycodon m.b.t. pijnstilling, OIC en kwaliteit van 
leven bij patiënten met chronische pijn welke behandeld werd met oxycodon en laxans-
refractaire OIC ervaarden. De studie bevestigde dat na 4 weken behandeling met PR 
OXN een klinisch relevante verbetering van de darmfunctie werd behaald bij patiënten 
met laxans-refractaire OIC. 
hoofdstuk 6 
Omdat de vergoedingsrichtlijnen voor laxans-refractaire OIC zeer strikt waren, werd 
ook een observationele studie uitgevoerd, waarin patiënten gevolgd werden die ge-
start waren met PR OXN na behandeling met WHO-stap 1, WHO-stap 2 of WHO-stap 3 
medicatie. De patiënten startten met PR OXN vanwege onvoldoende pijnstilling en/of 
onacceptabele bijwerkingen op de voorgaande medicatie, OIC was geen onderdeel van 
de inclusie-parameters.  Dit hoofdstuk beschrijft de resultaten van die studie. 
hoofdstuk 7 
Omdat kosten in het huidige gezondheidszorgstelsel van belang zijn werd ook een 
kosten-utiliteit analyse uitgevoerd. Hoofdstuk 7 beschrijft de resultaten van de kosten-
utiliteit analyse van PR OXN bij patiënten met laxans-refractaire OIC. De analyse toonde 
dat PR OXN kosteneffectief is bij patiënten met niet-maligne pijn en laxans-refractaire 
OIC met een incrementele kosteneffectiviteit ratio (ICER) € 6,924 per gewonnen levens-
jaar in goede kwaliteit (quality adjusted life years (QALY)). 
hoofdstuk 8
In de discussie wordt de focus van dit proefschrift besproken.  De bevindingen van de 
uitgevoerde studies worden besproken en bediscussieerd. Verder wordt de huidige 
kennis en theorie over OIC samengevat. Het bediscussieert het belang van duidelijke 
definities voor OIC en laxans-refractaire OIC. Daarnaast worden toekomstige mogelijk-
heden besproken voor vergelijkend onderzoek naar PR OXN in de behandeling van OIC 
vergeleken met het huidige laxans regime en andere opioïd antagonisten.  
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- Value Based Health Care, the basics (The Decision Group)
- Materclass Patient Support Programs (Smelt BV)
- VBHC green belt traject:
- Lean and other VBHC tools
- Your role in implementation
- VBHC Core Concepts
- VBHC implementation challenges
2010
2011
2012
2015
2015
2018
2018
2018
2018
2019
2019
8 hours/0.3
8 hours/0.3
8 hours/0.3
10 hours/0.4
16 hours/0.6
12 hours/0.45
8 hours/0.3
8.5 hours
8.5 hours
8.5 hours
8.5 hours
Presentations (0.5/presentation)
- Refereeravond Pijngeneeskunde
- Internal conference Mundipharma International
- Wetenschapsdag Anesthesiologie
2015
2016
2017
International conferences and symposia (0.3/dag)
-  8th Congress of The European Pain Federation EFIC® , “Pain in Europe VIII” 
in Florence, Italy, October 9-12, 2013 (poster presentation
-  7th World congress of the World Institute of Pain, Maastricht (poster 
presentation)
-  9th Congress of the European Pain Federation, EFIC®, “Pain in Europe IX” 
in Vienna, Austria, September 2-5, 2015
- ERS International Congress, London, September 3-7, 2016
- ERS International Congress, Milan, September 9-13, 2017
- IRW conference, March 15-16, Groningen
2013
2014
2015
2016
2017
2018
1
1
1
1
1
1
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seminars and workshops
- GRADE-cursus Vereniging Innovatieve Geneesmiddelen
-  GRADE workshop Academisch Medisch Centrum (moderators: Miranda 
Langendam and Annefloor van Ernst)
-  Three 4-hour workshops about therapy adherence inhalation medication 
(LAN)
- Pain Franchise Training Meeting on low-dose methoxyflurane
2015
2015
2017/2018
2016
4 hours/0.15
8 hours/0.3
12 hours/ 0.25
16 hours/0.6
2. Teaching activities
Year Workload 
(hours/eCTs)
lecturing
-  Several medical lectures and training according to farmeduca guidance 
of national Mundipharma Pharmaceutical B.V. employees (e.g. national 
sales manager, product managers, receptionists and accountmanagers) 
on: pain, pain management and opioids
-  the respiratory system, asthma, asthma management, inhalation 
corticosteroids and long acting β2- agonists. 
2015-2016
2016-ongoing
32 hours/1
56 hours/2
ECTS (European Credit Transfer and Accumulation System) are training credits (‘studiepunten’). One ECTS 
stands for around 28 working hours (including preparation, self study, examinations etc.). 

